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1 Introduction 
This chapter is intended to give a brief introduction into the research field and to put the 
experimental data of the following chapters into a broader context. It is not considered to be 
a complete review of the whole scientific area. 
 
1.1 Nucleic acid therapeutics 
Since the elucidation of the molecular structure of nucleic acids by Francis Crick, 
James Watson, Maurice Wilkins and Rosalind Franklin [1-3] and the realization of 
their role in encoding, transfer and translation of genetic information [4-6], the 
knowledge about nucleic acid biology has increased continuously. The decryption of 
the human genome and the development of new sequencing technologies enabled 
the identification of disease causative or associated genes and thereby had 
enormous impact on the biomedical research [7-9]. The classical gene therapy, in 
terms of the substitution of deficient genes by transfer of genetical material, was the 
first concept for the therapeutic usage of nucleic acids [10, 11]. After two decades 
with over 2000 completed, ongoing or approved clinical gene therapy trials worldwide 
([12], June 2014), finally the first gene therapeutic treatment (alipogene tiparvovec, 
Glybera®) got marketing authorization by the European Commission in 2012 [13]. In 
addition, more and more biological roles of RNA, beyond the central dogma of 
molecular biology, have been identified [14, 15]. Non-coding RNA, such as miRNA, 
siRNA, piRNA, snRNA, riboswitches, self-cleaving ribozymes or antisense 
transcripts, serve as specific endogenous regulators of gene expression [16-22], 
whereas species such as rRNA, snoRNA, telomeric RNA [23-25] and many more 
play important roles in several other cellular processes. The increasing knowledge 
about the diverse biological functions of RNA one the one hand represents an 
additional level for the understanding of cellular homeostasis and disease associated 
malfunctions, on the other hand opens new possibilities for precise therapeutic 
interventions by using nucleic acids as drugs. For that reason, RNA therapeutics 
have attracted much attention in the medical research and drug development. An 
alternative approach to the delivery of DNA, for the restoration or extension of the 
proteome, represents direct transfer of mRNA, which does not require transport and 
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transcription in the nucleus [26-28]. The complementary effect on protein expression 
can be achieved by the use of antisense oligonucleotides, which suppress translation 
of the target mRNA by either steric-blocking or RNAse H dependent degradation [29]. 
Fomivirsen (Vitravene®), a 21-mer oligonucleotide with complementary sequence to 
the mRNA transcript of a cytomegalovirus (CMV) gene, represents the first marketed 
antisense therapeutic, which received FDA approval for the local treatment of CMV 
retinitis in 1998 [29]. In contrast to the antisense mechanism, based on the equimolar 
annealing of single-stranded oligonucleotides, double-stranded RNA (dsRNA) can 
mediate degradation of target RNA in a catalytic fashion by activation of the RNA-
induced silencing complex (RISC). The underlying mechanism of RNA interference 
(RNAi), first discovered with rather long dsRNA in C. elegans [30], was transferred to 
the silencing of target genes in human cells by introduction of the small interfering 
RNA (siRNA) [31]. The highly efficient gene knock-down by RNAi opened the 
possibility of a specific modulation of gene expression and therefore raised great 
expectations for the usage in molecular medicine [32]. Other examples of nucleic 
acid species with great therapeutic potential are splice-switching oligonucleotides 
(SSOs), which entered clinical trials for the treatment of Duchenne muscular 
dystrophy [33] and immunostimulatory nucleic acids, such as cytosine-phosphate-
guanosine (CpG) oligodeoxynucleotides [34, 35] or polyinosinic-polycytidylic acid 
poly(I:C) [36, 37]. The intracellular delivery of the synthetic dsRNA poly(I:C) simulates 
a viral infection and mediates immune response by activation of membrane-bound 
and cytosolic pattern recognition receptors, such as the dsRNA dependent protein 
kinase (PKR), Toll-like receptor 3 (TLR3), retinoic acid-inducible gene 1 (RIG-I) and 
melanoma differentiation-associated gene 5 (MDA5) [38]. A great potential of 
poly(I:C) for apoptosis induction and tumor cell killing in cancer immunotherapy 
approaches has been shown in several cases [39-41]. Another remarkable nucleic 
acid class is represented by aptamers, which bind target molecules with affinities 
comparable to antibodies, but can be engineered in vitro using evolutionary selection 
processes [42, 43] and are readily accessible by chemical synthesis [44]. The 
PEGylated anti-vascular endothelial growth factor (VEGF) aptamer pegaptanib 
(Macugen®), which received FDA approval for the treatment of age-related macular 
degeneration (ARMD) in 2004, represents the first aptamer based therapeutic on the 
market, and several more are in preclinical or clinical development stages currently 
[45]. Since RNA exhibits a very low chemical and enzymatic stability, numerous 
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chemical modifications have been developed in order to improve the pharmacokinetic 
and pharmacodynamic properties or to reduce immunogenicity [46]. Prevalent 
strategies include phosphorothioate backbone modification, 2’-O-methyl, 2’-O-
methoxyethyl or 2’-fluoro sugar modifications, 2’-O, 4’-C-methylene bridges (locked 
nucleic acid, LNA) and L-ribose oligonucleotides (spiegelmers) [33, 46, 47]. In 
addition, neutral nucleic acid analogs, such as peptide nucleic acid (PNA) or 
phosphorodiamidate morpholino oligomer (PMO) are used for antisense or splice-
correction therapy approaches [48, 49].  
Although the drug-like properties of nucleic acids can be adjusted by chemical 
modifications, the efficient and specific intracellular delivery of these macromolecular 
compounds remains a major limitation for therapeutic applications and therefore 
requires appropriate carrier systems. Viruses, which have been optimized by nature 
for the purpose of nucleic acid transfer into host cells, currently are the most 
investigated vectors for gene therapy. Over two-thirds of the clinical trials worldwide 
are based on viral delivery systems [12, 50]. However, despite their high efficiency, 
viral vectors also exhibit some serious drawbacks, such as immunogenicity, limited 
cargo capacity, virus-type depending cell tropism, sophisticated production and the 
inherent risk of reversion to wild-type or replication-competent virions [51, 52]. The 
complementary approach, to the modification of natural viruses, is based on the 
bottom-up development of ‘artificial viruses’ by synthetic chemistry [53, 54]. The high 
design flexibility, without restriction to natural building units, offers the possibility to 
engineer synthetic nucleic acid carriers with tailor-made properties. Moreover, 
scalable chemical strategies and drug formulation technologies can be used for the 
production [55-58]. However, the efficiency of current synthetic delivery systems is 
still low, compared to the viral counterparts. In order to develop improved nucleic acid 
carriers, the delivery pathway and the individual hurdles have to be considered in 
detail.  
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1.2 The delivery pathway of non-viral nucleic acid carriers 
Several barriers are faced and have to be overcome by non-viral nucleic acid carriers 
for efficient intracellular delivery. Scheme 1.1 shows a simplified illustration of the 
rather complex delivery pathway passed by polymer-based systems. In the following 
chapters, the particularly critical steps, nucleic acid complexation (1), (specific) 
cellular uptake (2), endosomal escape (3), cargo release and intracellular trafficking 
(4), are described and discussed individually.     
 
Scheme 1.1 The cellular delivery pathway of polymer-based nucleic acid carriers 
 
 
1.2.1 Nucleic acid complexation 
Since free nucleic acids are rapidly cleared from the blood stream, they have to be 
complexed and condensed to form particles, which increase the circulation time and 
protect the payload against nucleases. A convenient and frequently used mechanism 
is based on the ionic interaction between the negatively charged nucleic acid and 
multivalent cations. The nucleic acid condensation by positively charged polymers is 
an entropy driven process and produces nanosized complexes, called ‘polyplexes’ 
[59, 60]. Scheme 1.2 shows some examples of nucleic acid binding polymers. 
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Scheme 1.2 Basic polymers used for nucleic acid complexation and delivery 
 
PLL, poly-L-lysine [61]; PDMAEMA, poly[(2-dimethylamino)ethyl methacrylate] [62]; chitosan, (partially) 
deactetylated chitin [63]; LPEI, linear polyethylenimine prepared by hydrolysis of poly(2-ethyl-2-oxazoline)  [64]; 
PAsp(DET), diethylene triamine N-substituted polyaspartamide [65]; BPEI, branched polyethylenimine [66], 
PAMAM, poly(amido)amine dendrimer [67].   
 
The size of nanoparticles for a systemic administration is a critical parameter with big 
impact on the pharmacokinetics and biodistribution. Particles with a hydrodynamic 
diameter of 5.5 nm and below are rapidly cleared by the kidneys [68]. Particle sizes 
of up to 400 nm can facilitate accumulation in highly vascularized solid tumors, as a 
result of the enhanced permeability and retention (EPR) effect based on particle 
passage through leaky vessels in the tumor tissue [69]. However, the extent of 
passive accumulation and the size-threshold of the porous tumor vasculature depend 
on the certain type of cancer [70, 71]. As reported by Cabral et al., within a set of 
polymeric micelles with hydrodynamic diameters ranging from 30 to 100 nm, only the 
smallest were able to accumulate in poorly permeable pancreatic tumors, whereas all 
micelles showed comparable penetration in another tumor model. The polyplex 
stability in biological fluids is an additional serious issue, since the interaction with 
proteins and electrolytes can cause polyplex dissociation due to counter ion 
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exchange. Stable packaging predominantly depends on the size and charge density 
of the cationic polymer, but can be improved by crosslinking or the introduction of 
hydrophobic elements [72-79]. 
 
1.2.2 Cellular uptake 
Although it has been shown that the injection of naked nucleic acids under 
hydrodynamic pressure can mediate in vivo transfection [80, 81], in general the 
cellular uptake of free DNA and RNA is very low. The nucleic acid complexation by 
cationic polymers produces particles with positive surface potential, which can induce 
internalization by electrostatic interaction with the negatively charged cell membrane 
(cf. Scheme 1.1). However, this adsorptive endocytosis mechanism is rather 
unspecific and less efficient than a receptor-mediated uptake route [82, 83]. 
Therefore, the attachment of targeting ligands to exposed parts of the polyplexes is a 
convenient approach to enhance cellular internalization in a receptor-specific fashion. 
The selection of appropriate target-receptors depends on the individual expression of 
the target-cells. Since oncogenic transformation generally is accompanied by 
excessive proliferation and a high metabolic activity [84], transport proteins for the 
uptake of nutrients and cofactors, such as the folate receptor (FR) and transferrin 
receptor (TfR), are frequently overexpressed in various types of cancer and can be 
used for a receptor-mediated uptake into tumor cells [61, 85-88]. Other receptors for 
tumor-targeted delivery are represented by growth factor receptors [39, 40, 83, 89, 
90] or integrins [91-93]. In addition, the physiological tissue-specific expression of 
membrane proteins, such as the asialoglycoprotein receptor (ASGPR), which is 
exclusively expressed by parenchymal hepatocytes [94], can be used for the targeted 
delivery to cells without malignant transformation [95-97]. The parameter 
predominantly determining the potency of a homing ligand is its affinity toward the 
target receptor. However, ligands can also vary in the triggered uptake mechanism, 
efficiency and kinetic, e.g. depending on simple receptor binding or additional 
activation of a signaling cascade [83, 98]. The cell binding potency can be strongly 
increased by the exposure of multiple ligands on the nanoparticle surface, which 
results in an avidity due to multivalent interactions [99-101]. Moreover, the 
combination of different ligands, binding to different surface-receptors of the target-
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cells, can enhance both the internalization rate as well as the selectivity of the 
delivery devices [102-104].  
In case of positively charged polyplexes, the selectivity due to the usage of targeting 
ligands can partly be impaired by unspecific ionic interactions. Therefore, the 
introduction of targeting ligands is frequently combined with the attachment of 
hydrophilic molecules, which shield the surface potential from the exterior 
environment. The most common shielding agent is polyethylene glycol (PEG), which 
efficiently reduces unspecific interactions with non-target cells or blood components 
and increases the circulation time of nanoparticles [105]. However, some safety 
concerns about the use of PEG in repeatedly administered drug formulations have 
been raised. The non-biodegradability and tissue accumulation of PEG, as well as 
the formation of anti-PEG antibodies [106, 107] gave reason for the investigation of 
alternatives. Examples for alternative hydrophilic polymers, used in the context of 
nucleic acid delivery, are hydroxyethyl starch (HES), polysarcosine or poly[N-(2-
hydroxypropyl) methacrylamide] (polyHPMA) [108-110].  
 
1.2.3 Endosomal escape 
After cellular uptake by an endocytic process, the next barrier within the delivery 
pathway is represented by endosomes. These intracellular vesicles are the major site 
for the sorting, trafficking and recycling of endocytosed material [111, 112]. Vacuolar 
ATPases (V-ATPases) generate a proton gradient with a lumenal pH between 
approx. 5.9 and 6.5 of early endosomes (sorting endosomes and endocytic recycling 
compartment) and down to pH 5.0 of late endosomes and lysosomes [112]. The 
entrapped polyplexes have to be released from the vesicles to reach the site of 
action and to evade recycling to the cell membrane or degradation in late endo- and 
lysosomes. The endosomal escape is considered to be a major limitation for the 
intracellular delivery of macromolecules. Several strategies have been exploited in 
order to improve the endosomal escape of non-viral nucleic acid carriers, such as the 
conjugation of endosome-disruptive adenovirus [113], incorporation of lytic or 
fusogenic peptides (e.g. hemagglutinin derived Inf7 [114, 115], melittin from apitoxin 
[116, 117], synthetic KALA or GALA [118-120]), hydrophobic membrane 
destabilization [121] or photochemical internalization [122, 123]. Lysosomotropic 
   Introduction 
8 
chloroquine is widely used as an endosomolytic cell culture agent to enforce the 
endosomal escape in vitro [124-126]. However, nucleic acid delivery systems 
containing chloroquine or other quinolone derivatives as an integral part have also 
been developed [127, 128]. The rather weak and hydrophobic base chloroquine can 
enter endo- and lysosomes, gets protonated and thereby accumulates in the acidic 
vesicles. Hypothesized mechanisms for the enhanced endosomal escape are the 
generation of osmotic pressure and vesicle swelling as well as the inhibition of 
endosome maturation due to pH buffering [111, 129]. In contrast to several other 
basic, nucleic acid binding polymers, polyethylenimine (PEI) exhibits a potent intrinsic 
endosomal escape performance and high transfection efficiency. The proposed 
mechanism relies on the presence of unprotonated basic groups at physiological pH, 
which generate a buffer capacity in the acidic endosomal environment. Buffering of 
the endosomal pH triggers an intensified active transport of protons by V-ATPases, 
accompanied by the passive diffusion of chloride counterions. In consequence of the 
increased osmotic pressure, water flows into the vesicles, causes endosome swelling 
and finally rupture. A simplified illustration of the described ‘proton-sponge' 
mechanism, first proposed be Jean-Paul Behr [130], is shown in Scheme 1.3.  
 
Scheme 1.3 The hypothesized proton-sponge effect, facilitating endosomal escape due to osmotic 
pressure and vesicle burst 
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Mechanistic studies, supporting the proton-sponge hypothesis, have been reported. 
Kichler et al. investigated the impact of endosome acidification on PEI mediated gene 
transfer [131]. The use of V-ATPase inhibitors during PEI-transfections displayed a 
clear dependancy of reporter gene expression on endosomal acidification. Moreover, 
since PEI did not exhibit a hemolytic activity in erythrocyte leakage assays at neutral 
or acidic pH, the underlying mechanism indeed seems to be different from those of 
lytic or fusogenic peptides. Various reports about beneficial effects of an increased 
endosomal buffer capacity on endosomal escape and transfection efficiency can be 
found in the literature [65, 132-134]. Histidines or other imidazole derivatives with a 
pKa around 6 have been shown to be useful motifs for an increase of endosomal 
buffer capacity [132-134]. However, there is also some debate about mechanistic 
details of the proton-sponge hypothesis [135-138]. Alternative mechanisms suggest a 
protonation-dependent membrane permeabilisation due to the interaction with 
cationized polyplexes, rather than complete osmotic burst of the vesicles [136, 137]. 
But also in this case a proton-sponge driven increase of osmotic pressure and 
membrane tension could be part of the mechanism [136].  
 
1.2.4 Intracellular trafficking and cargo release 
Depending on the type of transported nucleic acid, the site of action differs. Delivery 
of pDNA or splice-correcting oligonucleotides has its destination in the nucleus, 
whereas the targets of antisense therapeutics, siRNA or miRNA are located in the 
cytosol. Capecchi reported that transgene expression can be observed in 50-100 % 
of cells treated with a direct intranuclear microinjection of DNA, whereas the 
efficiency of cytoplasmic injections was less than 0.1 % [139]. This makes clear that 
DNA has to be guided to the nucleus. Fortunately, polyplexes can mediate nuclear 
uptake of DNA with efficiencies depending on the individual transfecting agents [140-
142]. In addition, there have been several attempts to further enhance the DNA 
transfection efficiency by the conjugation of nuclear localization signal (NLS) peptides 
[143, 144]. However, the detailed mechanisms of intracellular trafficking and peptide 
directed nuclear entry are not entirely clear and the benefit of NLS peptides on gene 
transfer is controversial [145-147]. 
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As mentioned in chapter 1.2.1, the polyplex stability is a critical issue - also in context 
of intracellular trafficking and cargo release. Since the nucleic acid has to be liberated 
at the target site, high stability and strong binding does not necessarily correlate with 
transfection efficiency. Itaka et al. reported intracellular trafficking studies of pDNA 
polyplexes with poly-L-lysine (PLL), linear PEI (LPEI) or branched PEI (BPEI). In 
contrast to PLL, both LPEI and BPEI were capable of mediating endosomal escape, 
but differed in the subsequent pDNA release. The disintegration of LPEI polyplexes 
correlated with a higher and faster transgene expression compared to the BPEI 
polyplexes with restricted cargo release [148]. For this reason, the particle firmness 
has to be balanced between a sufficient extracellular polyplex stability, but fast and 
complete nucleic acid release at the target site. An elaborate approach to combine 
these opposing prerequisites is represented by ‘smart’ delivery vehicles with dynamic 
response to environmental changes, such as the translocation into the cell. The 
approx. 100- to 1000-fold elevated intracellular glutathione (GSH) levels generate a 
reduction potential, which can serve as a stimulus for a redox-driven disassembly of 
nucleic acid carriers [149]. Widely used structural motifs for this purpose are 
bioreducible disulfide-crosslinks [149-151]. It has been shown in numerous cases 
that the integration of thiols or disulfide-bridges can offer several advantages, such 
as polyplex stabilization, redox-triggered disassembly and a reduction of cytotoxicity 
due to the biodegradability into smaller units [74-76, 152-155]. 
 
1.3 Sequence-defined nucleic acid carriers 
As described in chapter 1.2, several barriers have to be overcome within the nucleic 
acid delivery pathway. Just like natural viruses, artificial nucleic acid carriers have to 
be multifunctional, bioresponsive to a changing environment and precise [55]. 
However, the production of multifunctional materials and the investigation of clear-cut 
structure-activity relationships require a precise synthetic strategy and definite 
compound identification. The properties of a macromolecular compound are not 
necessarily determined alone by the presence of certain subunits. The exact size, 
topology (linear, branched, comb, dendrimeric, etc.) and order of subunits can play 
additional important roles for the biological activity [156-159]. In case of oligomers 
with multiple different subunits, a maximal degree of precision is achieved by 
   Introduction 
11 
‘sequence-definition’, where a sequence can be used for the unique compound 
identification and definite discrimination between isomers. It provides all compound 
information and descriptive parameters, such as the monodisperse molecular weight, 
exact monomer order, orientation and topology. Especially in context of synthetic 
materials for clinical application and their regulatory compliance, this high degree of 
precision, reproducibility and compound identification is desirable.  
New polymerization strategies have shown their applicability for the production of 
multifunctional, ‘well-defined’ polymers for nucleic acid delivery [160-163]. This high 
degree of definition generally implies a narrow size-distribution, low polydispersity, 
controlled architecture and subunit composition. Nevertheless, microstructures, such 
as the exact order of monomers and subunits, are still hard to control in statistical 
polymerization reactions [164]. Therefore, the expression ‘sequence-defined‘ 
suggests a sequential assembly of the compounds. Recently, an intriguing concept of 
template-assisted synthesis has been reported, where monomers are converted into 
sequence-defined oligomers in a single step due to a sequence-specific pre-
arrangement at a DNA template [165]. But also here, at least the template, which 
provides the sequence information, has to be prepared in a sequential manner. Solid-
phase peptides synthesis, invented by Robert Bruce Merrifield [166], is a famous 
example of a highly efficient sequential oligomer synthesis. Hartmann et al. 
developed a solid-phase supported synthesis of sequence-defined 
oligo(amidoamines) by alternating coupling of diacids and diamines [167, 168]. 
Schaffert et al. extended this strategy by establishing artificial polyamino acids (PAA) 
with appropriate protecting groups for complete compatibility with common Fmoc 
solid-phase synthesis (SPS) [169]. Scheme 1.4 shows the chemical structures of the 
polyamino acids in protected and unprotected form; scheme 1.5 represents a 
simplified illustration of the SPS approach.  
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Scheme 1.4 Artificial polyamino acids for the SPS of sequence-defined oligo(ethanamino)amides 
 
Gtt, glutaryl-triethylene tetramine; Stp, succinyl-tetraethylene pentamine; Gtp, glutaryl-tetraethylene pentamine; 
Sph, succinyl-pentaethylene hexamine.  
 
 
Scheme 1.5 Illustration of the Fmoc SPS approach  
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Using the artificial PAA building blocks together with commercially available Fmoc α-
amino acids, a multitude of sequence-defined oligo(ethanamino)amides has been 
synthesized. Scheme 1.6 shows examples of some published oligomer architectures. 
Reported topologies, which were realized with the SPS strategy, include oligomers 
with linear [154, 170], two-arm [115], three-arm [170], four-arm [155] and comb 
architectures [159] as well as PEGylated two-arm compounds with targeting ligands 
[115, 126]. Branching points were introduced by lysines, which provide two amines 
after deprotection during synthesis. Additional cysteines served for the lateral 
polyplex stabilization based on the formation of bioreducible disulfides.  
 
Scheme 1.6 Examples of published oligomer topologies realized by the SPS strategy 
 
PAA, polyamino acid; A, alanine; C, cysteine; K, lysine.  
 
1.4 Aims of the thesis 
Despite expectations that therapeutic nucleic acids will be innovative 
biopharmaceuticals with diverse clinical applications, only a few examples have so 
far received marketing authorization. A major hurdle for the development of nucleic 
acid based drugs is the safe and efficient intracellular delivery. Polymer-based 
nucleic acid carriers face several barriers within their delivery pathway. Particularly 
critical steps are stable nucleic acid complexation, cellular uptake, endosomal escape 
and intracellular cargo release at the target site. Therefore, efficient nucleic acid 
carriers have to combine multiple functionalities, which are optimized to overcome 
each of the separate hurdles. The recently established solid-phase synthesis platform 
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for the assembly of sequence-defined oligo(ethanamino)amides allows the design of 
nucleic acid carriers with precise architectures, containing different modules and 
functionalities. Using this modular assembly approach, the thesis focuses on the 
optimization of the proton-sponge activity and specific receptor-mediated uptake of 
polyplexes.  
The first aim of the thesis was the development of strategies to modulate the 
endosomal buffering of oligo(ethanamino)amides and the investigation of their impact 
on gene transfer efficiency. For this purpose, the individual protonation 
characteristics of different polyamino acid building blocks and the influence of 
additional heterocyclic amino acids with low pKa, such as histidine and pyridylalanine, 
had to be examined. The oligomer basicity and endosomal protonation was to be 
correlated with the activity in different stages of pDNA delivery, especially the 
endosomal escape. The structure-activity relationship studies aimed at the 
identification of important parameters and suitable strategies to achieve a beneficial 
endosomal buffering and enhanced proton-sponge activity of pDNA polyplexes in 
vitro and in vivo. 
The second aim was the combination of the sequence-defined 
oligo(ethanamino)amides with a set of heterogeneous receptor-targeting ligands to 
investigate the compatibility of the nucleic acid carrier platform with ligands of diverse 
chemical nature. Peptides, a protein, multivalent carbohydrates and small molecules 
were to be used as ligands. After establishment of required synthetic strategies, the 
most potent candidate within each group had to be identified in structure-activity 
relationship studies.  
As a final aim, the results of the two separate optimization processes were to be 
combined in selected cases to generate efficient nucleic acid carriers with improved 
proton-sponge activity and a receptor-specific targeting.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Solvents and reagents 
For all experimental procedures solvents and reagents in high quality were used. 
Table 2.1 and 2.2 summarize the used solvents and reagents together with their 
unique CAS numbers and the sources of supply.   
 
Table 2.1 Solvents used for experimental procedures  
Solvent CAS-No. Source 
1,4-Dioxane1 123-91-1 BASF (Ludwigshafen a. Rh., Germany)a 
Acetonitrile2 75-05-8 VWR Int. (Darmstadt, Germany) 
Chloroform3 67-66-3 VWR Int. (Darmstadt, Germany) 
Chloroform-d4 865-49-6 Euriso-Top (Saint-Aubin Cedex, France) 
Deuterium oxide4 7789-20-0 Euriso-Top (Saint-Aubin Cedex, France) 
Dichloromethane5  75-09-2 Bernd Kraft (Duisburg, Germany) 
N,N-Dimethylformamide6  68-12-2 Iris Biotech (Marktredewitz, Germany) 
Dimethyl sulfoxide7 67-68-5 Sigma-Aldrich (Munich, Germany) 
Ethanol absolute5 64-17-5 VWR Int. (Darmstadt, Germany) 
Ethyl acetate8 141-78-6 Staub & Co. (Nürnberg, Germany) 
n-Heptane1 142-82-5 Grüssing (Filsum, Germany) 
n-Hexane1 110-54-3 Brenntag (Mülheim/Ruhr, Germany) 
Methanol5 67-56-1 Fisher Scientific (Schwerte, Germany) 
Methanol-d4
4 811-98-3 Euriso-Top (Saint-Aubin Cedex, France) 
Methyl-tert-butyl ether9 1634-04-4 Brenntag (Mülheim/Ruhr, Germany) 
N-Methyl-2-pyrrolidone6 872-50-4 Iris Biotech (Marktredewitz, Germany) 
Tetrahydrofuran5 109-99-9 Fisher Scientific (Schwerte, Germany) 
Water10 7732-18-5 In house purification 
1
 purissimum; 
2
 HPLC grade; 
3
 DAB grade, distilled before use; 
4
 NMR grade (> 99.9 %); 
5
 analytical grade;            
6
 peptide grade; 
7
 BioReagent grade (> 99.9 %); 
8
 purum, distilled before use; 
9
 synthesis grade, distilled before 
use; 
10
 purified, deionized; 
a
 1,4-Dioxane was kindly provided by BASF as donation to the LMU.  
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Table 2.2 Reagents used for experimental procedures 
Reagent CAS-No. Source 
1,3-Diaminopropane · 2 HCl 10517-44-9 Sigma-Aldrich (Munich, Germany) 
1,4-Diaminobutane · 2 HCl 333-93-7 Sigma-Aldrich (Munich, Germany) 
1,5-Diaminopentane · 2 HCl 1476-39-7 Sigma-Aldrich (Munich, Germany) 
1,6-Diaminohexane 124-09-4 Alfa Aesar (Karlsruhe, Germany) 
1-Hydroxybenzotriazole hydrate 123333-53-9 Sigma-Aldrich (Munich, Germany) 
2,2,2-Trifluoroethylamine · HCl 373-88-6 Alfa Aesar (Karlsruhe, Germany) 
2-Chlorotritylchloride resin 42074-68-0 Iris Biotech (Marktredewitz, Germany) 
4-[[(2,4-diamino-6-pteridinyl) 
methyl]methylamino] benzoic 
acid 
19741-14-1 Clauson-Kass A/S (Farum, Denmark) 
Alexa Fluor® 488 NHS ester - Life Technologies (Darmstadt, Germany) 
Ammoniumhydroxide solution 1336-21-6 Carl Roth (Karlsruhe, Germany) 
Boc-L-Cys(Trt)-OH 21947-98-8 Iris Biotech (Marktredewitz, Germany) 
Boric acid 10043-35-3 Sigma-Aldrich (Munich, Germany) 
BPEI 25987-06-8 Sigma-Aldrich (Munich, Germany) 
Bromophenol blue 115-39-9 Sigma-Aldrich (Munich, Germany) 
Chloroacetic acid 79-11-8 Sigma-Aldrich (Munich, Germany) 
Chloroquine diphosphate 50-63-5 Sigma-Aldrich (Munich, Germany) 
D-(+)-Glucose monohydrate 14431-43-7 Merck Millipore (Darmstadt, Germany) 
DBCO-PEG5-NHS - Jena Bioscience (Jena, Germany) 
DBU 6674-22-2 Sigma-Aldrich (Munich, Germany) 
Dde-L-Lys(Fmoc)-OH 156648-40-7 Iris Biotech (Marktredewitz, Germany) 
Diethylene triamine 111-40-0 Sigma-Aldrich (Munich, Germany) 
EDTA disodium salt dihydrate 6381-92-6 Sigma-Aldrich (Munich, Germany) 
Ethylene diamine 107-15-3 Sigma-Aldrich (Munich, Germany) 
Fmoc-L-5ANV-OH 1097192-04-5 Sigma-Aldrich (Munich, Germany) 
Fmoc-L-3PAL-OH 175453-07-3 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-4PAL-OH 169555-95-7 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Ala Wang resin LL - Merck Millipore (Darmstadt, Germany) 
Fmoc-L-Ala-OH 35661-39-3 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Arg(Pbf)-OH 154445-77-9 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Asp(OtBu)-OH 71989-14-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Cys(Trt)-OH 103213-32-7 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Glu-OtBu 84793-07-7 Merck Millipore (Darmstadt, Germany) 
Fmoc-L-Gly-OH 29022-11-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-His(Trt)-OH 109425-51-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Ile-OH 71989-23-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Leu-OH 35661-60-0 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Boc)-OH 71989-26-9 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Fmoc)-OH 78081-87-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(ivDde)-OH 204777-78-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Phe-OH 35661-40-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Pro-OH monohydrate 71989-31-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Ser(tBu)-OH 71989-33-8 Iris Biotech (Marktredewitz, Germany) 
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Fmoc-L-Trp(Boc)-OH 43824-78-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Tyr(tBu)-OH 71989-38-3 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Val-OH 68858-20-8 Iris Biotech (Marktredewitz, Germany) 
Fmoc-N-amido-dPEG24-acid 756526-01-9 Quanta Biodesign (Powell, Ohio, USA) 
Fmoc-OSu 82911-69-1 Iris Biotech (Marktredewitz, Germany) 
GelRed - Biotium Inc. (Hayward, CA, USA) 
HBTU 94790-37-1 Multisyntech (Witten, Germany) 
HEPES 7365-45-9 Biomol (Hamburg, Germany) 
Hydrazine monohydrate 7803-57-8 Sigma-Aldrich (Munich, Germany) 
Hydrochloric acid solution (1 M) 7647-01-0 Sigma-Aldrich (Munich, Germany) 
Iminodiacetic acid 142-73-4 Sigma-Aldrich (Munich, Germany) 
LPEI 9002-98-6 In house synthesis [89] 
Methylamine · HCl 593-51-1 Sigma-Aldrich (Munich, Germany) 
Methyliminodiacetic acid 4408-64-4 Sigma-Aldrich (Munich, Germany) 
MTT 298-93-1 Sigma-Aldrich (Munich, Germany) 
N,N’-Dicyclohexylcarbodiimide 538-75-0 Sigma-Aldrich (Munich, Germany) 
N,N-Diisopropylethylamine 7087-68-5 Iris Biotech (Marktredewitz, Germany) 
N10-(Trifluoroacetyl)pteroic acid 37793-53-6 Clauson-Kass A/S (Farum, Denmark) 
Ninhydrin 485-47-2 Sigma-Aldrich (Munich, Germany) 
Pentaethylene hexamine 4067-16-7 Sigma-Aldrich (Munich, Germany) 
Phenol 108-95-2 Sigma-Aldrich (Munich, Germany) 
Piperidine 110-89-4 Iris Biotech (Marktredewitz, Germany) 
Poly-L-arginine · HCl 26982-20-7 Sigma-Aldrich (Munich, Germany) 
Poly-L-histidine 26062-48-6 Sigma-Aldrich (Munich, Germany) 
Poly-L-lysine · HBr 25988-63-0 Sigma-Aldrich (Munich, Germany) 
Potassium cyanide 151-50-8 Sigma-Aldrich (Munich, Germany) 
Pybop® 128625-52-5 Multisyntech GmbH (Witten, Germany) 
Pyridine 110-86-1 Sigma-Aldrich (Munich, Germany) 
Sephadex® G-10 9050-68-4 GE Healthcare (Freiburg, Germany) 
Sodium hydroxide (anhydrous) 1310-73-2 Sigma-Aldrich (Munich, Germany) 
Sodium hydroxide solution 
(0.05 M) 
1310-73-2 Sigma-Aldrich (Munich, Germany) 
Superdex® 75 Prep Grade - GE Healthcare (Freiburg, Germany) 
Tetraethylene pentamine · 5HCl 4961-41-5 Sigma-Aldrich (Munich, Germany) 
Triethylamine 121-44-8 Sigma-Aldrich (Munich, Germany) 
Triethylene tetramine 112-24-3 Sigma-Aldrich (Munich, Germany) 
Trifluoroacetic acid 76-05-1 Iris Biotech (Marktredewitz, Germany) 
Triisopropylsilane 6485-79-6 Sigma-Aldrich (Munich, Germany) 
Triton™ X-100 9002-93-1 Sigma-Aldrich (Munich, Germany) 
Trizma® base 77-86-1 Sigma-Aldrich (Munich, Germany) 
 
 
 
 
   Materials and Methods 
18 
2.1.2 Buffers 
Table 2.3 gives an overview over used buffers and their composition. 
 
Table 2.3 Buffers used for experimental procedures 
Buffer Composition 
Electrophoresis loading Buffer 
6 mL glycerine, 1.2 mL 0.5 M EDTA solution (pH 8.0),  
2.8 mL H2O, 20 mg bromophenol blue 
  
HBG 20 mM HEPES, 5 % glucose, pH 7.4 
  
TBE buffer 89 mM Trizma® base, 89 mM boric acid, 2 mM EDTA-Na2 
 
 
2.1.3 Equipment for solid-phase synthesis 
Automated single peptide synthesis at room temperature (RT) was carried out using 
an ABI 431A peptide synthesizer (Applied Biosystems, Foster City, CA, USA). For 
the automated parallel synthesis or synthesis with microwave irradiation, a Biotage 
Syro Wave (Biotage AB, Uppsala, Sweden) peptide synthesizer was used. 
Disposable polypropylene (PP) syringe microreactors with the volume sizes 2 mL, 5 
mL, and 10 mL were purchased from Multisyntech (Witten, Germany). Manual solid-
phase synthesis was carried out on a laboratory vacuum manifold (Promega 
Corporation, Madison, WI, USA) using microreactors with polyethylene filters for 
vacuum filtration. The automated synthesis with the Biotage Syro Wave synthesizer 
was conducted with polytetrafluoroethylene (PTFE) filters. The size of the reactors 
was chosen according to the resin amount. 
 
2.1.4 Proteins 
Recombinant murine epidermal growth factor (mEGF) was purchased from 
PeproTech Germany (Hamburg, Germany).  
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2.1.5 Nucleic acids 
The plasmid pCMVLuc (encoding for firefly luciferase under control of the CMV 
promoter) was purchased from Plasmid Factory (Bielefeld, Germany) for in vivo 
experiments. For in vitro experiments pCMVLuc was amplified in E. coli DH5α and 
purified from the bacterial lysate using a Qiagen Plasmid Giga Kit (Qiagen, Hilden, 
Germany). Poly(I:C) sodium salt and poly(I) potassium salt were purchased from 
Sigma-Aldrich (Munich, Germany). The concentration of nucleic acid solutions was 
determined photometrically using an Eppendorf BioPhotometer (Eppendorf, 
Hamburg, Germany). Cy5-labeled nucleic acids were produced with a Cy5-labelling 
kit obtained from Mirus Bio (Madison, WI, USA). 
 
2.1.6 Cell culture  
Cell culture work was carried out by Dr. Petra Kos, Ana Krhac Levacic, Katharina 
Müller (Pharmaceutical Biotechnology, LMU) and Valentin Wittmann (graduate 
student, LMU). All cell culture media, antibiotics and fetal calf serum (FCS) were 
purchased from Invitrogen (Karlsruhe, Germany). The individual media used for the 
different cell cultures are summarized in Table 2.4. All media were supplemented 
with 10 % FCS, 4 mM stable glutamine, 100 U/mL penicillin and 100 μg/mL 
streptomycin. Exponentially growing cells were detached from the culture flasks using 
trypsin-EDTA solution (Invitrogen, Karlsruhe, Germany) and cell suspensions were 
seeded at the desired density for each experiment. Luciferase cell culture lysis buffer 
and D-luciferin sodium salt were purchased from Promega (Mannheim, Germany). 
 
Table 2.4 Overview over the used cell lines and culture media  
Cell line Description Medium 
DU145 Human prostate cancer cells RPMI-1640 
Huh7 Human hepatocellular carcinoma cells DMEM/Ham's F12 1:1 
KB Human cervix carcinoma cells RPMI-1640, folate-free 
Neuro2A Mouse neuroblastoma cells DMEM 
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2.2 Methods 
2.2.1 Synthesis of polyamino acid building blocks 
Scheme 2.1 illustrates the approach for the synthesis of the polyamino acid (PAA) 
building blocks. Fmoc-Gtt(Boc2)-OH, Fmoc-Stp(Boc3)-OH, Fmoc-Gtp(Boc3)-OH and 
Fmoc-Sph(Boc4)-OH were synthesized as described before [155, 169]. Briefly, the 
two primary amines of the polyamines 1 (TETA, TEPA or PEHA) were selectively 
protected with ethyl trifluoroacetate (EtOTFA). Subsequently the remaining 
secondary amines were Boc-protected by reaction with di-tert-butyl dicarbonate 
(Boc2O) in a one-pot reaction. Work-up and recrystallization gave the compounds 2, 
bis-tfa-Tt(Boc2), bis-tfa-Tp(Boc3) or bis-tfa-Ph(Boc4) respectively. The primary amines 
were deprotected by alkaline hydrolysis with aqueous NaOH containing 45 % EtOH 
to obtain the compounds 3, Tt(Boc2), Tp(Boc3) or Ph(Boc4). In the final step, the two 
primary amines were asymmetrically substituted by reaction with a cyclic anhydride 
(succinic or glutaric anhydride) and Fmoc-OSu. Purification of the products 4a was 
carried out by dry column vacuum chromatography (DCVC) [171].  
 
Scheme 2.1 Synthesis of Fmoc polyamino acid building blocks for SPS, adapted from [155, 169]  
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In case of the IDA derived building blocks 4b, TEPA (n=3) was used as the 
polyamine element. The first steps to obtain Tp(Boc3) were carried out in the same 
manner as published for the other building blocks. In the last step, IDA derived 
anhydrides were used instead of succinic or glutaric anhydride, and the published 
synthesis protocol was adapted without additional modification.  
 
2.2.1.1 Synthesis of Fmoc-Boc-IDAtp(Boc3)-OH 
N-(tert-Butoxycarbonyl)iminodiacetic acid (Boc-IDA) 
 
 
N-tert-Butoxycarbonyl protected iminodiacetic acid (Boc-IDA) was synthesized using 
the procedure reported elsewhere [172] with slight modification. Briefly 13.3 g 
iminodiacetic acid (0.1 mol) and 200 mL 1,4-dioxane were put into a 1 L round-
bottom flask. 200 mL of 1 M sodium hydroxide solution were added and the mixture 
was stirred until a clear solution formed. 24.0 g of di-tert-butyl dicarbonate (0.11 mol, 
1.1 eq) were dissolved in 50 mL 1,4-dioxane and added to the reaction mixture, 
which was stirred at RT for 72 h. The mixture was concentrated to approx. 200 mL 
under reduced pressure, washed twice with 150 mL diethyl ether. After acidification 
with 100 mL 10 % HCl, the reaction product was extracted with EtOAc (3 x 150 mL). 
The organic phases were combined and dried over anhydrous sodium sulfate. The 
EtOAc was evaporated after filtration, yielding 22.3 g of Boc-IDA (0.096 mol, 96 %) 
as white crystals.  
1H-NMR (400 MHz, methanol-d4) δ = 1.44 (s, 9H, -CH3), 3.99 (s, 2H, -CH2-), 4.04 (s, 
2H, -CH2-).  
ESI-MS: [M-H]- calcd for C9H15NO6 232.0827; found 232.0826.  
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N-(tert-Butoxycarbonyl)iminodiacetic acid anhydride (Boc-IDA anhydride) 
 
 
The cyclic anhydride of Boc-IDA was prepared by using dicyclohexylcarbodiimide 
(DCC) as dehydrating agent. 10.0 g of Boc-IDA (43 mmol) were put into a 500 mL 
round-bottom flask and 250 mL DCM were added. 8.9 g of DCC (43 mmol, 1 eq) 
were dissolved in 50 mL DCM and added into the round-bottom flask. The 
heterogeneous mixture was stirred at RT over night. The next day the mixture was 
concentrated to a volume of approx. 100 mL under reduced pressure and the 
insoluble dicyclohexyl urea was removed by filtration. The DCM was removed in the 
rotary evaporator and at high vacuum to yield 8.4 g of Boc-IDA anhydride (39 mmol, 
91 %) as a solid.   
  
Fmoc-Boc-IDAtp(Boc3)-OH 
 
 
Fmoc-Boc-IDAtp(Boc3)-OH was prepared by adaption of the published protocol for 
the synthesis of Fmoc-Stp(Boc3)-OH and Fmoc-Gtp(Boc3)-OH [169] using Boc-IDA 
anhydride instead of succinic or glutaric anhydride. 13.5 g Tp(Boc3) (27.6 mmol) were 
dissolved in 50 mL THF and cooled to -78 °C in a dry ice/acetone cooling bath. 7.4 g 
of Boc-IDA anhydride (34.4 mmol, 1.25 eq) were dissolved in 400 mL THF and added 
dropwise to the cooled solution over a period of 2 hours. After complete addition, the 
solution was stirred for 1 h at -78 °C and for 1 h at RT. 14.4 mL DIPEA (82.7 mmol, 3 
eq) were added and the reaction mixture was cooled to 0 °C in an ice bath. 14.0 g 
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Fmoc-OSu (41.5 mmol, 1.5 eq) were dissolved in 60 mL MeCN and 30 mL THF and 
added dropwise to the cooled reaction mixture, which was stirred over night. The 
solution was concentrated to approx. 50 mL and 100 mL DCM were added. The 
solution was washed 5 times with 100 mL trisodium citrate buffer (0.1 M, pH 5.5) and 
dried over anhydrous sodium sulfate. The reaction product was purified by DCVC 
using a n-heptane/EtOAc gradient followed by an EtOAc/MeOH gradient yielding 6.9 
g Fmoc-Boc-IDAtp(Boc3)-OH (7.4 mmol, 27 %) as a white foamy solid. 
1H-NMR (400 MHz, chloroform-d) δ = 1.42 (s, 36H, -CH3 Boc), 3.08-3.52 (m, 16H, -
CH2- TEPA), 3.89 (s, 4H, -CH2- IDA), 4.18 (t, J = 7 Hz, 1H, Fmoc), 4.25-4.46 (m, 2H, 
Fmoc), 7.29 (d, J = 7.5 Hz, 2H, Ar-H Fmoc), 7.38 (t, J = 7.5 Hz, 2H, Ar-H Fmoc), 7.56 
(d, J = 7.5 Hz, 2H, Ar-H Fmoc), 7.74 (d, J = 7.7 Hz, 2H, Ar-H Fmoc).   
ESI-MS: [M-H]- calcd for C47H70N6O13 925.4928; found 925.4910. 
 
2.2.1.2 Synthesis of Fmoc-M-IDAtp(Boc3)-OH 
Methyliminodiacetic acid anhydride (M-IDA anhydride) 
 
 
The cyclic anhydride of methyliminodiacetic acid (M-IDA) was prepared analogously 
to Boc-IDA anhydride (cf. 2.2.1.1) by using DCC. 5.0 g of M-IDA (34 mmol) were put 
into a 250 mL round-bottom flask and 180 mL DCM were added. 7.0 g of DCC (34 
mmol, 1 eq) were dissolved in 30 mL DCM and added into the round-bottom flask. 
The mixture was stirred at RT over night. The mixture was concentrated to a volume 
of approx. 80 mL under reduced pressure and the insoluble dicyclohexyl urea was 
removed by filtration. DCM was evaporated to yield 3.6 g of M-IDA anhydride (28 
mmol, 82 %) as a solid.   
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Fmoc-M-IDAtp(Boc3)-OH  
 
 
Fmoc-M-IDAtp(Boc3)-OH was prepared analogously to Fmoc-Boc-IDAtp(Boc3)-OH 
(cf. 2.2.1.1). 9.1 g Tp(Boc3) (18.6 mmol) were dissolved in 30 mL THF and cooled to  
-78 °C in a dry ice/acetone cooling bath. 3.0 g of M-IDA anhydride (23.2 mmol, 1.25 
eq) were dissolved in 250 mL THF and added dropwise to the cooled solution over a 
period of 2 hours. After complete addition, the solution was stirred for 1 h at -78 °C 
and for 1 h at RT. 9.7 mL DIPEA (55.8 mmol, 3 eq) were added and the reaction 
mixture was cooled to 0 °C in an ice bath. 9.4 g Fmoc-OSu (27.9 mmol, 1.5 eq) were 
dissolved in 40 mL MeCN and 20 mL THF and added dropwise to the cooled reaction 
mixture, which was stirred over night. The solution was concentrated to approx. 50 
mL and 100 mL DCM were added. The solution was washed 5 times with 100 mL 
trisodium citrate buffer (0.1 M, pH 5.5) and dried over anhydrous sodium sulfate. The 
reaction product was purified by DCVC using a n-heptane/EtOAc gradient followed 
by an EtOAc/MeOH gradient yielding 4.4 g Fmoc-M-IDAtp(Boc3)-OH (5.2 mmol, 28 
%) as an amber foamy solid. 
1H-NMR (400 MHz, chloroform-d) δ = 1.42 (s, 27H, -CH3 Boc), 2.29-2.41 (m, 3H,        
-CH3 M-IDA), 2.97-3.55 (m, 20H, -CH2- TEPA, -CH2- M-IDA), 4.17 (t, J = 7.1 Hz, 1H, 
Fmoc), 4.25-4.46 (m, 2H, Fmoc), 7.28 (d, J = 7.7 Hz, 2H, Ar-H Fmoc), 7.37 (t, J = 7.5 
Hz, 2H, Ar-H Fmoc), 7.56 (d, J = 7.8 Hz, 2H, Ar-H Fmoc), 7.74 (d, J = 7.5 Hz, 2H,  
Ar-H Fmoc). 
ESI-MS: [M-H]- calcd for C43H64N6O11 839.4560; found 839.4548. 
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2.2.1.3 Synthesis of Fmoc-TFE-IDAtp(Boc3)-OH 
 
N-(Trifluoroethyl)iminodiacetic acid (TFE-IDA) 
 
 
TFE-IDA was prepared by modification of a published protocol for the synthesis of 
methyliminodiacetic acid [173]. 27.9 g chloroacetic acid (295.2 mmol, 2 eq) were 
placed in a 500 mL round-bottom flask. 22 mL H2O were added and the flask was 
cooled in an ice bath. A cold solution of 29.5 g NaOH (738 mmol, 5 eq) in 93 mL H2O 
was added slowly under stirring. After the complete addition, the cooling bath was 
removed and a solution of 20.0 g trifluoroethylamine hydrochloride (147.6 mmol, 1 
eq) in 65 mL H2O was added dropwise. After complete addition, the solution was 
stirred overnight. 60 g BaCl2 dihydrate in approx. 140 mL boiling H2O were added 
and the mixture was heated for 1.5 hours. The solid was filtered off and dried in the 
drying cabinet over 2 days yielding 27.6 g of TFE-IDA barium salt (78.8 mmol). The 
dry TFE-IDA barium salt was placed in 500 mL RBF. 65 mL H2O were added and 
heated to boiling. 31.5 mL of a 2.5 M H2SO4 solution (78.8 mmol) were added 
gradually over 1 hour under continuous heating to boiling. After cooling to RT, the 
mixture was centrifuged to remove the solid BaSO4. The clear supernatant was 
freeze-dried yielding 16.1 g of TFE-IDA (74.8 mmol, 51 %) as colorless crystals. 
1H-NMR (400 MHz, deuterium oxide) δ = 3.42 (q, J = 9.6 Hz, 2H, -CH2-CF3), 3.65 (s, 
4H, O=C-CH2-).  
ESI-MS: [M-H]- calcd for C6H8F3NO4 214.0333; found 214.0332. 
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N-(Trifluoroethyl)iminodiacetic acid anhydride (TFE-IDA anhydride) 
 
 
The cyclic anhydride of TFE-IDA was prepared analogously to the anhydrides of Boc-
IDA and M-IDA (cf. 2.2.1.1 and 2.2.1.2) by using DCC. 5.0 g TFE-IDA (23.2 mmol) 
were placed in a 250 mL round-bottom flask. 140 mL DCM were added. 4.8 g DCC 
(23.2 mmol, 1 eq) were dissolved in 30 mL DCM and added into the flask. The 
mixture was stirred at RT overnight. The mixture was concentrated to approx. 80 mL 
under reduced pressure and the insoluble dicyclohexyl urea was removed by 
filtration. The DCM was removed in the rotary evaporator and at high vacuum to yield 
4.3 g TFE-IDA anhydride (21.8 mmol, 94 %) as a solid. 
 
Fmoc-TFE-IDAtp(Boc3)-OH  
 
 
Fmoc-TFE-IDAtp(Boc3)-OH was prepared analogously to Fmoc-Boc-IDAtp(Boc3)-OH 
and Fmoc-M-IDAtp(Boc3)-OH (cf. 2.2.1.1 and 2.2.1.2). 7.1 g Tp(Boc3) (14.5 mmol) 
were dissolved in 30 mL THF and cooled to -78 °C in a dry ice/acetone cooling bath. 
3.6 g of TFE-IDA anhydride (18.1 mmol, 1.25 eq) were dissolved in 200 mL THF and 
added dropwise to the cooled solution over a period of 2 hours. After complete 
addition, the solution was stirred for 1 h at -78 °C and for 1 h at RT. 7.6 mL DIPEA 
(43.6 mmol, 3 eq) were added and the reaction mixture was cooled to 0 °C in an ice 
bath. 7.4 g Fmoc-OSu (21.8 mmol, 1.5 eq) were dissolved in 40 mL MeCN and 20 
mL THF and added dropwise to the cooled reaction mixture, which was stirred over 
night. The solution was concentrated to approx. 50 mL and 100 mL DCM were 
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added. The solution was washed 5 times with 100 mL trisodium citrate buffer (0.1 M, 
pH 5.5) and dried over anhydrous sodium sulfate. The reaction product was purified 
by DCVC using a n-heptane/EtOAc gradient followed by an EtOAc/MeOH gradient 
yielding 3.4 g Fmoc-TFE-IDAtp(Boc3)-OH (3.7 mmol, 26 %) as a yellow foamy solid. 
1H-NMR (400 MHz, chloroform-d) δ = 1.43 (s, 27H, -CH3 Boc), 3.06-3.67 (m, 22H, -
CH2- TEPA, -CH2- TFE-IDA), 4.18 (t, J = 7.0 Hz, 1H, Fmoc), 4.24-4.51 (m, 2H, 
Fmoc), 7.29 (d, J = 7.5 Hz, 2H, Ar-H Fmoc), 7.38 (t, J = 7.5 Hz, 2H, Ar-H Fmoc), 7.56 
(d, J = 7.7 Hz, 2H, Ar-H Fmoc), 7.75 (d, J = 7.6 Hz, 2H, Ar-H Fmoc). 
ESI-MS: [M-H]- calcd for C44H63F3N6O11 907.4434; found 907.4430. 
 
2.2.2 Resin loading  
2.2.2.1 Loading of 2-chlorotrityl resin 
The desired amount of 2-chlorotrityl chloride resin (chloride loading 1.6 mmol/g) was 
placed in a syringe reactor and preswelled in dry DCM (10 mL/g resin; dried over 
CaCl2) for 30 min, the DCM was discarded subsequently. A solution containing 0.45 
mmol Fmoc-amino acid and 0.9 mmol DIPEA (157 µL) in dry DCM (10 mL) were 
added per gram resin and incubated for 1 h at RT. After disposal of the reaction 
mixture, the resin was incubated with a mixture of DCM/MeOH/DIPEA (10 mL/g 
resin; 80/15/5 v/v/v) for 30 min at RT to cap residual reactive chloride functions. The 
resin was washed 5 times with DCM (10 mL/g resin) and a resin sample was 
separated and dried under vacuum for the loading determination. The residual resin 
was washed twice with DMF (10 mL/g resin) and treated 5 times for 10 minutes with 
20 % piperidine in DMF. Finally, the resin was washed 3 times with DMF, 3 times 
with DCM, 3 times with n-hexane and dried under vacuum. In general, by this 
procedure resin loadings between 0.28 and 0.35 mmol/g were achieved. 
 
2.2.2.2 Loading of four-arm branching core on Fmoc-Ala-Wang resin  
To avoid aggregation of the highly branched four-arm oligomers during chain 
assembly, a very low load of the four-arm branching core (AK(K)2, AK(AK)2 or 
AK(HK)2) was prepared on Ala-Wang resins. The desired amount of Fmoc-L-Ala 
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wang resin (loading 0.35 mmol/g) was placed into a syringe reactor and preswelled 
with DCM (10 mL/g resin) for 30 min. The Fmoc protecting group was removed by 
treating the resin 5 times for 10 minutes with 20 % piperidine in DMF and subsequent 
washing 3 times with DMF, 3 times with DCM (10 mL/g resin). 0.07 mmol of Fmoc-
Lys(Fmoc)-OH per gram resin (0.2 eq relative to resin amines) were dissolved 
together with equimolar amounts of HOBt, PyBop and twofold molar amount of 
DIPEA (0.4 eq, 24 µL/g resin) in DCM/DMF 50/50 (10 mL/g resin). The coupling 
solution was incubated with the resin for 1 h and discarded subsequently. The resin 
was washed 3 times with DMF, 3 times with DCM (10 mL/g resin) and residual free 
amines were acetylated by a 10-fold excess (3.5 mmol/g resin) of acetic anhydride 
(Ac2O) using a mixture of DCM/Ac2O/DIPEA (8450/330/1220 µL/g resin). After 
incubation for 1 h, the reaction mixture was discarded and the resin was washed 3 
times with DMF and 3 times with DCM (10 mL/g resin). The Fmoc protecting group 
was removed and the resin was washed as before. According to the individual 
oligomer sequence, 1.4 mmol of Fmoc-Lys(Fmoc)-OH, Fmoc-Ala-OH or Fmoc-
His(Trt)-OH per gram resin (4 eq relative to initial resin loading) were dissolved 
together with equimolar amounts of HOBt, PyBop and twofold molar amount of 
DIPEA (8 eq, 488 µL/g resin) in DCM/DMF 50/50 (10 mL/g resin). The coupling 
solution was added to the resin and incubated for 1 h. Subsequently the reaction 
mixture was discarded and the resin was washed 3 times with DMF and 3 times with 
DCM (10 mL/g resin). In case of the AK(AK)2 and AK(HK)2 cores, Fmoc was 
deprotected and the resin was washed before 1.4 mmol of Fmoc-Lys(Fmoc)-OH per 
gram resin (4 eq relative to initial resin loading), equimolar amounts of HOBt, PyBop 
and twofold molar amount of DIPEA (8 eq, 488 µL/g resin) in DCM/DMF 50/50 (10 
mL/g resin) were incubated with the resin for 1 h. The reaction mixture was discarded 
and the resin was washed 3 times with DMF and 3 times with DCM (10 mL/g resin). 
In all cases, after coupling of the second Fmoc-Lys(Fmoc)-OH and subsequent resin 
wash, resin samples were separated and dried under vacuum for the loading 
determination. The remaining resin was deprotected, washed and dried under 
vacuum for storage. In general, by this procedure resin loadings between 0.04 and 
0.05 mmol/g related to the branched alanine lysine peptide were achieved, which 
corresponds to an amine content at the four N-termini between 0.16 and 0.2 mmol/g.  
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2.2.2.3 Loading determination 
The resin loading was determined by the quantification of released fluorenyl 
derivative after piperidine deprotection. The vacuum-dried resin was weighed 
accurately (triplicates, in the range between 5 - 15 mg) into Eppendorf reaction tubes. 
1 mL of 20 % piperidine was added to each sample, which was vortexed briefly and 
incubated for 1 h at RT under shaking. Subsequently the samples were vortexed 
again and the resin was allowed to settle for 1 min. 25 µL of the supernatant were 
diluted with DMF to 1 mL. An analog dilution of 20 % piperidine in DMF served as 
blank solution. The absorption at 301 nm (A301) against the blank solution was 
determined using a Genesys 10S UV-VIS spectrophotometer (Thermo Scientific, 
Dreieich, Germany), and the resin loading was calculated for each sample according 
to the following formula. The arithmetic mean of the triplicate values was used as the 
final result of resin loading. 
𝐿 =
1000 ∙  𝐴301
𝑚 ∙  7800 ∙  𝐷
 
L, resin loading [mmol/g]; A301, extinction at 301 nm; m, resin mass [mg]; 7800, molar extinction coefficient under 
the specified conditions [L mol
-1
 cm
-1
]; D, dilution factor (0.025).   
 
2.2.3 Standard solid-phase synthesis conditions 
2.2.3.1 General SPS algorithm 
The sequential synthesis on solid-phase was carried out in defined steps of a 
synthesis cycle. Starting with a deprotected peptide resin, Table 2.5 summarizes the 
steps of a manual synthesis cycle and Table 2.6 the steps of an automated synthesis 
cycle. After the initial resin preswell (step 0), the steps 1 to 6 in case of the manual 
synthesis and steps 1 to 4 in case of the automated synthesis were continuously 
repeated according to the oligomer sequence. In the manual synthesis, the presence 
of free amines on the solid support was determined qualitatively by the Kaiser test 
(cf. 2.2.3.2) after each deprotection and coupling step. In case of an inadequate 
result (negative after deprotection or positive after coupling), the last deprotection or 
coupling step respectively was repeated. Since the automated synthesis does not 
offer the opportunity to separate resin samples for the Kaiser test, extended 
deprotection steps and double couplings were used in this case. In the coupling 
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steps, the resin was incubated with a 4-fold excess of the appropriate preactivated 
Fmoc amino acid (Fmoc-AA) specified by the oligomer sequence. Preactivation of the 
Fmoc-AA during manual synthesis was carried out with an equimolar amount of 
HOBt (1-Hydroxybenzotriazole), equimolar amount of PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate) and a twofold molar amount of 
DIPEA. In case of the automated synthesis, HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate) was used instead of PyBOP. Incubation 
times during a coupling cycle were 60 min at RT or 10 min at 60 °C (microwave 
irradiation). Scheme 2.2 shows an illustration of the synthesis algorithms.     
 
Table 2.5 General steps of a manual synthesis cycle 
Step Description Solvent V Time 
0a Resin preswell DCM 10 mL/g resin 30 min 
     
1 Coupling  DCM/DMF 50/50 5 mL/g resinc 60 min 
     
2 Wash DMF, DCM 10 mL/g resin 
3 x 1 min DMF 
3 x 1 min DCM 
     
3b Kaiser test - - - 
     
4 Fmoc deprotection 20 % piperidine/DMF 10 mL/g resin 4 x 10 min 
     
5 Wash DMF, DCM 10 mL/g resin 
3 x 1 min DMF 
3 x 1 min DCM 
     
6b Kaiser test - - - 
     
7a Cleavage 
TFA/TIS/H2O 
95/2.5/2.5 
10 mL/g resin 90 min 
a
 Initial resin preswell (step 0) and terminal cleavage (step 7) were only carried out once during a synthesis; steps 
1-6 were repeated according to the oligomer sequence. 
b
 In case of an inadequate result of the Kaiser test, the 
previous coupling or deprotection step respectively was repeated. 
c
 The exact volume of coupling solution was 
dependent on the resin loading and solubility of the building blocks. In case of a high loading or poor solubility, the 
minimum volume (≥ 5 mL/g resin) for complete dissolution was used.      
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Table 2.6 General steps of an automated synthesis cycle using the Biotage Syro Wave synthesizer 
Step Description Solvent V Time 
0a Resin preswell DMF 10 mL/g resin 30 min 
      
1 
Double 
coupling 
Coupling NMP/DMF 60/40 7 mL/g resin 
60 min at RT 
or 
10 min at 60 °Cb 
    
Wash DMF 8 mL/g resin 1 x 1 min 
    
Recoupling NMP/DMF 60/40 7 mL/g resin 
60 min at RT 
or 
10 min at 60 °Cb 
     
2 Wash DMF 8 mL/g resin 5 x 1 min 
     
3 Fmoc deprotection 20 % piperidine/DMF 7 mL/g resin 5 x 10 min 
     
4 Wash DMF 8 mL/g resin 5 x 1 min 
     
5a Cleavage 
TFA/TIS/H2O 
95/2.5/2.5 
10 mL/g resin 90 min 
a
 Initial resin preswell (step 0) and terminal cleavage (step 7) were only carried out once in a synthesis; steps 1-4 
were repeated according to the oligomer sequence. 
b
 Microwave irradiation.  
 
2.2.3.2 Kaiser test 
The presence of free amines on the resin was determined qualitatively by the Kaiser 
test [174]. A small sample of DCM washed resin was transferred into an Eppendorf 
reaction tube. Two drops of each 80 % phenol in EtOH (w/v), 5 % ninhydrin in EtOH 
(w/v) and 20 µM potassium cyanide (KCN) in pyridine (mixture of 1 mL aqueous 
0.001 M KCN solution and 49 mL pyridine) were added. The tube was incubated at 
99 °C for 4 min under shaking. The presence of free amines was indicated by a deep 
blue color.     
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Scheme 2.2 Illustration of the SPS algorithms during (A) manual oligomer synthesis and (B) 
automated oligomer synthesis using the Biotage Syro Wave synthesizer 
 
 
2.2.3.3 Oligomer cleavage 
After complete assembly of the sequence on solid phase and final Fmoc 
deprotection, cleavage was carried out using a mixture of TFA/TIS/H2O (95/2.5/2.5 
v/v/v). The cleavage mixture (10 mL/g resin) was added to the resin in a syringe 
reactor and incubated for 90 min under shaking. The solution was collected in a 
round-bottom flask and the resin was washed 3 times with TFA, 3 times with DCM 
(10 mL/g resin). The combined solutions were concentrated under reduced pressure 
to a final volume of approximately 1 mL and added dropwise to a cold mixture of 
MTBE/n-hexane (25/25 v/v) in a 50 mL centrifuge tube. After centrifugation for 20 min 
at 4000 RCF and 4 °C, the supernatant was discarded and the precipitate was dried 
under a nitrogen stream. The crude product was dissolved in 25 % acetonitrile in 
water, snap-frozen in liquid nitrogen and freeze-dried using a Christ Alpha 2-4 LDplus 
laboratory freeze-drier (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am 
Harz, Germany).    
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2.2.4 Oligomer synthesis 
2.2.4.1 Synthesis of linear oligomers  
(Oligomers 610-615) 
The linear topology oligomers were synthesized manually in 0.03 mmol scales under 
standard Fmoc SPS conditions (cf. 2.2.3) using 2-chlorotrityl resins preloaded with 
alanine or H-His(Trt)-OH. According to the individual sequences the polyamino acid 
building blocks Fmoc-Gtt(Boc2)-OH, Fmoc-Stp(Boc3)-OH or Fmoc-Sph(Boc4)-OH 
were alternatingly coupled with Fmoc-Ala-OH or Fmoc-His(Trt)-OH. After complete 
assembly on solid-phase and final Fmoc deprotection, the oligomers were cleaved 
under standard conditions (cf. 2.2.3), purified by SEC and analyzed by 1H-NMR, RP-
HPLC and ESI-MS.   
 
2.2.4.2 Synthesis of two-arm oligomers  
(Oligomers 754-757, 811-817) 
The two-arm topology oligomers were synthesized automatically in 0.015 mmol 
scales using the parallel synthesis option of the Biotage Syro Wave synthesizer. The 
synthesis was carried out at RT under the standard SPS conditions (cf. 2.2.3) starting 
with 2-chlorotrityl resins preloaded with alanine. For the introduction of the 
symmetrical branching point, Fmoc-Lys(Fmoc)-OH was coupled. After Fmoc 
deprotection, the assembly was continued at both the α- and ε-amine of the 
branching lysine and therefore the scale size regarding resin bound amines was 
doubled. According to the individual oligomer sequences Fmoc-Gtt(Boc2)-OH, Fmoc-
Gtp(Boc3)-OH, Fmoc-Stp(Boc3)-OH, Fmoc-Boc-IDAtp(Boc3)-OH, Fmoc-M-
IDAtp(Boc3)-OH, Fmoc-TFE-IDAtp(Boc3)-OH, Fmoc-His(Trt)-OH, Fmoc-3PAL-OH, 
Fmoc-4PAL-OH and Boc-Cys(Trt)-OH were sequentially coupled. After the 
conjugation of N-terminal Boc-Cys(Trt)-OH in the last cycle, no Fmoc deprotection 
was required. The oligomers were cleaved under standard conditions (cf. 2.2.3), 
purified by SEC and analyzed by 1H-NMR and RP-HPLC.   
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2.2.4.3 Synthesis of four-arm oligomers 
(Oligomers 606-610) 
For the synthesis of four-arm topology oligomers, the standard SPS conditions were 
used with slight modification to avoid aggregation of the highly branched compounds 
during chain assembly (cf. [155]). Ala-Wang resins with a very low load (approx. 0.05 
mmol/g) of four-arm branching core (AK(AK)2 or AK(HK)2) were prepared (cf. 2.2.2.2) 
and 1 % Triton X-100 was added to the solvents of the coupling and deprotection 
steps. Beyond that, the standard SPS and cleavage procedures were followed (cf. 
2.2.3) using Fmoc-Ala-OH, Fmoc-His(Trt)-OH, Fmoc-Sph(Boc4)-OH and Boc-
Cys(Trt)-OH as building units. The oligomers were purified by SEC and analyzed by 
1H-NMR and RP-HPLC. 
   
2.2.4.4 Synthesis of four-arm HK peptides 
(Oligomers 582, 584) 
The four-arm HK peptides were synthesized by Wolfgang Rödl using the Biotage 
Syro Wave synthesizer. Ala-Wang resins with a very low load (approx. 0.05 mmol/g) 
of four-arm branching core (AK(K)2) were prepared (cf. 2.2.2.2) and 1 % Triton X-100 
was added to the solvents of the coupling and deprotection steps. Fmoc-Lys(Boc)-
OH and Fmoc-His(Trt)-OH were used according to the individual sequences. Double-
couplings were carried out under microwave irradiation (5 min, 75 °C) and Fmoc 
deprotection was accomplished by 3 times incubation for 20 min with a solution of 20 
% piperidine and 2 % DBU in DMF. After complete assembly on solid-phase and final 
Fmoc deprotection, the oligomers were cleaved under standard conditions (cf. 2.2.3), 
purified by SEC and analyzed by 1H-NMR and RP-HPLC.   
 
2.2.4.5 Synthesis of PEGylated two-arm oligomers with C-terminal alanine  
(Oligomers 188, 440, 616) 
The PEGylated two-arm oligomers with C-terminal alanine as substitute for a 
targeting ligand were synthesized manually in 0.02 – 0.05 mmol scales under 
standard Fmoc SPS conditions (cf. 2.2.3) using a 2-chlorotrityl resin preloaded with 
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alanine. Fmoc-N-amido-dPEG24-acid, Fmoc-His(Trt)-OH, Fmoc-Lys(Fmoc)-OH, 
Fmoc-Stp(Boc3)-OH and Boc-Cys(Trt)-OH were used as building units. In the first 
cycle, Fmoc-N-amido-dPEG24-acid was coupled and the synthesis was continued 
according to the individual sequences of the oligomers. After the conjugation of N-
terminal Boc-Cys(Trt)-OH in the last cycle, no Fmoc deprotection was required. The 
oligomers were cleaved under standard conditions (cf. 2.2.3), purified by SEC and 
analyzed by 1H-NMR and RP-HPLC.   
 
2.2.4.6 Synthesis of PEGylated two-arm oligomers with B6 ligand 
(Oligomers 617, 618) 
The peptidic ligand B6 (GHKAKGPRK) [175] was synthesized on a 2-chlorotrityl resin 
preloaded with H-Lys(Boc)-OH in a 0.1 mmol scale using the Applied Biosystems 
431A synthesizer with FastMoc™ protocols. Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, 
Fmoc-Gly-OH, Fmoc-His(Trt)-OH and Fmoc-Pro-OH were used for the synthesis of 
the peptide sequence. After complete assembly on solid phase and terminal Fmoc 
deprotection, the resin was divided for subsequent oligomer syntheses. The 
syntheses of PEGylated two-arm oligomers with B6 ligand were continued manually 
in 0.02 mmol scales under standard Fmoc SPS conditions (cf. 2.2.3). Fmoc-N-amido-
dPEG24-acid, Fmoc-Ala-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-
Stp(Boc3)-OH and Boc-Cys(Trt)-OH were used as building units according to the 
individual oligomer sequences. After the conjugation of N-terminal Boc-Cys(Trt)-OH 
in the last cycle, no Fmoc deprotection was required. The oligomers were cleaved 
under standard conditions (cf. 2.2.3), purified by SEC and analyzed by 1H-NMR and 
RP-HPLC. 
   
2.2.4.7 Synthesis of PEGylated two-arm oligomers with cMBP ligands 
(Oligomers 442, 443, 694-700) 
Since the cMBP ligands were intended for N-terminal positions in the oligomers, an 
inverse synthesis approach was taken. A 2-chlorotrityl resin was preloaded with 
Fmoc-Lys(ivDde)-OH, which allows the assembly of asymmetric branches. After 
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Fmoc deprotection the peptides cMBP1 (YLFSVHWPPLKA) [176] and cMBP2 
(KSLSRHDHIHHH) [177-179] were synthesized in 0.1 mmol scales using the Applied 
Biosystems 431A synthesizer with FastMoc™ protocols. The scrambled sequences 
cMBP2sc1 (LHHHDRKSSIHH), cMBP2sc2 (KSHHRDHIHLHS), cMBP2sc3 
(HHSIHRLHHKSD) and cMBP2sc4 (RKIHHHLHSHSD) were created randomly from 
the sequence of cMBP2 using an online sequence permutation generator 
(RANDOM.ORG). The scrambled peptides were synthesized in 0.02 mmol scales 
using the parallel synthesis option of the Biotage Syro Wave synthesizer and 
standard Fmoc SPS conditions at RT (cf. 2.2.3). Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, 
Fmoc-Asp(OtBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Trp(Boc)-
OH, Fmoc-Tyr(tBu)-OH and Fmoc-Val-OH were used for the synthesis of the peptide 
sequences. After complete assembly on solid phase and final Fmoc deprotection, the 
N-terminal amines were protected by reaction with 10 eq Boc2O (di-tert-butyl 
dicarbonate) and 20 eq DIPEA in DCM (10 ml/g resin). After 1 h reaction time, the 
resins were washed 3 times with DMF and 3 times with DCM (10 mL/g resin). The 
ivDde protecting group at the ε-amine of the C-terminal lysine was removed by 
repeated incubation with 2 % hydrazine monohydrate in DMF (v/v) [180, 181]. The 
deprotection solution was exchanged every 5 min until no absorbance at 290 nm was 
detectable. The syntheses of the PEGylated two-arm oligomers were continued at 
the deprotected ε-amine of the C-terminal lysine in the same manner as described for 
the oligomers with B6 ligand (cf. 2.2.4.6).  
 
2.2.4.8 Synthesis of the PEGylated two-arm oligomer for SPAAC  
(Oligomer 479) 
The azide containing oligomer 479 for a strain-promoted alkyne-azide cycloaddition 
(SPAAC) was synthesized manually in a 0.05 mmol scale under standard SPS 
conditions (cf. 2.2.3). A 2-chlorotrityl resin was preloaded with Fmoc-Lys(ivDde)-OH. 
After Fmoc deprotection, the protected oligomer backbone with the sequence (C->Ν) 
K(ivDde)-dPEG24-K(Stp4-C)2  was assembled using Fmoc-N-amido-dPEG24-acid, 
Fmoc-Lys(Fmoc)-OH, Fmoc-Stp(Boc3)-OH and Boc-Cys(Trt)-OH as building units. 
After the conjugation of N-terminal Boc-Cys(Trt)-OH, the ivDde protecting group was 
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removed as described for the oligomers with cMBP ligands (cf. 2.2.4.7). After 
complete deprotection, Fmoc-L-δ-azidonorvaline-OH was coupled to the ε-amine of 
the C-terminal lysine. After final Fmoc deprotection, cleavage was carried out under 
standard conditions (cf. 2.2.3) and the oligomer 479 was purified by SEC and 
preparative RP-HPLC and analyzed by 1H-NMR and analytical RP-HPLC.  
 
2.2.4.9 Synthesis of mEGF conjugated PEGylated two-arm topology oligomer 
 
5 mg of mEGF (0.83 µmol) were dissolved in 1400 µL of 20 mM HEPES pH 7.4 
containing 30 % EtOH. 5.8 mg of DBCO-PEG5-NHS (10 eq, 8.3 µmol) were dissolved 
in 100 µL DMSO and added to the protein solution. The reaction mixture was 
incubated for 3 h at RT. Free DBCO-linker was removed by 5 times ultrafiltration 
using an Amicon Ultra-4 centrifugal filter unit with a MWCO of 3 kDa (Merck Millipore, 
Darmstadt, Germany). Fresh 20 mM HEPES pH 7.4 containing 30 % EtOH was 
added to a final volume of 4 mL before each centrifugation step. In the last step, the 
protein solution was concentrated to a volume of 750 µL. 57.4 mg of oligomer 479 
(TFA salt, 10 eq, 8.3 µmol) were dissolved in 3250 µL of 20 mM HEPES pH 7.4      
(30 % EtOH), mixed with the protein solution and incubated for 3 h at RT. The 
reaction mixture was concentrated to a final volume of 2 mL by ultracentrifugation 
using the Amicon Ultra-4 centrifugal filter unit. Finally, the mEGF conjugate was 
purified by SEC using Superdex 75 as gel filtration medium and 20 mM HEPES pH 
7.4 containing 30 % EtOH as eluent. The yield was 52 % (determined photometrically 
at 280 nm).   
 
2.2.4.10 Synthesis of PEGylated two-arm oligomers with carbohydrates 
(Oligomers 603-605, 651) 
The multivalent carbohydrate ligands were synthesized by Dr. Felix Wojcik (MPI of 
Colloids and Interfaces, Potsdam) and provided in a protected and resin bound form, 
ready for the subsequent solid-phase synthesis. The syntheses of the PEGylated 
two-arm oligomers were continued in 0.01 mmol scales under standard SPS 
conditions (cf. 2.2.3) using Fmoc-N-amido-dPEG24-acid, Fmoc-Lys(Fmoc)-OH, 
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Fmoc-Stp(Boc3)-OH and Boc-Cys(Trt)-OH as building units. Since the carbohydrate 
ligands were in a peracetylated form during the solid-phase synthesis, a 
deacetylation step by transesterification with 0.1 M sodium methoxide was introduced 
before cleavage (Zemplén deacetylation [182]). Cleavage of the oligomers was 
carried out with 50 % TFA and 5 % TIS in DCM to reduce the risk of acid catalyzed 
hydrolysis of glycosyl residues. The oligomers were analyzed by 1H-NMR and 
analytical RP-HPLC.  
 
2.2.4.11 Synthesis of PEGylated two-arm oligomers with FolA ligands 
(Oligomers 356, 619, 620)  
The folic acid containing oligomer 356 and the Alexa Fluor 488 labeled analog 583 
were synthesized as described before [115]. The oligomers 619 and 620 were 
prepared in 0.02 mmol scales. For the syntheses, a 2-chlorotrityl resin was preloaded 
with Fmoc-Lys(ivDde)-OH and protected oligomer backbones with the sequences     
(C->Ν) K(ivDde)-AK[A-(Stp-A)4-C]2 and K(ivDde)-HK[H-(Stp-H)4-C]2 were assembled 
under standard SPS conditions (cf. 2.2.3) using Fmoc-Ala-OH, Fmoc-His(Trt)-OH, 
Fmoc-Lys(Fmoc)-OH, Fmoc-Stp(Boc3)-OH and Boc-Cys(Trt)-OH as building units. 
The ivDde protecting group was removed as described for the oligomers with cMBP 
ligands (cf. 2.2.4.7). After complete deprotection, the two PEG24 segments were 
attached to the ε-amine of the C-terminal lysine by coupling and deprotection of 
Fmoc-N-amido-dPEG24-acid twice. Folic acid was assembled in two steps. First, 
Fmoc-Glu-OtBu was coupled to the N-terminus of the PEG amino acid and 
deprotected, second N10-(trifluoroacetyl)pteroic acid was attached. Both steps were 
carried out under the standard SPS conditions, however in case of the pteroic acid 
derivative, a mixture of NMP/DMF/DMSO (1/1/1 v/v/v) was used as solvent of the 
coupling solution. After washing of the resin 3 times with DMF and 3 times with DCM, 
the trifluoroacetyl protecting group was removed by incubation with a mixture of 25 % 
ammonium hydroxide solution and DMF (50/50 v/v, 10 ml/g resin) 4 times for 30 min. 
Cleavage was carried out under standard conditions (cf. 2.2.3) and the oligomers 
were purified by SEC and analyzed by 1H-NMR and analytical RP-HPLC. 
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2.2.4.12 Synthesis of PEGylated two-arm oligomers with MTX ligands 
(Oligomers 638-641, 672) 
The oligomers containing MTX ligands were synthesized in 0.02 mmol scales. For 
the syntheses, a 2-chlorotrityl resin was preloaded with Fmoc-Lys(ivDde)-OH and 
protected oligomer backbones with the sequences (C->Ν) K(ivDde)-K(Stp4-C)2 and 
K(ivDde)-HK[H-(Stp-H)4-C]2 were assembled under standard SPS conditions (cf. 
2.2.3) using Fmoc-His(Trt)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Stp(Boc3)-OH and Boc-
Cys(Trt)-OH as building units. The ivDde protecting group was removed as described 
for the oligomers with cMBP ligands (cf. 2.2.4.7). After complete deprotection, the 
PEG segment was attached to the ε-amine of the C-terminal lysine; according to the 
individual sequences, Fmoc-N-amido-dPEG24-acid was coupled once (638-641) or 
twice (672). MTX was assembled in two steps. First, Fmoc-Glu-OtBu was coupled 
and deprotected, second 4-[[(2,4-Diamino-6-pteridinyl)methyl]methyl-amino]benzoic 
acid was attached. Both steps were carried out under the standard SPS conditions, 
however in case of the pteroic acid derivative, a mixture of NMP/DMF/DMSO (1/1/1 
v/v/v) was used as solvent of the coupling solution. In case of the polyglutamylated 
oligomers 639-641 and 672, additional glutamic acid residues in the sequence 
between PEG and MTX were integrated by repeated coupling and deprotection of 
Fmoc-Glu-OtBu. Cleavage was carried out under standard conditions (cf. 2.2.3) and 
the oligomers were purified by SEC and analyzed by 1H-NMR and analytical RP-
HPLC. 
 
2.2.5 Oligomer purification 
2.2.5.1 Size-exclusion chromatography 
All oligomers were purified by size exclusion chromatography using the ÄKTApurifier 
10 system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) equipped with a P-
900 solvent pump module, a UV-900 UV/VIS multi-wavelength detector, a pH/C-900 
conductivity module and a Frac-950 automated fraction collector. Sephadex G-10 
(MWCO 700 Da) was used as the gel filtration medium and 10 mM hydrochloric acid 
solution/acetonitrile 7/3 as eluent. The absorption at 214, 260 and 280 nm was 
monitored and the fractions corresponding to the high-molecular weight oligomer 
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were pooled, snap-frozen and freeze-dried. The low molecular weight constituents 
with higher elution times, such as TIS, cleavage side-products and acetylated 
truncation products were discarded. In consequence of the used eluent, the final 
product was present as HCl salt after the purification. 
 
2.2.5.2 Preparative RP-HPLC 
If the purity of an oligomer determined by analytical RP-HPLC was considered to be 
unsatisfactory, additional purification was carried out by preparative RP-HPLC using 
a VWR LaPrep system (VWR International GmbH, Darmstadt, Germany) and a 
Waters SymmetryPrep C18 column (7µm, 19x150mm). A water/acetonitrile gradient 
containing 0.1 % TFA was adjusted to the individual compound. After collection of the 
product, the solution was snap-frozen and freeze-dried. In consequence of the used 
eluent, the final product was present as TFA salt after the purification.  
 
2.2.6 Analytics 
2.2.6.1 1H-NMR 
1H-NMR spectroscopy was carried out using a Jeol JNMR-GX 400 (400 MHz) or 
JNMR-GX 500 (500 MHz). Chloroform-d (CDCl3), deuterium oxide (D2O) and 
methanol-d4 (CD3OD) were used as solvents. Chemical shifts were calibrated to the 
residual proton signals of the solvent and are reported in ppm. Data is indicated with 
s = singlet, d = doublet, t = triplet, m = multiplet. Spectra were analyzed using 
MestReNova (Mestrelab Research). 
 
2.2.6.2 Analytical RP-HPLC 
The purity of the oligomers was analyzed by RP-HPLC using a Waters HPLC system 
equipped with a Waters 600E multisolvent delivery system, a Waters 996 PDA 
detector and a Waters 717plus autosampler. As indicated, the compounds were 
analyzed using a Waters Sunfire C18 or Xbridge C18 column (5 µm, 4.6 x 150 mm) 
and a water/acetonitrile gradient (95:5 – 0:100) containing 0.1 % TFA. For the 
detection the extinction at 214 nm was monitored. 
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2.2.6.3 ESI-MS 
Electrospray ionization (ESI) mass spectrometry was carried out with a Thermo 
Scientific LTQ FT Ultra fourier transform ion cyclotron and an IonMax source. Water 
containing 1 % formic acid was used as solvent for oligomers. Building blocks were 
dissolved in water, ethyl acetate or chloroform. 
 
2.2.6.4 SDS-PAGE  
The samples were supplemented with Laemmli sample buffer (Biorad, Munich, 
Germany), denatured at 95 °C for 5 minutes and subsequently loaded on a 12 % 
polyacrylamide gel. Following electrophoresis, the gel was fixated with a solution 
containing 50 % methanol, 12 % acetic acid and 0.019 % formaldehyde for 1 hour. 
After treatment with a sodium thiosulfate solution (127 mg/L) for 1 min, the gel was 
incubated for 20 min with a silver nitrate solution (2 g/L) containing 0.019 % 
formaldehyde. The gel was developed by incubation with a solution containing 
sodium carbonate (60 g/L), sodium thiosulfate (2.5 mg/L) and 0.019 % formaldehyde. 
The reaction was stopped after 5 min by addition of a solution containing 50 % 
methanol and 12 % acetic acid.  
 
2.2.7 Alkalimetric titrations 
Automated titrations were carried out with a Metrohm Titrando 905 equipped with a 
Biotrode pH electrode (METROHM GmbH & Co. KG, Filderstadt, Germany). The 
sample amount corresponding to the indicated amount of protonatable amines was 
dissolved in 3.5 mL of 50 mM sodium chloride solution. The pH was adjusted below 2 
with hydrochloric acid. Titrations were carried out with 50 mM sodium hydroxide 
solution until the endpoint of pH 11 was reached. To distinguish polymer and solvent 
effects, a control titration of 50 mM sodium chloride solution without polymer was 
performed. Volume differences (ΔV) between defined pH values were determined. 
The total endosomal buffer capacity C in the pH range between 5 and 7.4 was 
calculated according to formula (1), the relative protonation C’ in endosomal sub-
ranges pHx to pHy (5 ≤ pHx < pHy ≤ 7.4) was determined according to formula (2).  
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(1)     𝐶𝑝𝐻5−7.4 =  
[∆𝑉(𝑆𝑎𝑚𝑝𝑙𝑒)𝑝𝐻5−7.4 −  ∆𝑉(𝑁𝑎𝐶𝑙)𝑝𝐻5−7.4] ∙ 50 𝑚𝑀 
𝑛
∙ 100 % 
(2)     𝐶′𝑝𝐻𝑥−𝑝𝐻𝑦  =  
∆𝑉(𝑆𝑎𝑚𝑝𝑙𝑒)𝑝𝐻𝑥−𝑝𝐻𝑦 −  ∆𝑉(𝑁𝑎𝐶𝑙)𝑝𝐻𝑥−𝑝𝐻𝑦  
∆𝑉(𝑆𝑎𝑚𝑝𝑙𝑒)𝑝𝐻5−7.4 −  ∆𝑉(𝑁𝑎𝐶𝑙)𝑝𝐻5−7.4
∙ 100 % 
C, total buffer capacity between the indicated pH values [%]; C’, relative protonation in the indicated pH subrange 
[%], total buffer capacity is set to 100 %; ∆V, volume difference between the indicated pH values [ml]; n, amount 
of protonatable amines [µmol].   
 
2.2.8 Polyplex formation 
2.2.8.1 pDNA polyplexes 
For in vitro transfections 200 ng of pDNA and the corresponding amount of oligomer 
at indicated N/P ratio were diluted in separate tubes in HBG to a volume of 10 µL 
each. The oligomer solution was added to the pDNA solution and mixed by pipetting. 
The polyplex formation was accomplished after incubation at room temperature for 
40 min. Polyplex solutions for DLS measurements, flow cytometry experiments and in 
vivo trials containing different amounts of pDNA were prepared similarly.     
 
2.2.8.2 Poly(I:C) and poly(I) polyplexes  
For in vitro transfections 1 µg of nucleic acid and the corresponding amount of 
oligomer at indicated N/P ratio were diluted in separate tubes in HBG to a volume of 
10 µL each. The oligomer solution was added to the nucleic acid solution and mixed 
by pipetting. The polyplex formation was accomplished after incubation at room 
temperature for 40 min. Polyplex solutions for DLS measurements, electrophoretic 
mobility shift assays or flow cytometry experiments containing different amounts of 
nucleic acids were prepared similarly.  
 
2.2.9 Ethidium bromide exclusion assay 
A Cary Eclipse spectrophotometer (Varian, Germany) was used for the quantification 
of ethidium bromide (EtBr) fluorescence at the excitation wavelength λex = 510 nm 
and emission wavelength λem = 590 nm. 1 mL HBG buffer containing 0.4 µg EtBr was 
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used as blank. After addition of 10 µg pDNA the solution was incubated for 3 minutes 
and EtBr fluorescence was assigned to 100 %. Increasing amounts of oligomer 
corresponding to indicated N/P ratios were added, incubated for 30 seconds and the 
EtBr fluorescence was determined in relation to the 100 % value. 
 
2.2.10 Electrophoretic mobility shift assay 
A 1 % agarose gel was prepared by dissolution of agarose in TBE buffer under 
heating. After cooling to 50 °C, GelRed for the nucleic acid staining was added and 
the agarose solution was poured into the casting unit. Polyplexes containing 200 ng 
pDNA or 800 ng poly(I:C) and loading buffer were placed into the sample pockets. 
For pDNA polyplexes electrophoresis was carried out during 80 min using a voltage 
of 80 V, for poly(I:C) polyplexes a voltage of 85 V over a time of 90 min was used.  
For the investigation of serum stability, polyplexes containing 0.8 µg poly(I:C) and 
oligomer at N/P 20 were initially prepared at a 10-fold higher concentration than in 
the regular formulations. Subsequently the polyplex solutions were diluted 1:10 with 
FCS and incubated at room temperature for 15, 45 or 90 minutes before 
electrophoresis. 
 
2.2.11 Particle size and zeta Potential 
Particle size and zeta potential of polyplexes were determined by dynamic and 
electrophoretic light scattering using a Zetasizer Nano ZS with backscatter detection 
(Malvern Instruments, Worcestershire, UK). Polyplexes containing 10 µg nucleic acid 
and oligomer at indicated N/P ratio were prepared in 50 µL HBG as described before 
(cf. 2.2.8.1 and 2.2.8.2). After complete polyplex formation, the solution was diluted to 
a total volume of 800 µL with 20 mM HEPES (pH 7.4) and placed in a folded capillary 
cell (DTS1061). Measurements were carried out at 25 °C using a refractive index of 
1.330 and a viscosity of 0.8872 cP as the defined parameters of the dispersion 
medium. The cumulants analysis method was used for the determination of the Z-
average diameter and polydispersity index (PDI). Each sample was measured three 
times with 10 subruns of 10 s during particle size measurements and 10 to 30 
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subruns of 10 s during zeta potential measurements. Values are reported as 
arithmetic mean and standard deviation of the three measurements.   
 
2.2.12 Luciferase reporter gene expression in vitro 
pDNA transfections were carried out by Dr. Petra Kos and Ana Krhac Levacic 
(Pharmaceutical Biotechnology, LMU). Cells were seeded 24 h prior to the 
transfections in 96-well plates. In case of DU145, KB and Neuro2A cells, 10.000 cells 
were seeded per well. Huh7 cells were seeded using 8.000 cells per well. After 24 h, 
the culture medium was replaced by 80 μL fresh medium containing 10 % FCS. 
Polyplexes containing 200 ng pCMVLuc, formed in 20 μL HBG were added to each 
well and incubated on the cells for 24 h at 37 °C. For transfection experiments with 
targeted oligomers, the incubation time was shortened to 45 min, followed by 
incubation with fresh medium containing 100 µM chloroquine (for control experiments 
without chloroquine, only fresh medium was added). After 4 h, the medium was again 
replaced by fresh medium and cells were further incubated for 20 h. LPEI at nontoxic 
optimum N/P 6 was used as positive control, HBG buffer was used as negative 
control. 24 h after the transfections, cells were treated with 100 μL cell culture lysis 
reagent (Promega, Mannheim, Germany). Luciferase activity in the cell lysate was 
measured using the luciferase assay kit (Promega, Mannheim, Germany) and a 
Centro LB 960 plate reader luminometer (Berthold Technologies, Bad Wildbad, 
Germany). Experiments were performed in quintuplicates. 
 
2.2.13 Luciferase reporter gene expression in vivo 
Animal experiments were carried out by Annika Herrmann and Dr. Petra Kos 
(Pharmaceutical Biotechnology, LMU). Female Rj:NMRI-nu (nu/nu) mice (Janvier, Le 
Genest-St-Isle, France) were used for the in vivo trials. 5x106 N2A or Huh7 cells were 
inoculated subcutaneously into the left flank. 12 days after tumor cell injection, 
polyplexes were injected into the tumor or into the tail vein. In case of the intratumoral 
administration, polyplexes containing 50 μg pCMVLuc at N/P 12 in a total volume of 
60 µL HBG were used and the mice were sacrificed after 24 h. For the systemic 
delivery, polyplexes at N/P 12 containing either 60 μg pCMVLuc (N2A tumor model) 
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or 80 µg pCMVLuc (Huh7 tumor model) in a total volume of 200 µL HBG were 
injected into the tail vein and the animals were sacrificed after 48 h. Organs and/or 
tumors were dissected and homogenized in cell culture lysis reagent using a tissue 
and cell homogenizer (FastPrep®-24, MP Biomedicals, USA). Samples were 
centrifuged at 3000 g and 4 °C for 10 min to remove insoluble tissue components. 
Luciferase activity of the supernatant was determined using a Centro LB 960 
luminometer (Berthold Technologies, Bad Wildbad, Germany). All animal procedures 
were approved and controlled by animal experiments ethical committee of Regierung 
von Oberbayern (District Government of Upper Bavaria, Germany) and carried out 
according to the guidelines of the German law of protection of animal life.  
 
2.2.14 Flow cytometry 
2.2.14.1 Cellular association of pDNA polyplexes 
Flow cytometry experiments with pDNA polyplexes were carried out by Dr. Petra Kos 
(Pharmaceutical Biotechnology, LMU). Cells were seeded into 24-well plates coated 
with collagen at a density of 5x104 cells/well. After 24 h, the culture medium was 
replaced by 400 μL fresh growth medium. pDNA polyplexes containing 1 µg pDNA 
(20 % Cy5-labeled) and oligomer at N/P 12 in 100 μL HBG were added to each well 
and incubated on ice for 30 min. The cells were washed twice with 500 µL PBS 
subsequently. Cells were detached with trypsin/EDTA and collected in PBS 
containing 10 % FCS. Cy5 fluorescence was detected by excitation at 635 nm and 
emission at 665 nm. DAPI (4',6-diamidino-2-phenylindole) was used to discriminate 
between viable and dead cells. Data was recorded using a Cyan™ ADP flow 
Cytometer (Dako, Hamburg, Germany) and Summit™ acquisition software (Summit, 
Jamesville, NY, USA). Data evaluation was carried out using FlowJo® 7.6.5 flow 
cytometry data analysis software. 
 
2.2.14.2 Cellular uptake of pDNA polyplexes 
Flow cytometry experiments with pDNA polyplexes were carried out by Dr. Petra Kos 
(Pharmaceutical Biotechnology, LMU). Cells were seeded into 24-well plates coated 
with collagen at a density of 5x104 cells/well. After 24 h, culture medium was 
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replaced by 400 μL fresh growth medium. pDNA polyplexes containing 1 µg pDNA 
(20 % Cy5-labeled) and oligomer at indicated N/P in 100 μL HBG were added to 
each well and incubated for 30 min at 37 °C. Cells were then washed with PBS and 
incubated with 500 µL PBS containing 100 I.U. of heparin for 15 min to remove non-
internalized polyplexes on the cell surface. Cells were detached with trypsin/EDTA 
and collected in PBS containing 10 % FCS. Cy5 fluorescence was detected by 
excitation at 635 nm and emission at 665 nm. DAPI was used to discriminate 
between viable and dead cells. Data was recorded using a Cyan™ ADP flow 
Cytometer (Dako, Hamburg, Germany) and Summit™ acquisition software (Summit, 
Jamesville, NY, USA). Data evaluation was carried out using FlowJo® 7.6.5 flow 
cytometry data analysis software. 
 
2.2.14.3 Cellular uptake of poly(I:C) polyplexes 
Flow cytometry experiments with poly(I:C) polyplexes were carried out by Valentin 
Wittmann (graduate student, LMU). Cells were seeded on collagen coated 24-well 
plates at a density of 5x104 cells/well one day before the experiment. After 24 h, 
culture medium was replaced by 450 μL fresh growth medium either folate-free or 
saturated with folic acid. Polyplexes containing 2.5 µg poly(I:C) (20 % Cy5-labeled) 
and oligomer at N/P 16 in 50 μL HBG were added to each well and incubated for 30 
min at 37 °C. The medium was removed and cells were treated twice with PBS 
containing 100 I.U. Heparin/mL for 15 min to remove non-internalized polyplexes. 
Cells were detached with trypsin/EDTA and collected in PBS containing 10 % FCS. 
Cy5 fluorescence was detected by excitation at 635 nm and emission at 665 nm. 
DAPI was used to discriminate between viable and dead cells. Data were recorded 
using a Cyan™ ADP flow Cytometer (Dako, Hamburg, Germany) and Summit™ 
acquisition software (Summit, Jamesville, NY, USA). Data evaluation was carried out 
using FlowJo® 7.6.5 flow cytometry data analysis software. All experiments were 
performed in triplicates. 
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2.2.15 Metabolic activity assay (MTT) 
2.2.15.1 Metabolic activity of pDNA transfected cells  
MTT assays with pDNA transfected cells were carried out by Dr. Petra Kos and Ana 
Krhac Levacic (Pharmaceutical Biotechnology, LMU). Cells were transfected as 
described in 2.2.12. 24 h after the transfections, 10 µL of a MTT solution (5 mg/mL) 
were added to the medium. After 2 h incubation, the supernatant was removed and 
cells were lysed by freezing at -80 °C and thawing at room temperature. The colored 
formazan product was dissolved in dimethyl sulfoxide (100 µL/well) and quantified 
photometrically at 590 nm using a SpectraFluor™ Plus microplate reader (Tecan, 
Groedig, Austria). The relative metabolic activity was calculated by comparison with 
control cells treated with HBG. Experiments were performed in quintuplicates.   
 
2.2.15.2 Metabolic activity of poly(I:C) transfected cells  
MTT assays with poly(I:C) transfected cells were carried out by Valentin Wittmann 
(graduate student, LMU) and Katharina Müller (Pharmaceutical Biotechnology, LMU). 
KB cells were seeded into 96-well plates coated with collagen at a density of 4x103 
cells/well in 100 μL growth medium 24 h prior to the treatment. The medium was 
replaced by 80 μL fresh medium and 20 μL of polyplex solution in HBG. After 48 h 
incubation time (37 °C, 5 % CO2), the medium was replaced by 100 μL fresh growth 
medium. 10 μL of MTT solution (5 mg/mL) were added to each well. After 2 h 
incubation, the supernatant was removed and cells were lysed by freezing at -80 °C 
and thawing at room temperature. The colored formazan product was dissolved in 
dimethyl sulfoxide (100 µL/well) and quantified photometrically at 590 nm using a 
SpectraFluor™ Plus microplate reader (Tecan, Groedig, Austria). The relative 
metabolic activity was calculated by comparison with control cells treated with HBG.    
Experiments were performed in triplicates. 
 
2.2.15.3 Metabolic activity of cells treated with oligomer and MTX solutions  
MTT assays with cells treated with oligomer and MTX solutions were carried out by 
Valentin Wittmann (graduate student, LMU) and Katharina Müller (Pharmaceutical 
Biotechnology, LMU). KB cells were prepared as described in 2.2.15.2. 24 h after 
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seeding, the medium was replaced by 100 µL of oligomer or MTX solution (80 % 
medium, 20 % HBG) with defined concentration between 3 nM and 10 µM.  After 48 
h incubation time (37 °C, 5 % CO2), the medium was replaced by 100 μL fresh 
growth medium and 10 μL of MTT solution (5 mg/mL) were added. Subsequent steps 
were carried out in the same way as described in 2.2.15.2. The dose-response 
relationships were approximated by four-parameter logistic models and the values for 
the half maximal effective concentration (EC50) and the maximal effect (Emax) were 
determined. 
 
2.2.16 Dihydrofolate reductase activity assay 
The enzymatic activity of DHFR in presence of MTX or MTX conjugates was 
determined by a dihydrofolate reductase assay kit (Sigma-Aldrich, Munich, Germany) 
based on the NADPH dependent reduction of dihydrofolic acid to tetrahydrofolic acid. 
The assay was conducted according to the manufacturer’s protocol. MTX and all 
tested compounds were dissolved in the provided assay buffer and used at a final 
concentration of 100 nM in the reaction mixture. The reaction progress was 
monitored photometrically (Genesys 10S, Thermo Scientific, Dreieich, Germany) over 
a period of 5 min by measurement of NADPH absorption at 340 nm each 15 s. 
Control reactions in absence of inhibitors were carried out. Data points were fitted by 
linear regression and the gradient was determined. Relative enzyme activity was 
calculated as ratio between the gradient of the reaction with test compound to the 
gradient of the control reaction without inhibition according to formula (3). For each 
compound the assay was carried out in triplicates.   
(3)     𝐷𝐻𝐹𝑅 𝐴𝑐𝑡. [%] =
∆𝐴
∆𝑡 (𝑆𝑎𝑚𝑝𝑙𝑒)
∆𝐴
∆𝑡 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙)
 ∙ 100 % 
A, absorption at 340 nm; t, time [s].   
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2.2.17 Fluorescence microscopy 
2.2.17.1 Calcein release assay 
Calcein release assays were carried out by Dr. Frauke Mickler (Physical Chemistry, 
LMU). 10.000 DU145 cells per well were seeded on ibidi µ-slides (ibidi GmbH, 
Planegg/Martinsried, Germany) 48 h prior to particle addition. For the determination 
of calcein release by B6 targeted oligomers, 20 µL of polyplexes (400 ng DNA, N/P 
16) were coincubated with 0.5 mg/mL calcein in 200 µL RPMI medium containing 10 
% FCS for 3.5 hours on the cells. Afterwards cells were washed 4 times with PBS, 
and the medium was replaced with 300 µL CO2 independent medium (Gibco Life 
Technologies GmbH, Darmstadt, Germany) containing 10 % FCS. Z-slices of single 
cells were imaged by spinning disk confocal microscopy (Nikon TE2000E microscope 
with Yokogawa CSU10 spinning disk unit, an EM-CCD camera (iXon DV884, Andor) 
and a Nikon 1.49 NA 100x Plan Apo oil immersion objective) with 488 nm laser 
excitation. In case of the cMBP targeted oligomers, polyplexes at N/P 12 containing 
400 ng pDNA were added to 200 µL fresh RPMI medium on the cells. After 40 min 
incubation time, the cell medium was replaced by 300 µL fresh RPMI medium 
containing 0.5 mg/ml calcein. Cells were imaged 20 h after particle addition. Calcein 
fluorescence in the cytosol was quantified by digital image analysis in ImageJ. Mean 
grey values of pixels from extracellular regions (background) and endosomal 
compartments (endosome fluorescence) were determined and two threshold values 
were set to exclude those regions from quantification. The integrated intensity of 
cytosolic pixels above the lower background threshold and below the upper 
endosomal threshold was then calculated (integrated intensity = number of selected 
pixels * mean grey value of selected pixels).   
 
2.2.17.2 Live cell imaging 
Live cell imaging experiments were carried out by Dr. Frauke Mickler (Physical 
Chemistry, LMU). Spinning disk confocal microscopy was performed with a Nikon 
TE2000E microscope equipped with a Yokogawa CSU10 spinning disk unit, an EM-
CCD camera (iXon DV884, Andor) and a Nikon 1.49 NA 100x Plan Apo oil immersion 
objective. 640 nm laser light was used for the excitation of Cy5. Wide-field 
fluorescence microscopy was performed with a custom built Nikon Ti microscope 
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equipped with a Plan Apo 60x, 1.49 NA oil immersion objective and EM-CCD 
cameras (DU-897 iXon+, Andor). 633 nm laser light was used for the excitation of 
Cy5.   
 
2.2.17.3 Intracellular distribution of poly(I:C) polyplexes 
Fluorescence microscopy with poly(I:C) polyplexes was carried out by Katharina 
Müller and Miriam Höhn (Pharmaceutical Biotechnology, LMU). KB cells were 
seeded at a density of 2x104 cells/well in 300 μL growth medium into a 8 well Labtek 
chamber slide coated with collagen 24 h prior to treatment. Polyplexes were formed 
as described using 1.5 µg of a mixture of 80 % unlabeled and 20 % Cy5 labeled 
poly(I:C) and a mixture of the depicted oligomer at N/P 16 (80 %) and Alexa Fluor 
488 labeled oligomer 583 at N/P 4 (20 %) in 60 µL HBG. Medium was replaced with 
240 µL fresh growth medium and the polyplex solution was added. The chamber 
slide was incubated at 37 °C for 30 minutes. Cells were washed twice with 500 µL 
PBS and cell nuclei were stained with Hoechst 33342 dye. A Leica TCS SP8 
confocal microscope was used for image acquisition. 
 
2.2.18 Statistical analysis 
Unless otherwise stated, results are presented as arithmetic mean ± standard 
deviation (SD) and the number of replicates. Statistical significance was determined 
in one-tailed t-tests. Significance levels are indicated with star symbols. *: P ≤ 0.05; 
**: P ≤ 0.01; ***: P ≤ 0.001. 
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3 Results 
3.1 The modulation of proton-sponge activity in 
oligo(ethanamino)amides  
Basic polymers can facilitate nucleic acid delivery in several steps by means of their 
properties as protonatable bases. Protonated cationized groups account for the 
electrostatic nucleic acid binding and cellular uptake. Residual unprotonated 
functions can offer a buffer capacity to mediate polyplex escape from acidifying 
vesicles via the hypothesized proton-sponge effect. However, to serve these 
separate purposes, different basic strengths have to be combined and balanced. 
Therefore, not all basic polymers are suited as transfecting agents. Several basic 
polymers, despite a potent pDNA binding, do not mediate transgene expression. In 
general, the endosomal escape is regarded as one of the most critical barriers within 
the nucleic acid delivery pathway. This chapter describes different approaches, which 
were taken to modulate the endosomal buffering of oligo(ethanamino)amides and to 
identify requirements for an enhanced proton-sponge activity in pDNA polyplexes.  
 
3.1.1 The protonation of basic polymers and polyamines 
The characteristics of different basic compounds regarding the protonation and 
buffering in certain pH ranges were investigated by alkalimetric titrations. Poly-L-
arginine (PLR), poly-L-lysine (PLL), poly-L-histidine (PLH) and branched 
polyethylenimine (BPEI) were chosen as a set of well-known basic polymers 
(Scheme 3.1 A). Figure 3.1 shows the titration curves with the highlighted endosomal 
range between pH 5 and 7.4. The titration curve of PLR did not show a big difference 
compared to the sodium chloride reference titration, since the highly stable 
guanidinium groups are not deprotonated to a notable extent in the investigated 
titration range below pH 11. PLL showed a similar course through the endosomal pH 
range like sodium chloride and PLR, but the gradient decreased in the range around 
pH 10.2, which represents the pKa value of the primary ε-amines of lysine.  
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Scheme 3.1 Compounds investigated by alkalimetric titrations 
 
(A) Selection of common basic polymers and (B) polyamines. PLL, poly-L-lysine; PLR, poly-L-arginine; PLH, poly-
L-histidine; BPEI, branched polyethylenimine; 1,2-DAE, 1,2-diaminoethane; EDA, ethylene diamine; 1,3-DAP, 1,3-
diaminopropane; 1,4-DAB, 1,4-diaminobutane; 1,5-DAP, 1,5-diaminopentane; 1,6-DAH, 1,6-diaminohexane; 
DETA, diethylene triamine; TETA, triethylene tetramine; TEPA, tetraethylene pentamine; PEHA, pentaethylene 
hexamine. 
 
 
Figure 3.1 Titration curves between pH 2 and 11 of common basic polymers. Polymer solutions containing 30 
µmol protonatable nitrogens were acidified with hydrochloric acid and backtitrated with 50 mM sodium hydroxide 
solution. Sodium chloride was used for a reference titration without buffering agent. PLL, poly-L-lysine; PLR, poly-
L-arginine; PLH, poly-L-histidine; BPEI, branched polyethylenimine. 
 
Within the whole set, the flattest slope between pH 5 and 7.4, indicating the highest 
endosomal buffer capacity, was observed in the titration curve of PLH. The gradient 
of the curve had its minimum around pH 6. However, above pH 7.4 the titration curve 
showed a similar course as sodium chloride or PLR, since the amount of 
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imidazolinium groups available for deprotonation decreases exponentially with 
increasing pH. As a result of the definite pKa values of arginine, histidine and lysine, 
the protonation (and deprotonation) of the peptidic homopolymers occurred in a 
rather narrow pH range. The exclusive protonation and buffering in a defined range 
of the pH scale explains the inability of the three basic polymers to mediate efficient 
gene transfer without additional modifications, since different pH ranges have to be 
covered for this purpose. In sharp contrast, BPEI exhibited a continuous buffering 
over a broad range, including the endosomal area and above, which provides 
sufficient protonation at neutral pH for pDNA binding but also a buffer capacity for 
proton-sponge activity in the endosomes. This can be explained by the proximity of 
the protonatable groups within the polymer. The protonation of the diaminoethane 
nitrogens in PEI affects the basicity of neighboring groups. With proceeding 
protonation the basicity of unprotonated groups decreases resulting in a continuous 
buffering. Thus the titration curve of BPEI is the result of a wide array of changing 
pKa values, which depend on the pH and the protonation state of the polymer.  
To investigate the sequential protonation of linear polyamines in more detail, two sets 
of compounds were arranged (Scheme 3.1 B). First, diamines with different length of 
the aliphatic spacer (C2 to C6) were used for alkalimetric back titrations to provide 
information about the influence of the distance between protonatable groups and the 
hindrance of protonation. Second, polyamines with different numbers of 
diaminoethane nitrogens (2N to 6N) were titrated. Figure 3.2 shows the titration 
curves of the different aliphatic diamines. Although all samples contained the same 
amount of primary amines, the curves deviated from each other as a result of the 
different hydrocarbon spacers. In all diamines the first protonation (second 
deprotonation) had its maximum at pH 10 or above. Since no big difference between 
the titration curves of 1,6-diaminohexane (1,6-DAH) and methylamine could be 
observed, the second protonation (first deprotonation) of 1,6-DAH seemed to be only 
marginally affected by the neighboring ammonium group. However, with decreasing 
length of the aliphatic spacer, the pKa values for the second protonation decreased, 
which can be seen by the shifts of the flattened upper part of the curves toward lower 
pH values. In case of three or less separating methylene groups (1,3-DAP, 1,2-DAE), 
the proximity of a neighboring protonated amine decreased the pKa for a second 
protonation to values below 9. Consequently, for the shortest compound 1,2-
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diaminoethane (1,2-DAE) the lowest pKa value of approx. 7.2, buffering also in the 
endosomal pH range, could be observed. These findings illustrate the utility of the 
diaminoethane motif to promote buffering in the biologically relevant pH ranges. 
       
 
Figure 3.2 Titration curves between pH 2 and 11 of diamines with different aliphatic spacers. Polymer solutions 
containing 200 µmol protonatable nitrogens were acidified with hydrochloric acid and backtitrated with 50 mM 
sodium hydroxide solution. Sodium chloride was used for a reference titration without buffering agent, 
methylamine for a titration with unhindered protonation of primary amines. MA, methylamine; 1,6-DAH, 1,6-
diaminohexane; 1,5-DAP, 1,5-diaminopentane; 1,4-DAB, 1,4-diaminobutane; 1,3-DAP, 1,3-diaminopropane; 1,2-
DAE, 1,2-diaminoethane. C2 to C6 indicate the length of the aliphatic spacer.    
 
The titration curves of larger polyamines, containing repeating diaminoethane units, 
revealed a remarkable pattern depending on an even or odd number of contained 
protonatable amines (Figure 3.3). The curves of diethylene triamine (DETA, 3N) and 
tetraethylene pentamine (TEPA, 5N) had a notably similar course. The same 
observation could be made for triethylene tetramine (TETA, 4N) and pentaethylene 
hexamine (PEHA, 6N). The compounds with even number of protonatable amines 
exhibited much higher buffering in the endosomal pH range than the odd numbered 
as a result of the location of their pKa values.  
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Figure 3.3 Titration curves between pH 2 and 11 of polyamines with different numbers of diaminoethane 
nitrogens. Polymer solutions containing 200 µmol protonatable nitrogens were acidified with hydrochloric acid and 
backtitrated with 50 mM sodium hydroxide solution. Sodium chloride was used for a reference titration without 
buffering agent. EDA, ethylene diamine; DETA, diethylene triamine; TETA, triethylene tetramine; TEPA, 
tetraethylene pentamine; PEHA, pentaethylene hexamine. N indicates the number of protonatable nitrogens per 
molecule.    
 
 
Figure 3.4 Total endosomal buffer capacity between pH 5 and 7.4 of linear polyamines as determined by 
alkalimetric titrations. Methylamine served as a reference compound with unhindered protonation of a primary 
amine. MA, methylamine; EDA, ethylene diamine; DETA, diethylene triamine; TETA, triethylene tetramine; TEPA, 
tetraethylene pentamine; PEHA, pentaethylene hexamine. N indicates the number of protonatable nitrogens per 
molecule.    
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Figure 3.4 illustrates the endosomal buffer capacity of the compounds, which 
measures the portion of basic groups getting protonated between pH 5 and 7.4. A 
clear even-odd correlation could be observed, since all polyamines with even number 
of diaminoethane nitrogens had higher buffer capacities than the members with odd 
number. The endosomal buffer capacities seemed to converge with increasing length 
of the polyamines. Obviously, the buffering over a broad pH range gets more 
homogeneous with increasing number of nitrogens (cf. Figure 3.1 BPEI). Therefore, 
the even-odd effect is most pronounced for short polyamines. 
 
 
3.1.2 The proton-sponge activity of different polyamino acids and their 
combinations with histidine 
 
This chapter has been adapted from: 
Lächelt U, Kos P, Mickler FM, Herrmann A, Salcher EE, Rödl W, Badgujar N, Bräuchle C 
and Wagner E, “Fine-tuning of proton sponges by precise diaminoethanes and histidines in 
pDNA polyplexes.”, Nanomedicine NBM, 2014, 10(1):35-44.  
 
Different polyamino acid (PAA) building blocks can be used for the synthesis of 
sequence-defined oligo(ethanamino)amides for pDNA delivery. Coupled at an 
internal position of the sequence, the polyamino acid glutaryl-triethylene tetramine 
(Gtt) offers two, succinyl-tetraethylene pentamine (Stp) three and succinyl-
pentaethylene hexamine (Sph) four protonatable amines. Since polyamines with 
different numbers of diaminoethane units exhibit different characteristics, regarding 
protonation and endosomal buffering (cf. Figure 3.3 and 3.4), the individual 
properties of oligo(ethanamino)amides, based on the separate building blocks, were 
investigated. Within the set of natural amino acids, histidine with a pKa of the 
imidazole group around 6 is ideal for a specific modulation of the endosomal buffer 
capacity. With this motivation, the additional effect of histidine on the endosomal 
buffering and proton-sponge activity of oligo(ethanamino)amides, based on the 
different PAA building blocks, was investigated.     
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3.1.2.1 Library design and synthesis 
Solid-phase assisted synthesis was used for the assembly of oligomers comprising 
different PAA building blocks and histidines as DNA-binding and buffering units, 
optionally α,ε-amidated lysines as branching points, cysteines for a stabilizing 
disulfide formation and ligand-PEG as functional shielding and cell targeting domain. 
Alanines were used as non-functional substitutes for histidine, cysteine or the 
targeting ligand, respectively. The library can be classified into three topology groups 
with incremental complexity. Scheme 3.2 and Table 3.1 give an overview over the 
synthesized compounds.  
 
Scheme 3.2 Illustration of the synthesized oligomers with different topologies 
 
(A) Linear topology, (B) four-arm topology, (C) four-arm topology HK peptides, (D) PEGylated two-arm topology, 
(E) chemical structures of building blocks. Adapted from [183]. 
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Table 3.1 Sequences, topologies and abbreviations of the investigated oligomers 
ID Sequence (C -> N) Topology Abbreviation 
610 A-Gtt-A-Gtt-A-Gtt-A linear A-(Gtt-A)3 
611 H-Gtt-H-Gtt-H-Gtt-H linear H-(Gtt-H)3 
612 A-Stp-A-Stp-A-Stp-A linear A-(Stp-A)3 
613 H-Stp-H-Stp-H-Stp-H linear H-(Stp-H)3 
614 A-Sph-A-Sph-A-Sph-A linear A-(Sph-A)3 
615 H-Sph-H-Sph-H-Sph-H linear H-(Sph-H)3 
580 AK[AK(A-Gtt-A-Gtt-A-Gtt-AA)2]2 four-arm Gtt-AA 
578 AK[HK(H-Gtt-H-Gtt-H-Gtt-HA)2]2 four-arm Gtt-HA 
579 AK[AK(A-Gtt-A-Gtt-A-Gtt-AC)2]2 four-arm Gtt-AC 
577 AK[HK(H-Gtt-H-Gtt-H-Gtt-HC)2]2 four-arm Gtt-HC 
576 AK[AK(A-Stp-A-Stp-A-Stp-AA)2]2 four-arm Stp-AA 
574 AK[HK(H-Stp-H-Stp-H-Stp-HA)2]2 four-arm Stp-HA 
575 AK[AK(A-Stp-A-Stp-A-Stp-AC)2]2 four-arm Stp-AC 
573 AK[HK(H-Stp-H-Stp-H-Stp-HC)2]2 four-arm Stp-HC 
609 AK[AK(A-Sph-A-Sph-A-Sph-AA)2]2 four-arm Sph-AA 
607 AK[HK(H-Sph-H-Sph-H-Sph-HA)2]2 four-arm Sph-HA 
608 AK[AK(A-Sph-A-Sph-A-Sph-AC)2]2 four-arm Sph-AC 
606 AK[HK(H-Sph-H-Sph-H-Sph-HC)2]2 four-arm Sph-HC 
582 AK[K(KH-(KHH)3-KHK)2]2 four-arm HK peptide (KHH)3-KHK 
584 AK[K(KH-(KHH)5-KHK)2]2 four-arm HK peptide (KHH)5-KHK 
616 A-(dPEG24)2-HK[H-(Stp-H)4-C]2 PEGylated two-arm Ala-His 
617 KRPGKAKHG-(dPEG24)2-AK[A-(Stp-A)4-C]2 PEGylated two-arm B6-Ala 
618 KRPGKAKHG-(dPEG24)2-HK[H-(Stp-H)4-C]2 PEGylated two-arm B6-His 
619 K[(dPEG24)2-FolA]-AK[A-(Stp-A)4-C]2 PEGylated two-arm FolA-Ala 
620 K[(dPEG24)2-FolA]-HK[H-(Stp-H)4-C]2 PEGylated two-arm FolA-His 
Oligomers 573-580 were synthesized by Dr. Edith Salcher, oligomers 582 and 584 were synthesized by Wolfgang 
Rödl. Adapted from [183]. 
 
In a first step, linear structures (Scheme 3.2 A) based on the three PAA building 
blocks Gtt, Stp and Sph were alternatingly assembled with histidine or alanine. These 
linear oligomers served as simple model compounds for alkalimetric titrations and the 
determination of endosomal buffer characteristics.  
In a second step, larger dendron-like four-arm topology oligomers (Scheme 3.2 B) for 
the formation of pDNA polyplexes were assembled. The oligomers were evaluated in 
pDNA complexation assays, size and zeta-potential measurements of the 
corresponding pDNA polyplexes and gene transfer experiments in vitro and in vivo. 
Four-arm histidine-/lysine (HK) peptides of different length (Scheme 3.2 C) were used 
as published benchmarks (cf. Leng & Mixson) [133] for the estimation of the 
transfection efficiency in direct comparison.  
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Finally, in order to investigate the effect of histidine incorporation on the endosomal 
escape under exclusion of a possible influence on the cellular uptake rate, 
PEGylated two-arm Stp oligomers with a peptidic ligand B6 (GHKAKGPRK) binding 
the transferrin receptor (TfR) [104, 175] or folic acid (FolA) for targeting the folate 
receptor (FR) were assembled (Scheme 3.2 D). Compounds with a comparable 
topology and the same targeting ligands, but no histidines, have been shown before 
to exhibit a rather low intrinsic endosomal escape performance [115, 126]. Therefore, 
this particular structure was chosen as an appropriate test system for enhancing 
effects on endosomal escape. The PEGylated two-arm compounds with alanine or 
histidine in the oligo(ethanamino)amide backbone were used for in vitro transfections 
and an endosomal calcein release assay by confocal microscopy.   
The PAA building blocks were synthesized according to the published protocols [155, 
169]. For the synthesis of the rather short linear topology oligomers, the standard 
Fmoc SPS conditions could be used. The synthesis of the more complex four-arm 
topology compounds required an optimized synthesis protocol, reported by Salcher et 
al., with the use of extremely low loaded peptide resins (loading ≤ 0.05 mmol 
amine/g) and DMF containing 1 % Triton X-100 to avoid aggregation of the highly 
branched structure [155]. The synthesis of PEGylated two-arm oligomers containing 
targeting ligands was accomplished under standard Fmoc SPS conditions within one 
continuous sequence. The PEGylation with a total of 48 ethylene oxide units was 
achieved by the twofold coupling of a discrete Fmoc-N-amido PEG carboxylic acid 
comprising an exact number of 24 ethylene oxide units. Folic acid was assembled at 
the exposed N-terminus of the PEG amino acid in two steps. First, coupling (and 
Fmoc deprotection) of Fmoc-Glu-OtBu, which ensures the site-specific attachment of 
folic acid via the γ-carboxy group, and second, coupling (and deprotection) of a 
pteroic acid derivative. All compounds were analyzed by 1H-NMR and RP-HPLC. 
Figure 3.5 shows analytical RP-HPLC chromatograms of representative members of 
the library. More analytical data can be found in the appendix.   
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Figure 3.5 Analytical RP-HPLC chromatograms of representative library members. The analysis was carried out 
using a Waters Sunfire C18 column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 – 0:100 in 20 min) 
containing 0.1 % TFA. For the detection the extinction at 214 nm was monitored. 
 
3.1.2.2 Protonation of linear oligomers 
Alkalimetric back titrations of acidified sample solutions were carried out to determine 
the protonation characteristics and endosomal buffer capacity of the synthesized 
oligomers. As a result of the location of the building blocks at internal positions of the 
sequence, the polyamines exist in a diacylated form. Therefore, each Gtt unit offers 
two, each Stp unit three and each Sph unit four protonatable amines. To illustrate the 
protonation of the different polyamines, titrations of diacetyl-TETA, diacetyl-TEPA 
and diacetyl-PEHA as representative minimal motifs were carried out. The 
characteristic titration curves are shown in Figure 3.6. In accordance with the 
even/odd correlation of unmodified polyamines, the titration curve of diacetyl-TETA 
exhibited a reflection point and buffer maximum in the endosomal pH range, whereas 
diacetyl-TEPA showed a high gradient and rather low buffering in the endosomal pH 
range. Diacetyl-PEHA mediated homogeneous buffering over a broad range 
including the endosomal pH.  
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Figure 3.6 Titration curves between pH 2 and 11 of bis-acetylated polyamines. Solutions containing 100 µmol 
protonatable nitrogens were acidified with hydrochloric acid and backtitrated with 50 mM sodium hydroxide 
solution. Sodium chloride was used for a reference titration without buffering agent. Adapted from [183]. 
 
 
Figure 3.7 Buffer capacities of linear oligomers, determined by alkalimetric titrations. Sample solutions containing 
15 µmol protonatable nitrogens were used for the titrations. N=3 for each compound. (A) Total endosomal buffer 
capacity (pH 5.0-7.4), (B) buffering profile of alanine analogs in the endosomal pH range, total endosomal buffer 
capacity was set to 100 %, (C) buffering profile of histidine analogs in the endosomal pH range, total endosomal 
buffer capacity was set to 100 %. Adapted from [183]. 
 
(A) 
(B) (C) 
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Consistent observations could be made by the quantitative evaluation of the titrations 
of the different linear oligo(ethanamino)amides (Figure 3.7). The oligomers 
comprising building blocks with even number of protonatable amines (Gtt, Sph) 
exhibited significantly higher total endosomal buffer capacities than structures with 
the odd number Stp block (Figure 3.7 A). Looking at the pH range between 5.0 and 
7.4 in more detail (Figure 3.7 B), Gtt (610/A-(Gtt-A)3) predominantly mediated high 
buffering in the lowest sub-range and to a minor extent in higher sub-ranges. In 
contrast, Stp (612/A-(Stp-A)3) showed the opposite distribution with highest buffering 
in the highest pH range and lower buffering in the more acidic ranges. Sph (614/A-
(Sph-A)3) with the longest continuous diaminoethane motif exhibited a rather 
homogeneous protonation distribution over the whole endosomal pH range.  
Incorporation of histidine increased the total endosomal buffer capacity of all 
oligomers, with the effect being most pronounced for the Stp oligomer with an odd 
number of neighboring protonatable amines within the building blocks (Figure 3.7 A). 
For Gtt and Stp oligomers with strong even/odd correlation and contrasting 
protonation profiles, incorporation of histidine (611/H-(Gtt-H)3, 613/H-(Stp-H)3) 
seems to serve as a compensating factor, mediating a more homogeneous buffering 
distribution between pH 5.0 and 7.4 (Figure 3.7 C). The already rather continuous 
relative protonation profile of Sph oligomers only changed slightly due to histidine 
incorporation (615/H-(Sph-H)3).  
 
3.1.2.3 pDNA complexation of four-arm oligomers 
The pDNA binding is expected to correlate with the basicity and the protonation of 
the oligomers at neutral pH. The exclusion of fluorescent ethidium bromide from 
pDNA during polyplex formation was used as a benchmark for the binding potency of 
the oligomers. The ethidium bromide fluorescence in absence of any pDNA 
complexing agent was set to 100 % and the decrease of intensity during the gradual 
addition of oligomer was monitored (Figure 3.8). Focusing on the 
oligo(ethanamino)amides without histidine modification, Sph four-arm oligomers 
(609/Sph-AA) exhibited the highest pDNA complexation capability, being followed by 
the Stp (576/Stp-AA) and Gtt (580/Gtt-AA) oligomers with the lowest pDNA 
complexation. In accordance with the influence of histidine on the relative protonation 
distribution (Figure 3.7 B/C), the incorporation of histidine slightly improved pDNA 
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condensation in case of Gtt four-arm oligomers (580/Gtt-AA versus 578/Gtt-HA), but 
worsened complexation in case of Stp oligomers (576/Stp-AA versus 574/Stp-HA), 
and did not change the complexation capability of Sph oligomers (609/Sph-AA 
versus 607/Sph-HA). However, histidines only affected the pDNA binding to a minor 
extent, since the general complexation potency order of the building blocks (Sph > 
Stp > Gtt) was preserved. 
 
 
Figure 3.8 Ethidium bromide (EtBr) exclusion from pDNA by different four-arm oligomers. EtBr fluorescence 
without pDNA was used as blank, EtBr fluorescence in presence of pDNA and absence of oligomer was set to 
100 %. Adapted from [183]. 
 
As reported by Schaffert et al. and Salcher et al., the incorporation of cysteines for 
the formation of disulfide-crosslinks has a highly positive effect on the polyplex 
stability beyond the electrostatic complexation [154, 155]. Since the ethidium bromide 
exclusion is based on the rapid interaction between pDNA and the basic oligomers, 
additional stabilization motifs, which need certain incubation times for the 
development of their potential, require other test systems. Therefore, agarose gel 
electrophoresis was used for electrophoretic mobility shift assays of pDNA polyplexes 
to investigate the stabilizing effect of disulfide-crosslinks (Figure 3.9). Free pDNA was 
used as a control with unhindered migration in the gel. A sharp band at the position 
of the sample pockets indicates a loss of electrophoretic mobility and the complete 
binding of pDNA. In all cases the integration of cysteines strongly improved the 
binding potency and the stability of the polyplexes. Especially for the Gtt oligomers 
with the lowest pDNA binding ability, the cysteine incorporation seemed to be 
essential to achieve a complete binding.  
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Figure 3.9 Electrophoretic mobility shift assays of different four-arm oligomers by agarose gel electrophoresis. All 
samples contained 200 ng pDNA and oligomer at indicated N/P ratio. Adapted from [183]. 
 
3.1.2.4 Size and zeta potential of pDNA polyplexes with four-arm oligomers 
The hydrodynamic diameter and zeta-potential of pDNA polyplexes were determined 
by dynamic and electrophoretic light scattering (Table 3.2). All compounds formed 
detectable particles with pDNA in the range between 114.3 and 500.8 nm with PDI 
values of 0.084 to 0.346. Generally, the Gtt oligomers formed larger particles (230.8–
500.8 nm) with lower zeta potential (12.7-16.4 mV) than Stp (114.3-127.8 nm, 24.4-
27.6 mV) or Sph (119.2-244.2 nm, 14.6-28.0 mV). This is in accordance with the 
observed lower basicity of Gtt at neutral pH and the lower nucleic acid binding 
potency, since a lower degree of protonation implies a lower charge density, less 
pDNA condensation and more loose complexes. However, no clear effect of 
contained histidines on the physicochemical properties could be observed in the 
measurements. This finding is of particular importance, since a pronounced change 
of size or zeta potential could affect the cellular uptake of the polyplexes and 
therefore impact the transgene expression independently from the endosomal 
escape mechanism. The two four-arm HK peptides 582 and 584 exhibited by far the 
highest zeta potential values (> 35 mV), as a result of the multiple contained primary 
amines with high basicity.     
   Results 
65 
Table 3.2 Hydrodynamic diameters and zeta potentials of pDNA polyplexes with different four-arm 
oligomers at N/P 12. N=3 for each compound.      
ID Abbr. 
 
Z-Average / [nm] PDI ζ-Potential / [mV] 
580 Gtt-AA 264.7 ± 30.5 0.212 ± 0.012  15.8 ± 0.3 
578 Gtt-HA 230.8 ± 16.3 0.084 ± 0.041 15.0 ± 0.4 
579 Gtt-AC 500.8 ± 77.1 0.346 ± 0.053 12.7 ± 0.5 
577 Gtt-HC 255.8 ± 20.6 0.072 ± 0.005 16.4 ± 0.5 
576 Stp-AA 127.8 ± 0.8 0.146 ± 0.028 27.6 ± 0.2 
574 Stp-HA 119.3 ± 1.7 0.169 ± 0.034 25.4 ± 0.6 
575 Stp-AC 114.3 ± 1.3 0.174 ± 0.017 24.4 ± 0.5 
573 Stp-HC 124.8 ± 0.7 0.213 ± 0.012 26.7 ± 0.6 
609 Sph-AA 129.5 ± 1.4 0.239 ± 0.005 14.6 ± 1.7 
607 Sph-HA 119.2 ± 2.5 0.232 ± 0.025 28.0 ± 0.6 
608 Sph-AC 244.2 ± 1.9 0.255 ± 0.006 26.3 ± 0.8 
606 Sph-HC 191.2 ± 2.5 0.328 ± 0.026 25.9 ± 1.0 
582 (KHH)3-KHK 128.5 ± 1.2  0.171 ± 0.003 35.2 ± 0.6 
584 (KHH)5-KHK 157.0 ± 2.7 0.277 ± 0.004 35.4 ± 1.0 
 
3.1.2.5 Gene transfer with four-arm oligomers in vitro 
Plasmid DNA encoding for firefly luciferase was used for transfections of Neuro2A 
neuroblastoma cells to allow the quantification of transgene expression via 
bioluminescence (Figure 3.10). A significantly improved transgene expression by at 
least 10-fold was observed due to histidine modification of the four-arm structures 
based on Stp (576/Stp-AA versus 574/Stp-HA) and Sph (609/Sph-AA versus 
607/Sph-HA) (Figure 3.10 A). The Stp oligomer containing histidine showed a strong 
N/P dependence with the highest gene expression values at the highest investigated 
N/P ratio, whereas for the Sph oligomer the N/P dependent variation was less. At the 
highest N/P ratio, the Stp-histidine oligomer achieved levels in the same range as the 
Sph-histidine oligomer at all investigated ratios, suggesting that Stp needs a higher 
N/P ratio to accumulate a critical endosomal buffer capacity and to achieve a 
vesicular escape, comparable to the Sph oligomer. For the Gtt oligomers (580/Gtt-AA 
versus 578/Gtt-HA) without additional cysteines no significant improvement due to 
histidine incorporation could be observed. For benchmarking, the four-arm topology 
Sph structure containing histidines was compared to two four-arm topology 
lysine/histidine (HK) peptides (cf. Leng & Mixson [133]) of different lengths (Figure 
3.10 B). The Sph based oligomer was significantly superior (20- to 80-fold) over both 
HK peptides at all investigated N/P values, showing the advantage of the artificial 
polyamino acids for gene delivery.  
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Figure 3.10 Luciferase pDNA transfections of Neuro2A neuroblastoma cells with four-arm oligomers at indicated 
N/P ratios. Bioluminescence levels are plotted as relative light units (RLU) per 10.000 cells. LPEI was used as a 
positive control agent, cells treated with HBG served as negative control cells. N=5 for each compound. (A) 
Comparison of Gtt, Stp and Sph based oligomers containing alanines or histidines, (B) comparison of histidine 
containing Sph based oligomer 607 with four-arm HK peptides 582 and 583 of different lengths, (C) comparison of 
Gtt based oligomers containing alanines, cysteines and /or histidines, (D) comparison of Stp and Sph based 
oligomers containing cysteines and alanines or histidines. Transfections were carried out by Dr. Petra Kos 
(Pharmaceutical Biotechnology, LMU). Adapted from [183]. 
 
The absence of an observable histidine effect on the pDNA transfections of Gtt 
oligomers without cysteine can be explained by the insufficient nucleic acid 
complexation. In accordance with the clear improvement of pDNA binding (cf. Figure 
3.9), the integration of cysteines also mediated a highly positive effect on the 
transfection efficiency (Figure 3.10 C). In direct comparison both the histidine 
incorporation in the cysteine containing Gtt oligomer (579/Gtt-AC versus 577/Gtt-HC, 
20- to 400-fold) as well as cysteine incorporation into the histidine containing Gtt 
oligomer (578/Gtt-HA versus 577/Gtt-HC, 7000- to 49000-fold) showed a highly 
significant improvement in transgene expression. The highest values were achieved 
when both elements, cysteine and histidine, were present in the structure. Since the 
‘histidylation’ had no big influence on the total endosomal buffer capacity of the Gtt 
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oligomers but on the relative buffering profile, the specific rearrangement in 
endosomal sub-ranges seems to be the reason for the beneficial effect. Incorporation 
of cysteines in Stp and Sph oligomers also mediated an additional improvement 
(Figure 3.10 D), however not as dramatic as for the Gtt analogs, since both oligomer 
types exhibited rather potent nucleic acid complexation and transfection efficiency 
already without cysteines. Notably, all histidine and cysteine containing oligomers 
were superior to the positive control LPEI. 
The cell viability of Neuro2A cells after transfections with the set of four-arm 
oligo(ethanamino)amides was evaluated by MTT assay (Figure 3.11). No member 
showed a significant impact on the metabolic activity indicating a good cellular 
tolerance toward the compound class.  
 
      
Figure 3.11 Metabolic activity of Neuro2A cells after pDNA transfections with different four-arm oligomers 
determined by MTT assay. The metabolic activity of control cells treated with HBG was set to 100 %. N=5 for 
each compound. MTT assays were carried out by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). Adapted 
from [183]. 
 
3.1.2.6 Gene transfer with four-arm oligomers in vivo 
Based on the encouraging results of the in vitro transfections with four-arm topology 
oligomers, the effect of histidine was evaluated in a xenograft mouse model in vivo. 
The best performer of the library 606/Sph-HC containing histidine and cysteine was 
compared to its histidine-free analog 608/Sph-AC in Neuro2A tumor bearing mice. 
The mice treated by systemic tail vein injection of polyplexes did not display any 
noticeable signs of toxicity. The luciferase activity in homogenized tissue samples of 
tumor, lung, liver, spleen, kidney and heart was measured 48 hours after 
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administration of the polyplexes (Figure 3.12). Importantly, the histidine containing 
606 polyplexes mediated the highest luciferase transgene expression in the tumor 
tissue (approx. 20000-fold above background). The tumor expression levels were 
over 32-fold improved over the histidine-free 608 polyplexes. Both formulations 
displayed significant transgene expression in the liver (approx. 3600- to 7500-fold 
above background), and low expression levels (approx. 600- to 800-fold above 
background) in lung and heart. In contrast to 608, the histidine-containing 606 
polyplexes also mediated considerable gene transfer (approx. 2300- to 2500-fold 
above background) in spleen and kidney. In sum, histidine containing 606 displayed 
32-fold, 5-fold, 4-fold and 2-fold enhanced activity over histidine-free 608 in tumor, 
kidney, spleen and liver, respectively.    
 
 
Figure 3.12 Luciferase reporter gene expression in vivo. Comparison of the four-arm Sph based oligomers 
containing cysteines and alanines (608/Sph-AC) or histidines (606/Sph-HC). Polyplexes containing pCMVLuc and 
oligomer at N/P 12 were injected intravenously in subcutaneous Neuro2A tumor bearing mice. Luciferase activity 
in homogenized tissue samples was measured 48 hours after administration. N=5 animals per group. Animal 
experiments were carried out by Annika Herrmann and Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). 
Adapted from [183]. 
 
3.1.2.7 Receptor-targeted gene transfer with PEGylated two-arm oligomers 
Since the advantageous effect of histidine on the pDNA transfections with 
oligo(ethanamino)amides could also be a result of a changed uptake rate of the 
polyplexes, PEGylated two-arm oligomers with attached targeting-ligands were 
synthesized (cf. Scheme 3.2 D). The shielding of the oligomer backbone charge was 
supposed to exclude any unspecific ionic interactions, while the targeting ligand 
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mediates a receptor-specific cellular uptake. Since the biggest effect of histidine 
modification on the total endosomal buffer capacity was observed for Stp based 
oligomers, this building block was chosen for the receptor-targeted pDNA delivery 
carriers. The peptidic ligand B6 binding to the transferrin receptor (TfR) and folic acid 
(FolA) targeting folate receptor (FR) were used for the ligand-equipped oligomers.  
 
 
Figure 3.13 Electrophoretic mobility shift assay of PEGylated two-arm oligomers by agarose gel electrophoresis. 
All samples contained 200 ng pDNA and oligomer at indicated N/P ratio.  
 
As illustrated by Figure 3.13 the oligomers with targeting ligand mediated complete 
pDNA binding at N/P 6 or higher and the hydrodynamic diameter of the PEGylated 
polyplexes is in the range between 336.3 and 493.2 nm (Table 3.3). The rather big 
size presumably is the result of a relatively loose condensation of pDNA into an 
elongated ‘spaghetti-like’ conformation, which has been reported for similar 
PEGylated compounds before [126]. Importantly, the PEGylation seems to achieve 
shielding of the oligo(ethanamino)amide backbone charge, since all polyplexes 
exhibited rather low zeta potentials.  
 
Table 3.3 Hydrodynamic diameters and zeta potentials of pDNA polyplexes with PEGylated two-arm 
oligomers at N/P 12. N=3 for each compound.      
ID Abbr. 
 
Z-Average / [nm] PDI Zeta-Potential / [mV] 
616 Ala-His 356.3 ± 28.2 0.389 ± 0.103 -0.2 ± 0.4 
617 B6-Ala 
B 
493.2 ± 200.4 0.469 ± 0.112 6.1 ± 2.1 
618 B6-His 336.3 ± 111.4 0.436 ± 0.054 12.8 ± 1.5 
619 FolA-Ala 
 
398.4 ± 15.9 0.438 ± 0.027 9.5 ± 0.4 
620 FolA-His 461.6 ± 43.2 0.794 ± 0.103 7.1 ± 0.2 
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Figure 3.14 Cellular uptake of Cy5-pDNA polyplexes with PEGylated two-arm oligomers at N/P 12 in TfR 
expressing DU145 cells as determined by flow cytometry. Cells treated with HBG served as negative control. 
Flow cytometry was carried out by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). Adapted from [183]. 
 
As quantitated by flow cytometry (Figure 3.14), the pDNA polyplexes containing 
histidine but no targeting ligand (616/Ala-His) did not show an enhanced cellular 
uptake into TfR positive DU145 prostate cancer cells compared to the negative 
control. Furthermore both B6 containing structures (617/B6-Ala and 618/B6-His) got 
internalized to the same extent, independent of alanine- or histidine in the backbone 
sequence.  
Very consistent observations could be made in the luciferase gene expression assay 
(Figure 3.15), where the untargeted structure lacking B6 (616/Ala-His) did not 
mediate signals above background level, with or without addition of chloroquine as 
endosomolytic agent. In case of the targeted structures containing B6, plus or minus 
histidine, the two analogs (618/B6-His, 617/B6-Ala) mediated comparable 
transfection levels when chloroquine was added in transfections to enforce the 
endosomal escape. This correlates with the comparable cellular uptake dominated by 
the presence of the receptor-targeting ligand. In the absence of chloroquine however, 
the histidine analog (618/B6-His) was 10- to 30-fold superior over the alanine analog 
(617/B6-Ala), indicating a far better intrinsic endosomal escape performance. In order 
to visualize effects on the endosomal release, the intracellular distribution of the 
fluorescent dye calcein, which was passively co-internalized into the cells during 
transfection, was monitored via spinning disk confocal microscopy (Figure 3.16). The 
transfection with the histidine-free analog 617 displayed primarily endosomal spotty 
calcein staining (Figure 3.16 A), whereas a clearly higher calcein release out of 
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endosomes was observable for the histidine containing oligomer 618 (Figure 3.16 B). 
The cytosolic calcein was quantified by digital image processing and a significant 
effect on the intracellular release could be found (Figure 3.16 C).  
 
 
Figure 3.15 Luciferase pDNA transfections of TfR expressing DU145 prostate cancer cells with PEGylated two-
arm oligomers. Comparison of oligomers containing histidine (616, 618) or alanine (617) in the cationic core and 
as targeting ligand the TfR binding peptide B6 (617, 618) or alanine as negative control ligand (616).  
Bioluminescence levels are plotted as relative light units (RLU) per 10.000 cells. Chloroquine was used as 
endosome disruptive agent in indicated transfections. N=5 for each compound. Transfections were carried out by 
Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). Adapted from [183]. 
 
 
 
Figure 3.16 Calcein release assay in DU145 cells via spinning disk confocal microscopy. Images show 
representative cells transfected with pDNA polyplexes of oligomer (A) 617/B6-Ala or (B) 618/B6-His, in medium 
containing 0.5 mg/mL calcein.  (C) Quantification of cytosolic calcein release by digital image processing (n=20 for 
617/B6-Ala, n=22 for 618/B6-His). Experiments were carried out by Dr. Frauke Mickler (Physical Chemistry, 
LMU). Adapted from [183]. 
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To confirm the positive effect of histidine modifications on pDNA transfections also in 
another cell model of receptor-mediated uptake, the analog oligomers containing 
FolA as targeting ligand and FR expressing KB cells were used (Figure 3.17). Also in 
the luciferase pDNA transfections of this cell line, the untargeted control lacking a 
targeting ligand (616/Ala-His), despite the presence of buffering histidine residues, 
did not mediate significant signals above background level with or without addition of 
chloroquine, indicating that the cellular uptake requires the presence of the receptor-
targeting ligand. In case of the FolA targeted oligomers and in the absence of 
chloroquine, the histidine containing compound (620/FolA-His) mediated 30- to 100-
fold higher transgene expression levels than the alanine analog (619/FolA-Ala). Thus 
also in this targeting-ligand and cell-line combination model the highly positive effect 
of histidines on endosomal escape and subsequently transgene expression could be 
shown.   
 
 
Figure 3.17 Luciferase pDNA transfections of FR expressing KB cells with PEGylated two-arm oligomers at 
indicated N/P ratios. Comparison of oligomers containing histidine (616, 620) or alanine (619) in the cationic core, 
and folic acid as targeting ligand (619, 620) or alanine as negative control ligand (616). Bioluminescence levels 
are plotted as relative light units (RLU) per 10.000 cells. Chloroquine was used as endosome disruptive agent in 
indicated transfections. N=5 for each compound. Transfections were carried out by Dr. Petra Kos (Pharmaceutical 
Biotechnology, LMU). Adapted from [183]. 
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3.1.3 The combination of TETA and TEPA based polyamino acids 
The diaminoethane building blocks Gtt, Stp and Sph based on polyamines of 
different lengths have shown to mediate individual protonation characteristics in 
oligo(ethanamino)amides with big impact on crucial stages of gene transfer, such as 
pDNA binding and endosomal escape. The two building blocks based on the 
polyamines triethylene tetramine (Gtt) and tetraethylene pentamine (Stp) exhibited 
big differences in the total endosomal buffer capacities and the relative protonation 
distribution. While Stp provided a rather low buffer capacity between pH 5 and 7.4 
(approx. 15 % of amines) with the most frequent protonation between pH 7 and 7.4, 
the Gtt amines were protonated in the endosomal pH range to a much higher extent 
(> 30 % of amines) and predominantly in the lowest sub-ranges between pH 5 and 6. 
As a result of the opposing characteristics, both building blocks have their own 
drawbacks: Stp offers good pDNA binding but low endosomal buffering; Gtt exhibits a 
high buffer capacity, but poor binding. It has been shown that the integration of 
histidines modulates the endosomal protonation and affects pDNA delivery in a highly 
positive fashion. However, based on the made observations, it is also a consequent 
approach to combine the building blocks with opposing characteristics within one 
structure.  
 
3.1.3.1 Library design and synthesis 
Oligomers comprising different ratios of the two diaminoethane building blocks 
glutaryl-triethylene tetramine (Gtt) and glutaryl tetraethylene pentamine (Gtp) were 
assembled by solid-phase synthesis. Scheme 3.3 and Table 3.4 give an overview 
over the synthesized compounds. Coupled at an internal position of the sequence Gtt 
offers two and Gtp three protonatable amines, however in both building blocks 
glutaric acid serves as the molecular connecter of the polyamine segments (Scheme 
3.3 B). A topology comparable to the PEGylated two-arm oligomers (cf. Scheme 3.2 
D) was chosen since these structures exhibit a rather poor intrinsic endosomal 
escape performance, which makes the clear observation of effects on endosomal 
escape possible.  
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Scheme 3.3 Illustration of the synthesized oligomers with combinations of Gtt and Gtp 
 
(A) Schemes of oligomers with two-arm topology, (B) chemical structures of the used building blocks. 
 
Table 3.4 Sequences, protonatable amines and abbreviations of the synthesized oligomers  
ID Sequence (C -> N) 
Proton. Amines Abbreviation 
Gtp Gtt Total 
754 AK(Gtp4-C)2 24 - 26 Gtp 
815 AK[(Gtp-Gtt)2-Gtp-C]2 18 8 28 Gtp3-Gtt2 
816 AK[(Gtt-Gtp)2-Gtt-C]2 12 12 26 Gtt3-Gtp2 
817 AK(Gtt4-C)2 - 16 18 Gtt 
The number of protonatable amines, provided by the different building blocks, as well as the total number 
including N-terminal primary amines are indicated. 
 
The polyamino acid Gtp was synthesized as reported previously [169]. For the 
synthesis of the oligo(ethanamino)amides, the same standard Fmoc SPS conditions 
were used as for the PEGylated two-arm oligomers before (cf. 3.1.2). All compounds 
were analyzed by 1H-NMR and RP-HPLC. Figure 3.18 shows the analytical RP-
HPLC chromatograms of the compounds. 1H-NMR data can be found in the 
appendix.       
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Figure 3.18 Analytical RP-HPLC chromatograms of two-arm oligomers with combinations of Gtt and Gtp. The 
analysis was carried out using a Xbridge C18 column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 
– 0:100 in 10 min) containing 0.1 % TFA. For the detection the extinction at 214 nm was monitored. 
 
3.1.3.2 Protonation of two-arm oligomers with combinations of Gtt and Gtp 
Alkalimetric back titrations of acidified samples were carried out to determine the 
buffer capacity between pH 5 and 7.4 as well as the relative protonation in sub-
ranges of the endosomal pH (Figure 3.19). Consistent with the previous 
observations, the oligomer 817/Gtt mediated an over two-fold higher total buffer 
capacity than its analog 754 based on Gtp only (Figure 3.19 A). Moreover, the total 
buffer capacity of the Gtp oligomer was gradually increased with increasing content 
of Gtt. Looking at the protonation in the endosomal range in more detail, the 
previously observed opposing protonation characteristics of the oligomers containing 
Gtp (754) or Gtt (817) only could be reconfirmed (Figure 3.19 B). The protonation 
distributions of the mixed oligomers 815/Gtp3-Gtt2 and 816/Gtt3-Gtp2 represent 
hybrid forms of the contrary distributions of 754 and 817. Since Gtp has its highest 
buffering in the highest pH sub-range and Gtt in the lowest, the increase of the total 
buffer capacity due to the integration of Gtt is based on a particularly enhanced 
buffering at low pH 5 to 6 and none of the compounds exhibited a maximal buffering 
in a medium sub-range. This is in sharp contrast to the effect of histidine integration, 
since the pKa of the imidazole group particularly mediates buffering around 6 and 
therefore causes a more homogeneous protonation distribution in the whole 
endosomal pH range.      
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(A)             (B) 
     
Figure 3.19 Buffer capacities of two-arm oligo(ethanamino)amides with combinations of Gtt and Gtp determined 
by alkalimetric titrations. Oligomer amounts containing 15 µmoles of protonatable amines were used for the 
titrations. (A) Total endosomal buffer capacity (pH 5.0-7.4), (B) buffering profile in the endosomal pH range, total 
endosomal buffer capacity was set to 100 %.  
 
3.1.3.3 pDNA complexation of two-arm oligomers with combinations of Gtt 
and Gtp 
In Figure 3.20 the ethidium bromide exclusion from pDNA due to ionic complexation 
by the oligomers is shown. Within the set 817/Gtt, 816/Gtt3-Gtp2 and 754/Gtp, the 
decreased basicity at neutral pH due to an increased content of Gtt building block 
can be recognized. However, the differences are not as pronounced as in case of the 
four-arm oligomers (cf. 3.1.2). The compound 815/Gtp3-Gtt2 exhibited the highest 
pDNA complexation potency, which cannot be explained by the basicity of the single 
building blocks only, since a portion of the protonatable amines in this mixed oligomer 
is provided by the less basic Gtt. One simple explanation could be that 815 
represents the member with the highest total number of protonatable amines (cf. 
Table 3.4). Looking at the electrophoretic mobility shift assay (Figure 3.21), all 
oligomers containing the Gtp building block (754, 815 and 816), exhibited 
comparable efficient pDNA complexation. The analog 817 containing Gtt only clearly 
showed lower binding, since complete shift of the pDNA band could first be observed 
at a higher N/P of 12.  
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Figure 3.20 Ethidium bromide (EtBr) exclusion from pDNA by two-arm oligomers with combinations of Gtt and 
Gtp. EtBr fluorescence without pDNA was used as blank, EtBr fluorescence in presence of pDNA and absence of 
oligomer was set to 100 %.  
 
 
Figure 3.21 Electrophoretic mobility shift assay of two-arm oligomers with combinations of Gtt and Gtp by 
agarose gel electrophoresis. All samples contained 200 ng pDNA and oligomer at indicated N/P ratio.  
 
3.1.3.4 Size and zeta potential of pDNA polyplexes with two-arm oligomers 
containing combinations of Gtt and Gtp 
In Figure 3.22 the different z-average diameters of the pDNA polyplexes as 
determined by DLS are illustrated. Consistent with the lower degree of protonation at 
neutral pH, an increasing content of Gtt increases the particle size, since the pDNA 
gets less compacted by oligomers with lower charge density. In case of the Gtt 
oligomer 817 huge aggregates and particles with high polydispersity were observed. 
Therefore, no reliable size or zeta potential determinations were possible. For 
reasons of completeness and to note the destructive effect of Gtt, the recorded 
values are also depicted in the graph.    
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Figure 3.22 Hydrodynamic diameter and zeta potential of pDNA polyplexes at N/P 12 of two-arm oligomer with 
combinations of Gtt and Gtp. N=3 for each compound. (A) Z-average in nm (left axis, black bars) and PDI (right 
axis, shaded bars), (B) zeta potential in mV. * Oligomer 817 did not form appropriate particles meeting the criteria 
for reliable determinations. 
 
3.1.3.5 pDNA transfections with two-arm oligomers containing combinations 
of Gtt and Gtp 
Neuro2A cells were transfected with pCMVLuc and the set of two-arm oligomers. As 
shown in Figure 3.23 the Gtp oligomer 754 mediated remarkable transgene 
expression levels superior to LPEI with the addition of chloroquine as endosome 
disruptive agent. However, in the absence of chloroquine, no transgene expression 
above background level could be observed. This clearly shows the potential and 
requirement for strategies to enhance the endosomal escape. Unfortunately, despite 
the gradually increased endosomal buffer capacities, none of the two-arm oligomers 
with combinations of Gtp and Gtt mediated transgene expression. Since all 
compounds containing Gtp showed sufficient pDNA binding as well as comparable 
particle formation and zeta potentials, obviously the integration of Gtt is not suitable 
to enhance the endosomal escape. As determined by the alkalimetric titrations, the 
increase of total endosomal buffer capacity results from a modulation in the low 
range between pH 5 and 6. In contrast, histidine increases buffering in the higher 
less acidic ranges of endosomal pH. Obviously the buffer maximum of Gtt alone is 
not appropriate to promote proton-sponge activity of polyplexes and to enhance 
transgene expression. This explanation is consistent with the observation that Gtt 
based four-arm oligomers also showed a great benefit due to histidine incorporation, 
although the total buffer capacity of the Gtt four-arm oligomers was not greatly 
(A) (B) 
* 
* 
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enhanced. However, the histidines caused a rearrangement of the protonation 
distribution of Gtt oligomers and a higher buffering in higher pH sub-ranges. 
 
 
Figure 3.23 Luciferase pDNA transfections of Neuro2A neuroblastoma cells with two-arm oligomers at indicated 
N/P ratios. Bioluminescence levels are plotted as relative light units (RLU) per 10.000 cells. N=5 for each 
compound. Chloroquine was added in indicated transfections with 754 to illustrate the effect of an enhanced 
endosomal escape. Transfections were carried out by Ana Krhac Levacic (Pharmaceutical Biotechnology, LMU).  
 
 
3.1.4 The influence of pyridyl amino acids on the proton-sponge activity 
The integration of histidines in oligo(ethanamino)amides has shown an enhancement 
of the buffer capacity with great improvement of endosomal escape and the final 
transgene expression. Within the set of proteinogenic amino acids, histidine with a 
pKa of the imidazole group around 6 offers the most appropriate properties for this 
purpose. However, the oligo(ethanamino)amide synthesis platform is not limited to 
natural α-amino acids. Therefore, it is unclear whether other protonatable building 
blocks or artificial amino acids with slightly different pKa values could offer even more 
suitable buffering properties for a higher boost of proton-sponge activity and gene 
transfer efficiency. Pyridine is a basic heterocyclic compound with a lower pKa 
(approx. 5.2) than imidazole. The pKa values of alkylated pyridines depend on the 
exact position at the pyridine ring. The methylpyridine derivatives 3-picoline and 4-
picoline for instance exhibit pKa values of approx. 5.6 or 6.0 respectively (Figure 
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3.24) [184]. To investigate the effect of pyridines with gradual lower basicities 
compared to histidine, 3-(3-pyridyl)-alanine and 3-(4-pyridyl)-alanine, abbreviated 
3PAL or 4PAL below, were integrated in Stp based oligo(ethanamino)amides to 
investigate the effect on the endosomal buffering and endosomal escape. 
  
Figure 3.24 Chemical structures and pKa values of pyridine derivatives [184]. 
 
3.1.4.1 Library design and synthesis 
Commercially available Nα-Fmoc derivatives of 3PAL and 4PAL were used in the 
solid-phase assisted synthesis of two-arm oligomers. Scheme 3.4 and Table 3.5 give 
an overview over the set of compounds. Three members contained either 3PAL 
(811/Stp-3PAL), 4PAL (812/Stp-4PAL) or histidine (813/Stp-H) alternatingly coupled 
with Stp in the backbone. Compound 202/Stp represents the control oligomer without 
additional buffering units beside Stp.  
 
Scheme 3.4 Illustration of the synthesized oligomers with additional pyridylalanines or histidine  
 
(A) Schemes of oligomers with two-arm topology, (B) chemical structures of the used building blocks. 
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Table 3.5 Sequences, protonatable nitrogens and abbreviations of the synthesized oligomers 
ID Sequence (C -> N) Proton. Nitrogens Abbreviation 
202 AK(Stp4-C)2 26 Stp 
811 A-3PAL-K[(3PAL-Stp)4-3Pal-C]2 37 Stp-3PAL 
812 A-4PAL-K[(4PAL-Stp)4-4Pal-C]2 37 Stp-4PAL 
813 AHK[(H-Stp)4-HC]2 37 Stp-H 
Oligomer 202 was synthesized by Dr. Irene Martin (visiting scientist, IRB Barcelona, Spain). 3PAL, 3-(3-Pyridyl)-
alanine; 4PAL, 3-(4-Pyridyl)-alanine. 
 
 
Figure 3.25 Analytical data of two-arm oligomers with pyridylalanines or histidine. (A) Analytical RP-HPLC 
chromatograms. The analysis was carried out using a Xbridge C18 column (5µm, 4.6 x 150mm) and a 
water/acetonitrile gradient (95:5 – 0:100 in 10 min) containing 0.1 % TFA. For the detection the extinction at 214 
nm was monitored. (B) 
1
H-NMR spectra of oligomers containing pyridylalanines. 
 
The standard Fmoc SPS conditions were used. All compounds were analyzed by 1H-
NMR and RP-HPLC. Figure 3.25 shows the analytical RP-HPLC chromatograms of 
the compounds and 1H-NMR spectra of the pyridylalanine containing compounds 811 
and 812. More analytical data can be found in the appendix. Importantly, both 
pyridylalanine building blocks seemed to be compatible with the used solid-phase 
synthesis chemistry. Since pyridine derivatives can undergo N-acylation reactions 
(A) 
(B) 
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with activated carboxylic acids (e.g. anhydrides), which might decrease coupling 
efficiency or produce side-products due to a subsequent acyl transfer, the suitability 
of the chosen conditions is not trivial. However, no indication for interference with the 
synthesis procedure could be observed.  
 
3.1.4.2 Protonation of two-arm oligomers with pyridylalanines or histidines 
Figure 3.26 shows the total buffer capacity between pH 5 and 7.4 and the relative 
protonation in the accordant sub-ranges as determined by alkalimetric back titrations. 
Both pyridylalanine derivatives slightly increased the total buffer capacity of the 
corresponding oligo(ethanamino)amides (811, 19.3 %; 812, 22.4 %) compared to the 
bare Stp oligomer (202, 16.6 %). However, the effect of histidine (813, 35.8 %) could 
not be approached. Looking at the relative protonation (Figure 3.26 B), the oligomer 
202 exhibited the characteristic distribution of Stp as observed before. In case of 811 
and 812 the relative protonation is most influenced in the lowest pH range, indicating 
the lower pKa values of the pyridine derivatives. Consistent with the inductive effect 
depending on the position at the pyridine ring, 4PAL exhibited higher basicity. 
However, for both pyridylalanines a significant ratio of buffer capacity lies below pH 5 
and presumably is not biologically active. In the comparison of the pyridylalanines 
and histidines, a higher endosomal buffer capacity does not equal lower protonation 
at neutral pH, in consequence of the pKa location on the pH scale. 813/Stp-H exhibits 
much higher buffer capacity than 811/Stp-3PAL or 812/Stp-4PAL; but since the pKa 
of the imidazole group is closer to 7.4 it also exhibits a higher degree of protonation 
at neutrality.        
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Figure 3.26 Buffer capacities of two-arm oligomers with additional pyridylalanines or histidine determined by 
alkalimetric titrations. Oligomer amounts containing 15 µmoles of protonatable nitrogens were used for the 
titrations. (A) Total endosomal buffer capacity (pH 5.0-7.4), (B) buffering profile in the endosomal pH range, total 
endosomal buffer capacity was set to 100 %.  
  
3.1.4.3 pDNA complexation of two-arm oligomers with pyridylalanines or 
histidine 
The degree of protonation at neutral pH (811/Stp-3PAL < 812/Stp-4PAL < 813/Stp-H 
< 202/Stp) correlates with the pDNA binding potencies as determined by the 
electrophoretic mobility shift (Figure 3.27) and ethidium bromide exclusion assays 
(Figure 3.28). In both assays, the Stp oligomer 202 exhibited the highest binding 
ability, followed by the histidine analog 813 and finally the two compounds containing 
pyridylalanines with the lowest potency.  
 
 
Figure 3.27 Electrophoretic mobility shift assay of two-arm oligomers with additional pyridylalanines or histidine 
by agarose gel electrophoresis. All samples contained 200 ng pDNA and oligomer at indicated N/P ratios.  
 
(A) (B) 
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Figure 3.28 Ethidium bromide (EtBr) exclusion from pDNA by two-arm oligomers with additional pyridylalanines 
or histidine. EtBr fluorescence without pDNA was used as blank, EtBr fluorescence in presence of pDNA and 
absence of oligomer was set to 100 %.  
 
3.1.4.4 Size and zeta potential of pDNA polyplexes with two-arm oligomers 
containing pyridylalanines or histidine 
All oligomers formed pDNA polyplexes with a hydrodynamic diameter in the range 
between 239.3 and 365.3 nm (Figure 3.29 A). A slight tendency of the 
physicochemical properties of the polyplexes, in accordance with the correlation 
between basicity and pDNA binding, could be recognized. With increasing degree of 
protonation at neutral pH, the size of the polyplexes decreases. The results of the 
zeta potential measurements suggest a similar effect (higher protonation, higher zeta 
potential), however here the differences are even less pronounced and rather 
negligible (Figure 3.29 B).  
 
 
 
 
 
 
   Results 
85 
 
 
 
 
 
 
Figure 3.29 Hydrodynamic diameter and zeta potential of pDNA polyplexes with two-arm oligomers containing 
additional pyridylalanines or histidine. Polyplexes were formed at N/P 12. N=3 for each compound. (A) Z-average 
in nm (left axis, black bars) and PDI (right axis, shaded bars), (B) zeta potential in mV.  
 
3.1.4.5 pDNA transfections with two-arm oligomers containing 
pyridylalanines or histidine 
In pCMVLuc transfections of Neuro2A cells, the histidine containing oligomer 813 
was the only compound mediating notably high transgene expression (Figure 3.30 
A). At the highest N/P of 24, LPEI was even outperformed by this rather simple 
conjugate. In contrast, no significant indication of gene transfer was observed in case 
of transfections with the pyridylalanine analogs 811 or 812. Since no effect on the cell 
viability after transfection was found in any case (Figure 3.30 B), an increase of 
cytotoxicity due to incorporation of pyridylalanines is excluded as reason for the 
absence of transgene expression. Both pyridylalanine derivatives seem to be 
inappropriate for an enhancement of the endosomal escape of pDNA polyplexes. An 
obvious explanation is the only marginal effect on the total buffer capacity (cf. Figure 
3.26). In addition, the most pronounced effect on the endosomal protonation is 
located in the lowest sub-range between pH 5 and 5.5. As observed for the 
combinations of Gtt and Gtp before, the total buffer capacity between pH 5 and 7.4 
alone is no good predictor for proton-sponge activity (cf. Figure 3.19 and Figure 
3.23). The exact location of buffering in the endosomal pH range obviously is a 
critical parameter, which seems to be met by histidine in an ideal fashion.     
 
 
(A) (B) 
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Figure 3.30 Luciferase pDNA transfections of Neuro2A neuroblastoma cells with two-arm oligomers at indicated 
N/P ratios. N=5 for each compound. (A) Bioluminescence levels are plotted as relative light units (RLU) per 
10.000 cells. (B) Metabolic activity of transfected cells was determined by MTT assay, levels of control cells 
treated with HBG were set to 100 %. Experiments were carried out by Ana Krhac Levacic (Pharmaceutical 
Biotechnology, LMU).  
 
 
3.1.5 Iminodiacetic acid derived polyamino acids 
The combination of Stp and histidine showed remarkable potency and enhancement 
of transgene expression in several examples. Here, the polyamino acid building block 
Stp, with the lowest endosomal buffer capacity, predominantly served as pDNA 
binding unit, whereas histidine offered the required buffer capacity to promote 
endosomal escape. However, the integration of separate domains for both tasks 
within one building block would be an attractive approach to simplify the solid-phase 
synthesis process. The established building blocks (Gtt, Stp, Gtp, etc.) contain 
(A) 
(B) 
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dicarboxylic acids, which serve as molecular adapter for the linkage of the polyamine 
segments by amide formation. By using iminodiacetic acid (IDA) derivatives (Figure 
3.31) as the dicarboxylic acid part, an additional nitrogen can be introduced, giving 
the diacid part a new function beyond the simple chemical linkage. IDA and the two 
derivatives methyl-IDA (M-IDA) and trifluoroethyl-IDA (TFE-IDA) were used for the 
synthesis of TEPA based building blocks with gradually decreased basicity and 
compared to the structural analog Gtp.  
 
 
Figure 3.31 Chemical structures of different dicarboxylic acids. 
 
3.1.5.1 Building block synthesis  
IDA and M-IDA are commercially available organic compounds. TFE-IDA was 
synthesized as summarized in Scheme 3.5 A. Briefly, 2,2,2-trifluoroethylamine was 
reacted with two equivalents of chloroacetic acid in an aqueous alkaline solution. 
Since IDA derivatives can act as strong chelating agents, the disubstituted product 
could be precipitated selectively by addition of barium chloride solution. Finally, TFE-
IDA was obtained by heating with sulfuric acid and removal of the barium sulfate. For 
the intended use as building block during solid-phase synthesis, the secondary 
amine of IDA was protected with a tert-butoxycarbonyl (Boc) group (Scheme 3.5 B). 
Cyclic anhydrides of the derivatives Boc-IDA, M-IDA and TFE-IDA were prepared by 
dehydration with dicyclohexylcarbodiimide (DCC) in dichloromethane (Scheme 3.5 
C). The subsequent steps were carried out according to the published Gtp synthesis 
protocol but with substitution of glutaric anhydride against the IDA anhydrides 
(Scheme 3.5 D). 1H-NMR data and mass spectrums of intermediate products and 
building blocks can be found in the appendix. 
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Scheme 3.5 Synthesis of iminodiacetic acid (IDA) derived polyamino acid building blocks 
 
Boc2O, di-tert-butyl dicarbonate (Boc anhydride); DCC, dicyclohexylcarbodiimide; Fmoc-OSu, Fmoc 
N-hydroxysuccinimide ester.  
 
3.1.5.2 Library design and synthesis 
The two-arm topology, which was used before for the investigation of effects on 
endosomal escape, was chosen for the incorporation of the new IDA derived building 
blocks (755/IDAtp, 756/M-IDAtp, 757/TFE-IDAtp). The Gtp analog 754 and a new 
oligomer 814, with a repetitive (H-Stp) motif and the same number of protonatable 
nitrogens as the IDAtp based compounds, served as references. Scheme 3.6 and 
Table 3.6 give an overview over the set of compounds. For the syntheses, the 
standard Fmoc SPS conditions were used. Figure 3.32 shows the analytical RP-
HPLC chromatograms of the compounds. 1H-NMR data can be found in the 
appendix.  
 
 
 
 
(A) 
(B) 
(C) 
(D) 
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Scheme 3.6 Illustration of the synthesized oligomers with new IDA derived building blocks 
 
(A) IDA and Gtp oligomers, (B) control oligomer with (histidine-Stp) repeating unit, (C) chemical 
structures of building units.  
 
Table 3.6 Sequences, protonatable nitrogens and abbreviations of the synthesized oligomers  
ID Sequence (C -> N) Proton. Nitrogens Abbreviation 
754 AK(Gtp4-C)2 26 Gtp 
755 AK(IDAtp4-C)2 34 IDAtp 
756 AK[(M-IDAtp)4-C]2 34 M-IDAtp 
757 AK[(TFE-IDAtp)4-C]2 34 TFE-IDAtp 
814 AK[(H-Stp)4-C]2 34 (H-Stp) 
 
 
Figure 3.32 Analytical RP-HPLC chromatograms of IDA based two-arm oligomers. The analysis was carried out 
using a Xbridge C18 column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 – 0:100 in 10 min) 
containing 0.1 % TFA. For the detection the extinction at 214 nm was monitored. 
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3.1.5.3 Protonation of two-arm oligomers with IDA derived building blocks  
As illustrated by Figure 3.33 A, only oligomer 755 with the IDAtp building block 
exhibited a slightly increased total endosomal buffer capacity compared to the Gtp 
analog 754. Both M-IDAtp and TFE-IDAtp decreased the buffer capacity of the 
related compounds. The reason for this can be found by looking at the relative 
protonation (Figure 3.33 B). The secondary amine of IDA has a low basicity, which 
only affects protonation in the lower sub-ranges between pH 5 and 6. Like expected 
the basicity of the tertiary amine in M-IDA is lower, since only a slight effect on the 
lower pH ranges can be observed. In case of TFE-IDA no big difference compared to 
Gtp is observable, since the pKa lies far below pH 5 and therefore does not affect the 
protonation in the endosomal pH range at all. Since the M-IDA and TFE-IDA nitrogen 
almost had no effect on the endosomal pH range, but were considered in the 
calculation of the sample amounts for titrations, the determined total buffer capacity 
of 756 and 757 even decreased compared to 754.     
  
 
 
 
 
 
Figure 3.33 Buffer capacities of two-arm oligomers with IDA derived building blocks. Oligomer amounts 
containing 15 µmoles of protonatable nitrogens were used for the titrations. (A) Total endosomal buffer capacity 
(pH 5.0-7.4), (B) buffering profile in the endosomal pH range, total endosomal buffer capacity was set to 100 %.  
 
3.1.5.4 pDNA complexation of two-arm oligomers with IDA derived building 
blocks 
All compounds mediated comparable ethidium bromide exclusion from pDNA. This 
result was expected, since the building blocks were designed to keep the pDNA 
binding motif TEPA unmodified. 
(B) (A) 
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Figure 3.34 Ethidium bromide (EtBr) exclusion from pDNA by two-arm oligomers with IDA derived building 
blocks. EtBr fluorescence without pDNA was used as blank, EtBr fluorescence in presence of pDNA and absence 
of oligomer was set to 100 %.  
 
3.1.5.5 pDNA transfections with two-arm oligomers containing IDA derived 
building blocks 
In pCMVLuc transfections of Neuro2A cells no enhancing effect of the IDA building 
blocks on endosomal escape or transgene expression could be observed (Figure 
3.35 A). In contrast, the control oligomer 814 with the same number of TEPA units 
and protonatable nitrogens, but histidine instead of IDA derivatives, mediated distinct 
transgene expression. The basicity of the IDA nitrogens obviously is too low to affect 
the endosomal buffering in a proper way. Fortunately, no obvious sign of an 
increased cytotoxicity of the oligomers containing IDA derivatives could be found 
(Figure 3.35 B). Although the new building blocks did not serve the intended purpose, 
the described synthesis approach represents a possibility for the integration of new 
functionalities, giving the dicarboxylic acid part a new function without modifying the 
pDNA binding polyamine motif.  
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(B) 
 
Figure 3.35 Luciferase pDNA transfections of Neuro2A neuroblastoma cells with two-arm oligomers at indicated 
N/P ratios. N=5 for each compound. (A) Bioluminescence levels are plotted as relative light units (RLU) per 
10.000 cells. (B) Metabolic activity of transfected cells was determined by MTT assay, levels of control cells 
treated with HBG were set to 100 %. Experiments were carried out by Ana Krhac Levacic (Pharmaceutical 
Biotechnology, LMU). 
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3.2 Targeted and shielded oligo(ethanamino)amides for receptor-
specific nucleic acid delivery 
Bare basic polymers, which form nanosized polyplexes with pDNA, are subjected to a 
biodistribution after systemic administration, which depends on the individual 
physicochemical properties. Particle size and surface charge are key parameters 
determining the circulation time, tissue accumulation and clearance of nanoparticles. 
Shielding of the surface charge is a common approach to evade unspecific ionic 
interactions, opsonization and clearance by the mononuclear phagocyte system. The 
increased circulation time of shielded particles can result in a certain tissue specific 
accumulation, e.g. due to the enhanced-permeability and retention effect, also called 
‘passive targeting’. However, additional mechanisms are required to achieve a cell-
type specificity beyond the tissue accumulation. Moreover, since the cellular uptake 
of polycationic complexes is based on the positive surface charge, shielding not only 
suppresses unintended interactions but also the attachment to target cells. Targeting-
ligands, which bind to surface-markers of the target cells, can restore cellular uptake 
in a specific fashion after the unspecific interactions have been eliminated by surface 
shielding. The numerous ligands, which have been used for the general purpose of 
drug targeting, exhibit a great diversity of chemical nature. Examples of compound 
classes of targeting ligands are peptides, proteins (including antibodies), 
carbohydrates and small (organic) molecules. Here the compatibility and feasibility of 
the solid-phase synthesis approach for the assembly of targeted and shielded 
oligo(ethanamino)amides with ligands of different chemical nature was investigated. 
The PEGylated two-arm topology was used as platform for the nucleic acid carriers 
with different heterogeneous ligands (Scheme 3.7). This particular structure consists 
of a branched Stp sequence as charged nucleic acid binding core. Terminal 
cysteines are integrated for the formation of disulfide crosslinks, which increase the 
extracellular polyplex stability, but get disassembled in the reductive environment of 
the cytosol. A discrete PEG segment of defined length is located at the central 
position of the branching backbone lysine and coupled to the targeting ligand at the 
exposed terminus. Peptides (cMBP1, cMBP2), a protein (mEGF), carbohydrates (S-
glycoside mimetics of galactose and N-acetylgalactosamine) and small molecules 
(folic acid, MTX derivatives) were used as ligands.  
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Scheme 3.7 Illustration of the PEGylated two-arm topology with different ligands as flexible platform 
for targeted nucleic acid carriers  
 
(A) Overview over the used targeting ligands classified by their chemical nature, (B) concept of nucleic acid 
encaging by the targeted PEGylated two-arm oligomers based on ionic interaction of the Stp sequence and 
bioreducible disulfide links formed by cysteines. The structure of mEGF has been derived from the Protein Data 
Bank Japan: PDBj (dataset 1EGF). 
 
Two phage display derived c-Met binding peptides (cMBP1 and cMBP2) were 
reported in the literature as diagnostic agents for the purpose of in vivo tumor 
imaging [176-179]. Here active c-Met receptor-targeting was used for the first time in 
context of non-viral gene delivery (Chapter 3.2.1).  
In contrast to the integration of peptides, which can easily be integrated into the 
sequence during solid-phase synthesis, the conjugation of proteins requires a 
different strategy. Here a strain-promoted alkyne-azide cycloaddition (SPAAC) under 
mild aqueous conditions was used for the site-specific attachment of murine 
epidermal growth factor (mEGF) to a PEGylated two-arm oligo(ethanamino)amide, 
which has been synthesized by SPS before (Chapter 3.2.2). Although mEGF 
(approx. 6 kDa) is still a rather small member of the protein class, the conjugation 
represents a step forward toward larger macromolecular targeting ligands. Moreover, 
the chosen conjugation strategy was supposed to demonstrate the feasibility of the 
platform to be compatible also with ligands which cannot be coupled on solid-phase.  
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Beyond peptides and proteins, another particularly interesting class of biopolymers is 
represented by carbohydrates. The great importance of these compounds in 
molecular recognition processes such as intercellular contact and communication or 
antigen binding also account for their great potential as targeting ligands. In general, 
multivalent interactions are responsible for the selective binding of saccharides to 
their recognition partners. In collaboration with Prof. Dr. Laura Hartmann (University 
Düsseldorf; former MPI of Colloids and Interfaces, Potsdam) and Dr. Felix Wojcik 
(MPI of Colloids and Interfaces, Potsdam) several multivalent glycoligands were used 
in combination with the PEGylated two-arm oligo(ethanamino)amides and screened 
for their activity to mediate asialoglycoprotein receptor (ASGPR) targeted gene 
delivery (Chapter 3.2.3).  
As an example of small molecule ligands with additional function beyond receptor-
targeting, the antifolate methotrexate and a set of variants were used as drug 
conjugates with the nucleic acid carriers. The potency as targeting ligands, in 
comparison to folic acid, as well as the additional effect in cytotoxic poly(I:C) delivery 
were investigated (Chapter 3.2.4).   
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3.2.1 c-Met binding peptides for receptor-specific gene transfer by 
oligo(ethanamino)amides in vitro and in vivo  
The receptor tyrosine kinase c-Met (hepatocyte growth factor receptor, HGFR) 
triggers several cellular processes, such as mitogenesis, motogenesis and 
morphogenesis, after binding of its native ligand HGF [185]. For this reason c-Met 
plays an important role in physiological tissue development, homeostasis and 
regeneration. However, it can also promote malignant transformation, tumor 
progression and invasive growth [186]. Several studies indicated the overexpression 
of c-Met and dysregulation of its pathway to be a poor prognostic factor for 
therapeutic outcome and survival in a variety of different types of cancer [187-189]. 
Therefore, targeting the c-Met signaling pathway is considered as promising 
therapeutic approach and has attracted much attention in drug development and 
research. Most approaches focus on the inhibition of HGF binding or interference 
with the c-Met signaling pathway, e.g. by inhibition of the tyrosine kinase activity. 
Moreover, anti-c-Met antibodies have been used for immunotherapy and imaging 
purposes [190-192]. However, only a few published works demonstrate the potency 
of c-Met targeting in terms of drug delivery. Chen et al. reported c-Met dependent 
cytotoxicity and reduced side-effects of a doxorubicin conjugate with an anti-c-Met 
Fab fragment [193]. Nguyen et al. developed retroviral vectors with insertion of 
single-chain variable-fragments (scFv) against c-Met in the viral envelope protein 
[194]. By this means a higher selectivity of gene transfer to human hepatoma cells 
could be achieved. Beyond that, c-Met targeting has not been used for the purpose 
of non-viral gene delivery before.  
Here two published c-Met binding peptide sequences (cMBP1 and cMBP2, [176, 
177]) identified by phage display were integrated into PEGylated two-arm 
oligo(ethanamino)amides. The aim was the identification of the more potent ligand 
and a stepwise optimization process of the nucleic acid carrier for the final purpose of 
a targeted in vivo gene transfer.  
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3.2.1.1 Library design and synthesis 
The polyamino acid Stp was used for the assembly of the two-arm topology 
oligomers with PEGylation and cMBP ligands. Peptidic ligands are perfectly 
compatible with the used SPS approach and can readily be integrated in the 
sequences of the oligo(ethanamino)amide based compounds. Three different carrier 
variants were used for the structure-activity relationship studies and represent 
different stages of a gradual optimization process. Scheme 3.8 and Table 3.7 give an 
overview over the set of compounds. The first variant class (Scheme 3.8 A, 1 PEG, 
no His) consisted of the branched two-arm structure with a continuous Stp sequence 
and terminal cysteines as nucleic acid encaging core without additional backbone 
modifications. A monodisperse PEG24 was placed at the central position of the 
branching lysine. Both ligands, cMBP1 and cMBP2, as well as four scrambled 
sequences of cMBP2 (cMBP2sc1-4) and alanine as untargeted control were attached 
at the exposed part of the PEG segment in separate structures. With these first 
compounds, the potencies of the two cMBP ligands were compared and the 
sequence specificity of cMBP2 was investigated. The second carrier variant (Scheme 
3.8 B, 1 PEG, His) contained additional histidines in the backbone sequence and 
either cMBP2 as a ligand or alanine as control. In the last carrier class (Scheme 3.8 
C, 2 PEG, Ala or His) the influence of an extended PEG chain was investigated, as 
well as backbone histidine compared to backbone alanine without buffering effect.  
For the synthesis of the oligo(ethanamino)amides, the standard Fmoc SPS 
conditions were used. All compounds were analyzed by 1H-NMR and RP-HPLC. 
Figure 3.36 shows the analytical RP-HPLC chromatograms of representative 
members of the set and each variant class. 1H-NMR data can be found in the 
appendix.       
 
 
 
 
 
   Results 
98 
Scheme 3.8 Illustration of the synthesized oligomers with different ligands and structure variants  
 
(A) 1 PEG24, no backbone histidines, (B) 1 PEG24, additional backbone histidines, (C) 2 PEG24, additional 
backbone alanines or histidines, (D) chemical structures of sequence components and peptide ligand sequences. 
cMBP, c-Met binding peptide; cMBP2sc, scrambled sequence of cMBP2.   
 
 
Table 3.7 Sequences, structure variants and abbreviations of the synthesized oligomers 
ID Sequence (C -> N) Variant Abbreviation 
188 A-dPEG24-K(Stp4-C)2 1 PEG, no His Ala 
696 K[dPEG24-K(Stp4-C)2]-cMBP1 1 PEG, no His cMBP1 
443 K[dPEG24-K(Stp4-C)2]-cMBP2 1 PEG, no His cMBP2 
697 K[dPEG24-K(Stp4-C)2]-cMBP2sc1 1 PEG, no His cMBP2sc1 
698 K[dPEG24-K(Stp4-C)2]-cMBP2sc2 1 PEG, no His cMBP2sc2 
699 K[dPEG24-K(Stp4-C)2]-cMBP2sc3 1 PEG, no His cMBP2sc3 
700 K[dPEG24-K(Stp4-C)2]-cMBP2sc4 1 PEG, no His cMBP2sc4 
440 A-dPEG24-HK[H-(Stp-H)4-C]2 1 PEG, His Ala-His 
442 K[dPEG24-HK(H-(Stp-H)4-C)2]-cMBP2 1 PEG, His cMBP2-His 
616 A-(dPEG24)2-HK[H-(Stp-H)4-C]2 2 PEG, His Ala-2PEG-His 
694 K[(dPEG24)2-HK(H-(Stp-H)4-C)2]-cMBP2 2 PEG, His cMBP2-2PEG-His 
695 K[(dPEG24)2- AK(A-(Stp-A)4-C)2]-cMBP2 2 PEG, Ala cMBP2-2PEG-Ala 
 689* C-(H-Stp)3-HK[H-(Stp-H)3-C]2 three-arm - 
* Oligomer 689 was synthesized by Dongsheng He (Pharmaceutical Biotechnology, LMU) and was used as a co-
formulation oligomer for in vivo trials. 
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Figure 3.36 Analytical RP-HPLC chromatograms of representative library members. The analysis was carried out 
using a Waters Sunfire C18 column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 – 0:100 in 20 min) 
containing 0.1 % TFA. For the detection the extinction at 214 nm was monitored. 
 
3.2.1.2 Targeting ligand evaluation 
The first variant class (1 PEG, no His) was used for the evaluation of the two peptide 
ligands. For this purpose the cellular association of pDNA polyplexes with 
hepatocarcinoma Huh7 cells, which display high c-Met expression (PhD thesis Dr. 
Petra Kos, Pharmaceutical Biotechnology, LMU), was determined by flow cytometry 
(Figure 3.37 A). Both peptide sequences cMBP1 (696) and cMBP2 (443) mediated a 
greatly enhanced cellular association of the corresponding polyplexes (> 90 % 
positive cells) compared to the untargeted alanine control (188). In direct comparison 
of the two ligands, cMBP2 showed the higher potency and mediated higher cellular 
binding of the corresponding polyplexes, since a slightly higher number of Cy5 
positive cells was found. The sequence-specificity of cMBP2 was investigated by the 
use of scrambled sequences in analog carriers (697-700) and the same experimental 
set up (Figure 3.37 B). None of the four scrambled sequences cMBP2sc1-4 was able 
to mediate significant cellular association of the corresponding pDNA polyplexes, 
which indicates the cMBP2-mediated cell-binding to be a sequence-specific effect.  
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Figure 3.37 Cellular association of Cy5-pDNA polyplexes (1 PEG, no His) and luciferase reporter gene 
expression in Huh7 cells. Comparison of (A) cell binding of cMBP1 (696) or cMBP2 (443) targeted and untargeted 
Ala (188) polyplexes at N/P 12, (B) cell binding of polyplexes at N/P 12 with scrambled cMBP2 sequences (697-
700) and (C) transgene expression after transfections with cMBP1 (696), cMBP2 (443) targeted and untargeted 
Ala (188) polyplexes. Bioluminescence levels in (C) are plotted as relative light units (RLU) per 8.000 cells. Cells 
treated with HBG served as negative control. N=1 for each compound in the cellular association assays, N=5 for 
each compound in the transfection experiments. Experiments were carried out by Dr. Petra Kos (Pharmaceutical 
Biotechnology, LMU).    
 
The ability of the carriers to mediate gene transfer was evaluated by pCMVLuc 
transfections of Huh7 cells and subsequent bioluminescence quantification (Figure 
3.37 C). With the addition of chloroquine as endosome disruptive agent, both ligands 
significantly enhanced transgene expression compared to the untargeted control 
188/Ala. Consistent with the higher cellular association, the cMBP2 polyplexes also 
mediated significant higher luciferase activity than the cMBP1 analog and even 
outperformed LPEI, however only when chloroquine was added. Without chloroquine, 
the cMBP1 targeted oligomer did not mediate transgene expression above 
background level. Interestingly, the cMBP2 oligomers mediated increased luciferase 
activity compared to the untransfected (HBG) or 188 transfected cells even without 
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chloroquine. A reason for this presumably is the presence of several histidines in the 
cMBP2 sequence. Nevertheless, also for cMBP2 the effect on the transgene 
expression without addition of chloroquine is poor, indicating the need for an 
improved endosomal escape performance of the nucleic acid carriers.  
 
3.2.1.3 Carrier optimization 
Based on the gained experience with the modulation of endosomal buffer capacity 
and the correlation with endosomal escape, histidines were integrated in the 
oligo(ethanamino)amide backbone of the carriers (cf. Scheme 3.8 B). Additionally the 
PEG chain was extended to the two-fold length and backbone histidines substituted 
by alanines without buffering properties (cf. Scheme 3.8 C). The effect of the 
additional backbone histidines in the structure variants with one PEG24 on the cellular 
association of the related pDNA polyplexes as well as the difference between 
backbone alanines and histidines in the variants with two PEG24 were investigated by 
flow cytometry like before (Figure 3.38 A). No influence of the backbone histidines on 
the cellular association of the cMBP2 targeted or untargeted alanine polyplexes with 
one PEG could be observed. Likewise, backbone alanines or histidines did not alter 
the cellular association of the polyplexes with doubled PEG length. However, a clear 
effect of backbone histidines on the endosomal escape could be observed in an 
intracellular calcein release assay (Figure 3.38 B). Images of the intracellular 
distribution of fluorescent calcein, which was passively co-internalized with the 
polyplexes during the transfections, were acquired by spinning disk confocal 
microscopy. In case of the cMBP2 polyplexes with backbone histidines, a bright and 
homogeneously distributed cytosolic calcein fluorescence could be observed, 
whereas the analog with backbone alanines only caused a spotty calcein distribution, 
indicating a vesicular entrapment of the dye.     
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Figure 3.38 Cellular association of Cy5-pDNA polyplexes, endosomal escape performance and luciferase 
reporter gene expression after transfections of Huh7 cells. (A) Influence of backbone histidines on the cellular 
association of polyplexes at N/P 12 containing 1 or 2 PEG24, (B) influence of backbone histidines on the 
endosomal escape investigated by intracellular calcein release (cf. Fig. 3.16) and (C) influence of backbone 
histidines and PEG chain length on transgene expression levels. Bioluminescence levels in (C) are plotted as 
relative light units (RLU) per 8.000 cells. Cells treated with HBG served as negative control in (A) and (C). N=1 for 
each compound in the cellular association assays, N=5 for each compound in the transfection experiments. 
Cellular association and transgene expression experiments were carried out by Dr. Petra Kos (Pharmaceutical 
Biotechnology, LMU). Calcein release experiments were carried out by Dr. Frauke Mickler (Physical Chemistry, 
LMU). 
 
The introduction of backbone histidines also had great impact on the transgene 
expression without addition of chloroquine (Figure 3.38 C). Greatly enhanced 
luciferase activity could be observed in case of the histidine containing oligomers. 
Importantly, the cMBP targeted polyplexes with two PEG24 segments mediated lower 
expression levels than the analog with one PEG24, both with or without addition of 
chloroquine. Therefore, the structure variant containing one PEG24 element and 
backbone histidines was identified as the most potent and considered for the in vivo 
trials.  
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3.2.1.4 Gene transfer in vivo 
After the encouraging in vitro results with the most promising carrier, containing the 
cMBP2 ligand, one PEG24 element and backbone histidines, in vivo experiments with 
Huh7 tumor bearing mice were carried out (Figure 3.39). The oligomer 442/cMBP2-
His and its untargeted control 440/Ala-His were compared in their in vivo gene 
transfer efficiency after local intratumoral (IT) and intravenous (IV) injection of pDNA 
polyplexes at N/P 12 (Figure 3.39 A). A significant (approx. 15-fold) higher transgene 
expression, mediated by the cMBP2 targeted polyplexes compared to the alanine 
control, was observed after intratumoral injection. 
 
 
Figure 3.39 Luciferase reporter gene expression in vivo after local and systemic administration of single-oligomer 
or oligomer-blend polyplex formulations (1 PEG, His). Luciferase activity after (A) injection of cMBP2 targeted 
(442) or untargeted (440) pDNA polyplexes locally (IT) or systemically (IV), (B) intravenous injection of mixed 
442/689 or 440/689 pDNA polyplexes with an untargeted three-arm Stp/histidine oligomer 689. Polyplexes 
containing pCMVLuc and oligomer at N/P 12 were injected into Huh7 tumor bearing mice. Luciferase activity in 
homogenized tissue samples was measured 48 hours after administration. N=5 animals per group. Animal 
experiments were carried out by Annika Herrmann and Dr. Petra Kos, oligomer 689 was synthesized by 
Dongsheng He (Pharmaceutical Biotechnology, LMU). 
 
However, no difference between cMBP2 targeted and untargeted polyplexes could 
be found after the systemic administration; no effect of the homing ligand on the 
transgene expression in tumor, lung or liver could be observed. It has been shown by 
transmission electron microscopy before that similar PEGylated oligomers form loose 
‘spaghetti-like’ complexes with pDNA. Obviously the PEG chain hinders pDNA 
condensation, despite a potent pDNA binding of the basic oligomer backbone. Since 
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the spatial arrangement and tightness of the pDNA polyplexes can affect their 
biodistribution, an alternative approach with an untargeted Stp/histidine co-
formulation oligomer 689 was taken. The co-formulation oligomer has a three-arm 
topology with an alternating Stp/histidine sequence and three terminal cysteines. For 
the polyplex formation, a blend of the PEGylated oligomer (442/cMBP2-His or 
440/Ala-His) with the co-formulation oligomer 689 in an amine ratio of 70:30 (30 % of 
N/P ratio is covered by 689) was prepared before addition of the pDNA. It was shown 
by transmission electron microscopy and ethidium bromide exclusion assays that the 
co-formulation with 689 caused a great increase of pDNA compaction and a different 
spatial arrangement of the resulting polyplexes (PhD thesis Dr. Petra Kos, 
Pharmaceutical Biotechnology, LMU). With the alternative co-formulation approach, a 
greatly enhanced gene transfer in the tumor was observed after intravenous injection 
of the cMBP2 targeted polyplexes (Figure 3.39 B). The 442/689 polyplexes mediated 
approximately 22-fold higher transgene expression in the tumor tissue than the 
untargeted co-formulation 440/689 polyplexes, whereas no differences were 
observed in lung or liver tissue. In sum, these results show the tumor homing 
potential of the cMBP2 ligand as well as the suitability of the used nucleic acid carrier 
class to mediate targeted gene transfer in vivo. Moreover, the results indicate the 
importance of the pDNA condensation state and optimized polyplex formulations for a 
proper biodistribution and successful delivery to the target site.   
 
 
3.2.2 EGF receptor directed cellular uptake of pDNA polyplexes mediated by 
mEGF-oligo(ethanamino)amide conjugates 
The epidermal growth factor receptor (EGFR) is a member of the ERBB receptor 
tyrosine kinases, which play an important role in human cancer [195]. Binding of 
epidermal growth factor (EGF) triggers the receptor dimerization, phosphorylation 
and activation of downstream signaling pathways, which contribute to tumor cell 
proliferation, evasion of apoptosis, angiogenesis and metastasis [196]. An 
overexpression of EGFR has been observed in cancers of head and neck, ovary, 
cervix, bladder, oesophagus, stomach, brain, breast, endometrium, colon and lung 
[197]. Because of the significant role in neoplastic transformation and tumor 
progression, several drugs have been developed, which interfere with the activation 
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or signaling of EGFR, such as anti-EGFR antibodies or tyrosine kinase inhibitors. 
However, the high abundance of EGFR in a wide variety of human carcinomas 
makes it also an attractive target for the tumor homing purpose in drug delivery. 
Several antibody-drug conjugates, targeting members of the EGFR family, have been 
developed and reported [198-200]. The conjugate of trastuzumab with the 
antimicrotubule agent mertansine (trastuzumab emtansine) recently got approval by 
the FDA and EMA for the treatment of HER2-positive metastatic breast cancer. This 
makes clear that EGFR is also an interesting target for receptor-directed cancer gene 
therapy. Beside anti-EGFR antibodies, also artificial peptides, such as GE11, or the 
native ligand EGF can be used for targeting purposes [89, 201]. The investigation of 
the cellular uptake kinetic of EGF targeted pDNA/PEI polyplexes revealed a highly 
accelerated endocytosis compared to the GE11 targeted analogs [98]. In addition, 
with a rather small size, EGF is an ideal model protein to extend the compound 
space of compatible targeting ligands and to establish the required strategy for the 
conjugation with oligo(ethanamino)amides. 
 
3.2.2.1 Conjugate design and synthesis 
Since the PEGylated two-arm molecules contain multiple amino groups and 
cysteines which are indispensable for the functionality of the nucleic acid carriers, an 
orthogonal conjugation chemistry had to be chosen. Scheme 3.9 illustrates the used 
synthetic approach. The strain-promoted alkyne-azide cycloaddition (SPAAC) 
between dibenzocyclooctyne (DBCO) and azides was used for the site-specific 
attachment of EGF to the exposed part of the PEG segment. For this purpose, a 
PEGylated two-arm oligomer, containing the artificial α-amino acid 5-azido-L-
norvaline (5ANV), was prepared under standard conditions on solid-phase. Murine 
EGF (mEGF) exhibits high homology with the human variant (hEGF), and it is able to 
bind the human EGFR [89, 202]. However, in contrast to hEGF, the sequence of 
mEGF contains no lysines and therefore allows the site-specific modification of the N-
terminus with amine reactive groups. For this reason, mEGF was chosen to be 
functionalized with an excess of dibenzocyclooctyne-PEG5-NHS ester in solution. 
Remaining unreacted DBCO reagent was removed by ultrafiltration (UF). 
Subsequently the DBCO functionalized EGF was conjugated to the azide containing 
oligomer 479/5ANV-Stp by SPAAC in solution. The final reaction product EGF-Stp 
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(MW ≈ 10 kDa, free base) was purified and separated from the excess of free 479 
(MW ≈ 4 kDa, free base) or unreacted EGF (MW ≈ 6 kDa) by size-exclusion 
chromatography (SEC).  
 
Scheme 3.9 Illustration of the synthetic approach for the assembly of EGF-Stp         
 
Oligomer 479 was derived from SPS with the use of the artificial amino acid 5-azido-L-norvaline (5ANV). The 
conjugation of dibenzocyclooctyne (DBCO)-PEG5-NHS ester to murine EGF and subsequent alkyne-azide 
cycloaddition with 479 was carried out in solution. Free DBCO-linker was removed by ultrafiltration (UF) after the 
first coupling step. Purification of the final product was carried out by size-exclusion chromatography (SEC). 
 
1H-NMR data of 479 can be found in the appendix. The conjugation product EGF-Stp 
was analyzed by RP-HPLC and compared to the starting compound 479 and mEGF 
(Figure 3.40). Under the used HPLC conditions, the compounds eluted at retention 
times of 17.101 min (mEGF), 15.289 min (479) and 16.783 min (EGF-Stp). An 
additional smaller peak at 15.724 min with an integral of approximately 14 % at 214 
nm was observed in the chromatogram of EGF-Stp, which presumably represents 
remaining uncoupled 479 oligomer. Importantly, no free mEGF could be identified in 
the chromatogram of the final conjugation product. This could also be confirmed by 
SDS-PAGE (Figure 3.41 A). The EGF-Stp exhibited a complete shift of the protein 
band toward higher molecular weight (lane 3) compared to the control with free 
mEGF (lane 2). Unconjugated 479/5ANV-Stp could not be visualized. A suggested 
explanation is that the highly basic Stp oligomers are not compatible with the chosen 
SDS-PAGE conditions, which enforce a negative netto charge of the analytes and 
   Results 
107 
the migration toward the anode. An acetic acid-urea PAGE, which is frequently used 
for basic proteins, might be more suitable for oligo(ethanamino)amides. However, 
since the main focus was the identification of free and conjugated mEGF, SDS-PAGE 
was the method of choice.  
 
 
Figure 3.40 Analytical RP-HPLC chromatograms. The analysis was carried out using a Waters Sunfire C18 
column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 – 0:100 in 20 min) containing 0.1 % TFA. For 
the detection the extinction at 214 nm was monitored. 
 
The ability of EGF-Stp to complex pDNA was investigated by an electrophoretic 
mobility shift assay (Figure 3.41 B). The protein conjugate mediated an almost 
complete binding at N/P 6 and no free pDNA could be observed at higher N/P values. 
This result is comparable to the potency of related PEGylated two-arm oligomers with 
smaller targeting ligands (cf. Chapter 3.1.2, Figure 3.13). Since with increasing size 
of the ligand an increasing sterical hindrance of nucleic acid complexation is 
expected, the result is considered as an important finding. Despite the rather small 
size for a protein, mEGF represents the largest targeting ligand used with the 
oligo(ethanamino)amides so far and for the first time the molecular weight of the 
ligand exceeded the molecular weight of the carrier molecule.    
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Figure 3.41 (A) SDS-PAGE with silver staining of the conjugation product EGF-Stp and the reaction partners 
mEGF and oligomer 479/5ANV-Stp before conjugation, (B) electrophoretic mobility shift assay of the EGF-Stp 
conjugate by agarose gel electrophoresis; all samples contained 200 ng pDNA and oligomer at indicated N/P 
ratios.  
 
3.2.2.2 Cellular uptake and gene transfer in vitro 
The potency of the EGF conjugate to mediate cellular uptake of pDNA polyplexes 
into EGFR expressing Huh7 cells was investigated by flow cytometry and live cell 
imaging studies (Figure 3.42). The quantitative determination of the cells positive for 
Cy5 fluorescence (Figure 3.42 A) reveals a greatly enhanced uptake of EGF-targeted 
polyplexes compared to the control polyplexes with an alanine attached to the PEG 
instead of a targeting ligand (oligomer 188, cf. Chapter 3.2.1). At both investigated 
N/P values 6 and 12, the alanine control failed to mediate notable cellular uptake of 
Cy5-pDNA polyplexes, confirming the good shielding and absence of an unspecific 
cellular interaction. In contrast, with the EGF targeted polyplexes at both N/P ratios a 
distinct majority of the cells were found to be Cy5 positive. Considering that the 
cellular uptake was determined after a short incubation time of 30 minutes, the 
cellular uptake mediated by EGF seems to be considerably fast and efficient. The 
uptake kinetic of the EGF targeted polyplexes was investigated more in detail within 
live cell imaging experiments. Images of the Cy5-pDNA polyplexes were continuously 
acquired by confocal microscopy, which allows the identification of internalized 
particles by their characteristic intracellular motion [98, 203]. Figure 3.42 B shows 
images of representative cells at two time points. By this means, the rapid uptake 
kinetic of the mEGF targeted polyplexes could be confirmed. Already after 21 
minutes, intracellular polyplexes could be identified, and their number considerably 
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increased within the following 21 minutes. Importantly, the number of internalized 
polyplexes after two hours incubation time could be clearly reduced by competition 
with free EGF (Figure 3.42 C), which confirms the EGF specific cellular uptake via 
EGFR. 
 
 
Figure 3.42 Cellular uptake of Cy5-pDNA polyplexes in Huh7 cells as determined by flow cytometry (A) and live 
cell imaging (B and C). (A) Comparison of the cellular uptake of mEGF targeted or untargeted Ala polyplexes at 
indicated N/P ratios after 30 min incubation time. (B) Internalized EGF-Stp polyplexes (N/P 12) at two time points 
(21 min, 42 min), identified by the characteristic intracellular motion during live cell imaging. Confocal z-planes of 
representative cells are shown together with the transmission light image (TL) and the time projection (100 
frames, framerate 330 ms, equivalent to 33 s time interval). Nucleus is highlighted yellow, identified intracellular 
polyplexes are marked red. (C) Internalized EGF-Stp polyplexes (N/P 12) after 2 h incubation time and under 
EGF competition (+ EGF) or normal (- EGF) conditions. Flow cytometry was carried out by Dr. Petra Kos 
(Pharmaceutical Biotechnology, LMU). Microscopy experiments were carried out by Dr. Frauke Mickler (Physical 
Chemistry, LMU). 
 
The efficient cellular uptake of EGF targeted polyplexes also correlated with the 
luciferase reporter gene expression after transfections of Huh7 cells (Figure 3.43). As 
before, the untargeted alanine control 188 did not exhibit notable gene transfer 
efficiency. In contrast, EGF-Stp mediated over 1000-fold increased bioluminescence 
above background level, also exceeding the levels of LPEI, in transfections with the 
addition of chloroquine.  
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Figure 3.43 Luciferase pDNA transfections of Huh7 cells with EGF-Stp or untargeted Ala oligomers at indicated 
N/P ratios. Bioluminescence levels are plotted as relative light units (RLU) per 10.000 cells. N=5 for each 
compound. Transfections were carried out by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). 
 
However, as observed before, the used PEGylated two-arm oligomer with continuous 
Stp sequence and terminal cysteines exhibits a very poor intrinsic endosomal escape 
performance. Without addition of chloroquine, no transgene expression could be 
observed. Nevertheless, the well shielded structure allows the evaluation of the 
potency and suitability of different targeting ligands in a clear-cut fashion in vitro. By 
this means, mEGF has shown to be a very potent ligand, which is compatible with the 
nucleic acid carrier class. Therefore, the rational next step in the modular 
optimization process would be the combination of mEGF with improved carriers, 
which have demonstrated a better endosomal escape performance. 
 
 
3.2.3 Multivalent carbohydrate ligands for asialoglycoprotein receptor 
directed gene transfer by oligo(ethanamino)amides 
The asialoglycoprotein receptor (ASGPR) is a membrane bound lectin expressed on 
hepatocytes, which binds and internalizes glycoproteins with terminal galactose (Gal) 
or N-acetylgalactosamine (GalNAc) residues for a subsequent lysosomal processing. 
Therefore, the enzymatic removal of terminal sialic acids from protein glycosylation, 
which in consequence exposes subterminal galactose or N-acetylgalactosamine 
residues, represents a recognition feature for an upcoming clearance from the 
systemic circulation [204, 205]. The highly specific recognition, efficient cellular 
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uptake and exclusive expression make the ASGPR an attractive target for receptor-
specific delivery of nucleic acid therapeutics to hepatocytes [95, 206-208]. However, 
the use of simple monosaccharides results in a rather weak binding toward the 
receptor. In general, the complex branched architectures of glycan ligands offer 
multiple sites for interactions with carbohydrate recognitions domains, which are 
responsible for the specific binding with high affinity [209]. Therefore, multivalent 
carbohydrate ligands with precise distance and spatial orientation are required for 
high affinity binding.  
Dr. Felix Wojcik from the former lab of Prof. Laura Hartmann at the MPI of Colloids 
and Interfaces (Potsdam, Germany) developed a synthesis procedure for the 
assembly of S-glycoside functionalized diethylene triamine building blocks, which can 
be used for a subsequent solid-phase synthesis [210, 211]. The taken approach 
allows the precise control over the number of exposed sugar moieties as well as their 
distance and spatial orientation. By this means a set of four different ligands was 
provided by Dr. Felix Wojcik for the use in the solid-phase synthesis of carbohydrate 
targeted nucleic acid carriers.  
 
3.2.3.1 Library design and synthesis 
The set of oligomers used for the study consisted of five members, which were all 
based on the same PEGylated oligo(ethanamino)amide backbone with continuous 
Stp sequence and terminal cysteines, but differed in the conjugated targeting ligand. 
Scheme 3.10 and Table 3.8 give an overview over the set of compounds.  
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Scheme 3.10 Illustration of the synthesized oligomers with multivalent carbohydrate ligands  
  
(A) Schematic structures of the carriers. Multivalent ligands vary in the number of the repetitive ligand motif (3 or 6 
β-D-thiogalactose units, GalS), the spacer length (additional monoethylene glycol derivative) and the type of 
integrated S-glycoside (GalS, GalNAcS), (B) chemical structures of the multivalent glyco-ligands and sequence 
components. The carbohydrate ligands were synthesized by Dr. Felix Wojcik (MPI of Colloids and Interfaces, 
Potsdam). 
 
Table 3.8 Sequences, structure variants and abbreviations of the synthesized oligomers  
ID Sequence (C -> N) Variant Abbreviation 
188 A-dPEG24-K(Stp4-C)2 neg. control targeting Ala 
603 (GalS)3-dPEG24-K(Stp4-C)2 trivalent GalS (GalS)3-Stp 
604 (GalS)6-dPEG24-K(Stp4-C)2 hexavalent GalS (GalS)6-Stp 
605 (GalS-AEEAc)3-K(Stp4-C)2 trivalent GalS, MEG spacer (Gal-MEG)3-Stp 
651 (GalNAcS)3-dPEG24-K(Stp4-C)2 trivalent GalNAcS (GalNAcS)3-Stp 
 
The alanine analog 188 was used as untargeted control as before. Three oligomers 
contained β-D-thiogalactose residues (603-605) in different numbers (603, trivalent 
GalS; 604, hexavalent GalS) and optionally an additional monoethylene glycol 
derivative for increased distance of the sugar moieties (605, trivalent GalS, MEG). 
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Oligomer 651 is the structural analog of the trivalent ligand 603 with GalNAcS instead 
of GalS. The ligands were synthesized by Dr. Felix Wojcik and provided in a 
protected and resin bound form ready for the subsequent solid-phase synthesis of 
the PEGylated oligo(ethanamino)amide core. With the resin bound ligands, SPS was 
conducted according to the sequences listed in Table 3.8 under the standard 
synthesis conditions. However, since the carbohydrate ligands were in a 
peracetylated form during the solid-phase synthesis, a deacetylation step by 
transesterification with sodium methoxide was introduced [182]. The deacetylation 
was carried out before cleavage and deprotection of the resin bound oligomers, since 
an acetyl transfer to the multiple amines would be possible under the chosen 
conditions. In addition, milder cleavage conditions, without use of water as a 
scavenger, were chosen to reduce any risk of acid catalyzed hydrolysis of glycosyl 
residues. All compounds were analyzed by 1H-NMR and RP-HPLC. Figure 3.44 
shows the analytical RP-HPLC chromatograms of the carbohydrate containing 
compounds. 1H-NMR data can be found in the appendix.       
 
 
Figure 3.44 Analytical RP-HPLC chromatograms. The analysis was carried out using a Waters Sunfire C18 
column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 – 0:100 in 20 min) containing 0.1 % TFA. For 
the detection the extinction at 214 nm was monitored. 
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3.2.3.2 Cellular association and gene transfer in vitro 
Hepatocellular Huh7 cells and prostate carcinoma DU145 cells were used for the 
investigation of the cellular association of GalS targeted pDNA polyplexes by flow 
cytometry (Figure 3.45). As before, the alanine control (188) did not mediate a 
significant cell binding to any of the chosen cell lines, indicating the efficient shielding 
and low unspecific interaction of the used carrier system (Figure 3.45 B). In contrast, 
the GalS targeted polyplexes exhibited a ligand dependent cellular association to 
Huh7 cells and to a considerable lower extent to the control cell line DU145, with low 
ASGPR expression (Figure 3.45 A). The highest binding to Huh7 cells was mediated 
by the two compounds 603 and 605 with trivalent GalS ligands. The additional 
monoethylene glycol spacer in 605 did not seem to change the affinity of the pDNA 
polyplexes. Surprisingly, the increase of ligand valency in the polyplexes with 
oligomer 604 did not enhance but rather slightly diminish the cell binding potency. It 
has to be noted that as a result of the rather small size of this carrier class compared 
to other polymers used for gene delivery, several ligand equipped 
oligo(ethanamino)amide molecules are integrated into the polyplexes, which already 
causes a kind of multivalency, even if only monovalent ligands were used during 
synthesis. Taken into consideration that the ASGPR can bind tri- or tetra-antennary 
glycans [212], this might be an explanation, why the affinity is not enhanced by an 
additional increase of ligand density on the surface of the polyplexes. Moreover, 
there are examples for nanoparticles with optimal ligand densities on the surface, 
which must not be under- or overrun, for a most efficient receptor-targeting [213].    
However, a great improvement of cellular binding to Huh7 cells was achieved by the 
exchange of GalS for GalNAcS (Figure 3.46 A). In direct comparison of the two 
analogs 603 and 651, an increase from 24.2 to 78.6 % Cy5 positive cells due to the 
substitution of the sugar moiety could be observed. This is consistent with the 
severalfold higher binding affinity of ASGPR for terminal GalNAc than Gal residues in 
comparable structures [209]. In pCMVLuc transfections of Huh7 cells the potential of 
the trivalent GalNAcS ligand to mediate cellular uptake of pDNA polyplexes was 
confirmed (Figure 3.46 B). With the addition of chloroquine as endosome disruptive 
agent, luciferase activity levels of up to 800-fold above background were observed. 
At N/P 12 and higher, expression levels in the same magnitude as mediated by LPEI 
were achieved.   
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Figure 3.45 Receptor status and cellular association of Cy5-pDNA polyplexes at N/P 12 as determined by flow 
cytometry. (A) AsGPR expression in Huh7 and negative control DU145 cells. (B) The cellular association levels of 
pDNA polyplexes show a low but ligand dependent and cell-specific binding of GalS targeted polyplexes (603-
605) to Huh7 cells. Flow cytometry was carried out by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). 
 
 
Figure 3.46 Cellular association of GalNAcS targeted polyplexes at N/P 12 to Huh7 cells and luciferase reporter 
gene expression after transfections. (A) The cellular association of pDNA polyplexes to Huh7 cells shows an 
enhancement by the trivalent GalNAcS based ligand, (B) transfection with GalNAcS containing 651 polyplexes 
and chloroquine addition greatly increased transgene expression levels. Bioluminescence levels are plotted as 
relative light units (RLU) per 10.000 cells. N=5 for each compound in the transfection experiment. Experiments 
were carried out by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU). 
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In sum, the results demonstrate the feasibility to combine the carbohydrate building 
blocks of the collaboration partner with the nucleic acid carrier platform in one 
sequential solid-phase synthesis of glyco-functionalized conjugates for gene delivery. 
Moreover, the potential of the used carrier system to be used for the screening and 
comparison of related targeting ligands has been confirmed. By this means, the most 
potent ligand has been identified and can be used with the next generation nucleic 
acid carriers for hepatic gene delivery.   
 
 
3.2.4 Methotrexate polyglutamates as dual-functional ligands in 
oligo(ethanamino)amides for cytotoxic poly(I:C) delivery 
 
This chapter has been adapted from: 
Lächelt U, Wittmann V, Müller K, Edinger D, Kos P, Höhn M and Wagner E, “Synthetic 
polyglutamylation of dual-functional MTX Ligands for enhanced combined cytotoxicity of 
poly(I:C) nanoplexes.”, Mol Pharm, 2014, 11(8):2631-9. 
 
Folic acid (FolA, vitamin B9) and the related folate derivatives play important roles as 
single-carbon donors in several biosynthetic cellular pathways, such as the 
syntheses of purine bases, of the pyrimidine nucleotide dTMP from dUMP as well as 
the conversion of homocysteine to methionine. Therefore, folate is required for the 
maintenance of several cellular processes, especially in cells with high metabolic and 
proliferative activity. For this reason certain types of malignant cells and activated 
macrophages exhibit elevated expression levels of the folate receptor (FR). 
Methotrexate (MTX) and other antifolate drugs are widely used medications against 
different types of cancer and autoimmune diseases, such as rheumatoid arthritis. The 
discovery of dihydrofolate reductase (DHFR) as a key target of MTX and the 
elucidation of the detailed mode of action made an important contribution to the 
current understanding of molecular tumor pharmacology and the development of 
chemoresistance. Low molecular weight MTX is transported into cells via the reduced 
folate carrier (RFC) and undergoes an intracellular conversion to poly-γ-glutamyl 
derivatives due to acceptance as substrate of the enzyme folylpolyglutamyl 
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synthetase (FPGS). Polyglutamylation is a key step in the molecular mechanism of 
MTX and affects the drug’s activity in several ways, e.g. by evasion of efflux transport 
mechanisms and increased affinity toward DHFR and other target enzymes.  
Since it has already been shown that folic acid is compatible with the solid-phase 
synthesis platform and can easily be introduced in oligo(ethanamino)amides, the 
chemically closely related MTX could be a promising alternative with additional 
therapeutic effect. MTX could serve as a dual-functional ligand in antitumoral drug 
delivery, inducing both FR mediated cellular uptake and intrinsic cytotoxic action. 
However, the bioactivity of MTX changes by conjugation, since the activity is affected 
by the hampered intracellular conversion to the more potent poly-γ-glutamyl 
derivatives. In a cancer combination therapy approach for the co-delivery of cytotoxic 
dsRNA polyinosinic-polycytidylic acid poly(I:C), a set of molecularly precise 
oligo(ethanamino)amides was synthesized, comprising polyethylene glycol 
conjugated MTX-ligands. The conjugates differed in the number of additional 
glutamic acid residues to investigate the effect of different degrees of synthetic ‘a 
priori‘ polyglutamylation. In structure-activity relationship studies the bioactivity of 
these compounds concerning dihydrofolate reductase (DHFR) inhibition, cytotoxicity, 
nucleic acid binding potency, cellular uptake of poly(I:C) polyplexes and combined 
antifolate/poly(I:C) toxicity was investigated and correlated with the glutamylation 
degree.  
 
3.2.4.1 Library design and synthesis 
The polyamino acid Stp was used in combination with commercially available building 
blocks and α-amino acids for the solid-phase assisted assembly of the two-arm 
topology oligomers with PEGylation and dual-functional MTX ligands or control 
substitutes. Scheme 3.11 and Table 3.9 give an overview over the set of compounds 
used for the study. For the syntheses, the same standard Fmoc SPS conditions were 
used as for the PEGylated two-arm topology oligomers before. 
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Scheme 3.11 Illustration of the synthesized two-arm oligomers with (anti)folate ligands  
 
(A) Schematic structures of MTX carriers with different glutamylation degrees (639-641), additional histidines in 
the backbone (672) and control carriers (188, 356), (B) chemical structures of the sequence components.  
 
Table 3.9 Sequences, structure variants and abbreviations of the synthesized oligomers  
ID Sequence (C -> N) Variant Abbreviation 
188 A-dPEG24-K(Stp4-C)2 neg. control targeting Ala 
356 C-Stp4-K(Stp4-C)-dPEG24-FolA neg. control MTX-tox. FolA-Stp 
638 K(dPEG24-MTX)-K(Stp4-C)2 - MTX-Stp 
639 K(dPEG24-E2-MTX)-K(Stp4-C)2 polyglutam. 2E-MTX-Stp 
640 K(dPEG24-E4-MTX)-K(Stp4-C)2 polyglutam. 4E-MTX-Stp 
641 K(dPEG24-E6-MTX)-K(Stp4-C)2 polyglutam. 6E-MTX-Stp 
672 K[(dPEG24)2-E4-MTX]-HK[H-(Stp-H)4-C]2 polyglutam., His 4E-MTX-Stp-His 
583 C-Stp4-K(Stp4-C)-dPEG24-AlexaFluor488 fluoresc. label AF488-Stp 
 
MTX was attached to the exposed N-terminal part of the PEG segment in two steps: 
conjugation of (1) glutamic acid and (2) the pteroic acid derivative. The other MTX-
based ligands were varied in the number of glutamic acids incorporated additionally 
between PEG and MTX in the sequence. The rather untypical γ-peptide linkage 
(Scheme 3.11 B) of naturally occurring polyglutamates was assimilated in the 
oligomers by use of the proper Fmoc glutamic acid tert-butyl ester isomer with 
protected α-carboxy group. Folic acid was used as a nontoxic mono-functional 
targeting ligand (neg. control MTX-tox.) and alanine as a nonfunctional ligand 
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substitute (negative control targeting). In order to improve the efficiency of the carrier 
system, endosomal buffering histidines were incorporated in the basic core of a 
tetraglutamylated MTX conjugate to enhance endosomal release. In addition, a 
fluorescently labeled conjugate, carrying an Alexa Fluor 488 dye attached to the PEG 
segment in place of a folate ligand, was synthesized for fluorescence microscopy 
experiments.  
All compounds were analyzed by 1H-NMR and RP-HPLC. Figure 3.47 shows the 
analytical RP-HPLC chromatograms of the polyglutamylated MTX representatives. 
1H-NMR data can be found in the appendix.       
 
 
Figure 3.47 Analytical RP-HPLC chromatograms of oligomers with polyglutamylated MTX ligands. The analysis 
was carried out using a Waters Sunfire C18 column (5µm, 4.6 x 150mm) and a water/acetonitrile gradient (95:5 – 
0:100 in 20 min) containing 0.1 % TFA. For the detection the extinction at 214 nm was monitored. 
 
3.2.4.2 DHFR inhibition 
The inhibitory effect of MTX conjugates on human DHFR was investigated by 
determination of the relative DHFR activity in 100 nM solutions of the test compounds 
(Figure 3.48). Free MTX clearly showed stronger inhibitory effect than the 
corresponding conjugate 638 (MTX-Stp) without additional glutamic acid residues (95 
vs. 86 % inhibition). However, the inhibitory potency of the conjugates increased 
significantly with increasing degree of polyglutamylation between 638 and 641 (86 vs. 
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89 vs. 93 vs. 98 % inhibition). The tetraglutamylated member 640/4E-MTX-Stp 
showed an inhibitory effect comparable to free MTX, whereas the hexaglutamylated 
analog 641/6E-MTX-Stp even outperformed the effect of free MTX. These data 
indicate that even in conjugated form the inhibitory potency of MTX can be enhanced 
by polyglutamylation. 
 
Figure 3.48 Effect of polyglutamylation on dihydrofolate reductase (DHFR) inhibition. Relative DHFR activity in 
100 nM oligomer solutions was determined. A solution with 100 nm free MTX served as reference. N = 3 for each 
compound. Adapted from [214]. 
 
3.2.4.3 Oligomer toxicity 
The toxic effect of MTX and MTX-conjugates on human cervix carcinoma KB cells 
was determined by MTT assay over a concentration range between 3 and 10000 nM 
(Figure 3.49). Based on dose-response curve fittings the half maximal effective 
concentration (EC50, Figure 3.49 B, left scale black bars) and maximal efficacy (Emax 
= 100 % - cell viability [%], Figure 3.49 B, right scale white bars) were determined. 
Since the folic acid substituted control conjugate 356/FolA-Stp showed no notable 
reduction in cell viability, there is no evidence for unspecific oligomer toxicity in the 
investigated concentration range (Figure 3.49 A). Thus the folate conjugate seems to 
be an appropriate control with mono-functional ligand, serving for the purpose of 
targeting without intrinsic cytotoxicity (neg. control MTX-tox.). Looking at EC50 values, 
free MTX showed the highest potency in respect of the lowest EC50 value (5 nM). In 
case of the MTX conjugates, the potency seems to increase (EC50 values decrease) 
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with an increasing number of additional glutamates (EC50 of 195 vs. 86 vs. 82 vs. 15 
nM). Most importantly, all conjugates mediated higher maximal cell killing (Figure 
3.49 A and B) in the investigated concentration range than free MTX, indicating 
higher efficacy in the KB tumor cell line. Within the set of MTX conjugates, the 
hexaglutamylated variant 641 exhibited the best performance, almost reaching EC50 
levels of free MTX. 
 
 
Figure 3.49 Cytotoxicity of MTX-oligomers with different polyglutamylation degree on KB cells determined by 
MTT assay. N=3 for each compound. (A) Dose-response curves of free MTX and conjugates 356/FolA-Stp and 
638/MTX-Stp, (B) cytotoxicity parameters half maximal effective concentration (EC50, left scale, black bars) and 
maximal efficacy (Emax = 100 % - cell viability [%], right scale, white bars) of free MTX and MTX-conjugates were 
calculated by approximation of the dose-response curves with four-parameter logistic models. MTT assays were 
carried out by Valentin Wittmann (graduate student, LMU). Adapted from [214]. 
 
3.2.4.4 Physicochemical characterization of poly(I:C) polyplexes 
Poly(I:C) binding potency of the synthesized MTX conjugates at different nitrogen to 
phosphate (N/P) ratios was investigated in electrophoretic mobility shift assays 
(Figure 3.50 A). The conjugates 638-641 showed comparable binding potency with 
complete binding and shift of the nucleic acid band at N/P 6 and higher. Moreover, all 
conjugates also showed high serum stability (Figure 3.50 B). After incubation in 90 % 
FCS for up to 90 minutes, the majority of nucleic acid was retained within the 
complexes and no time-dependent destabilization at different time points could be 
observed. Importantly, the polyglutamylation of the MTX ligands did not affect nucleic 
acid binding potency of the cationic oligomer core, although additional negative 
charges were introduced into the structures.  
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Figure 3.50 Electrophoretic mobility shift assay of poly(I:C) polyplexes with MTX-oligo(ethanamino)amide 
conjugates. All samples contained 800 ng poly(I:C). (A) Poly(I:C) polyplexes at different N/P ratios, (B) poly(I:C) 
polyplexes at N/P 20 incubated in fetal calf serum (FCS) for indicated times. Adapted from [214]. 
 
The hydrodynamic diameter and zeta potential of poly(I:C) and poly(I) polyplexes 
were determined by dynamic and electrophoretic light scattering (Figure 3.51). The 
MTX oligomers formed poly(I:C) polyplexes with Z-average diameters between 439.2 
nm (640/4E-MTX-Stp) and 640.3 nm (641/6E-MTX-Stp) (Figure 3.51 A) and zeta 
potentials between 6.0 mV (640/4E-MTX-Stp) and 8.7 mV (641/6E-MTX-Stp). With 
poly(I), polyplexes in the range of 525.9 (638/MTX-Stp) to 688.3 nm (640/4E-MTX-
Stp) and with zeta potentials between 5.2 (640/4E-MTX-Stp) and 9.2 mV (638/MTX-
Stp) (Figure 3.51 B) were formed. However, in all cases the variation of the 
hydrodynamic diameters and zeta potentials was rather low. Therefore, neither the 
degree of polyglutamylation nor the type of nucleic acid used for polyplex formation 
showed a notable impact on the physicochemical parameters. These findings are of 
particular importance, since in subsequent cell culture experiments the influence of 
different glutamylation degrees as well as the effect of cytotoxic poly(I:C) and the 
nontoxic poly(I) control were compared.  
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Figure 3.51 Size parameters and Zeta potentials of polyplexes as determined by dynamic and electrophoretic 
light scattering. (A) Z-averages, PDI values and zeta potentials of poly(I:C) polyplexes at N/P 10, (B) Z-averages, 
PDI values and zeta potentials of poly(I) polyplexes at N/P 10. Polyplexes contained 10 µg of nucleic acids. N=3 
for each compound. 
 
3.2.4.5 Cellular uptake of poly(I:C) polyplexes 
Cellular uptake of poly(I:C) polyplexes in folic acid receptor (FR) expressing KB cells 
was investigated by flow cytometry (Figure 3.52 A and B) and confocal microscopy 
(Figure 3.52 C). The alanine substituted control 188/Ala did not mediate strong 
cellular uptake (< 4 % pos. cells), indicating good nanoparticle shielding by the 
incorporated PEG segment and absence of unspecific cellular interactions also in 
case of poly(I:C) polyplexes. In contrast, the analog folic acid 356 polyplexes 
exhibited remarkable high levels of cellular uptake (> 90 %) confirming the high 
potency of folate as a targeting ligand. In case of the MTX conjugate 638/MTX-Stp 
the majority of cells (approx. 60 %) was Cy5 fluorescence positive, however the high 
level of 356 was not reached. Looking at the MTX conjugates side-by-side, 
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polyglutamylation seems to enhance cellular uptake, with the tetraglutamylated 
analog 640/4E-MTX-Stp being the most potent candidate. Since the folic acid analog 
356 and the tetraglutamyl-MTX conjugate 640 exhibited highest potency of cellular 
uptake induction, both were challenged under folic acid competition conditions 
(Figure 3.52 B). In folic acid saturated medium the cellular uptake of the 
tetraglutamylated MTX conjugate 640 was suppressed to a value below 6 %, 
whereas cellular uptake of the folic acid analog 356 still reached levels of over 20 % 
positive cells.  
 
Figure 3.52 Cellular uptake of Cy5-poly(I:C) polyplexes in KB cells as determined by flow cytometry (A and B) 
and visualized by confocal microscopy (C). (A) Cellular uptake levels in folate free culture medium and (B) folic 
acid saturated culture medium. (C) Intracellular distribution of poly(I:C) polyplexes acquired by confocal laser 
scanning microscopy. Nuclei were stained with Hoechst 33342 (H). Poly(I:C) was spiked with 20 % Cy5 labeled 
poly(I:C). Polyplexes of oligomers 188 (Ala) and 640 (4E-MTX-Stp) were spiked with 20 % Alexa Fluor 488 
(AF488) labeled oligomer 583. Flow cytometry experiments were carried out by Valentin Wittmann (graduate 
student, LMU), microscopy experiments were carried out by Katharina Müller and Miriam Höhn (Pharmaceutical 
Biotechnology, LMU). Adapted from [214].        
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This finding is consistent with the reported higher affinity of folic acid to FR compared 
to MTX. However, the uptake of MTX targeted polyplexes seems to be tunable by 
polyglutamylation. The intracellular distribution of internalized poly(I:C) polyplexes of 
conjugate 180 and 640 was investigated by confocal laser scanning microscopy 
(Figure 3.52 C). Both the nucleic acids and conjugates were spiked with fluorescently 
labeled analogs to investigate the colocalization of the oligomers and the nucleic 
acids. The acquired images confirm the higher cellular uptake of the MTX-targeted 
polyplexes and the assumed colocalization of both therapeutic entities, conjugates 
and poly(I:C), in the combination therapy approach.  
 
3.2.4.6 Poly(I:C) transfections 
The combined cytotoxicity of MTX ligands and co-delivered poly(I:C) was 
investigated in transfections of KB cells and subsequent MTT assays (Figure 3.53). 
Poly(I) served as a nontoxic control nucleic acid for the differentiation between MTX 
and combined MTX/poly(I:C) mediated toxicity. The untargeted alanine control 
188/Ala showed neither oligomer or ligand mediated nor poly(I:C) triggered reduction 
of cell viability, in accordance with the previously shown extremely low cellular uptake 
of the untargeted polyplexes (cf. Figure 3.52 A) and the absence of unspecific 
oligomer cytotoxicity in the investigated concentration range. Although the folic acid 
conjugate 356 mediated the highest uptake levels of poly(I:C) polyplexes, within the 
transfections only a slight poly(I:C) mediated toxic effect could be observed at the 
highest N/P value. Moreover, the addition of free MTX in equimolar amounts 
compared to 356 only had a moderate additional effect on the poly(I:C) independent 
toxicity. In contrast, all MTX conjugates showed both more effective ligand and 
poly(I:C) mediated cell killing. The degree of glutamylation only marginally affected 
cell viability within poly(I) transfections, indicating that polyglutamylation does not 
seem to have a big impact on the exclusive ligand-toxicity of the polyplexes. 
However, in poly(I:C) transfections, a pronounced effect of polyglutamylation could 
be observed. The combined MTX/poly(I:C) mediated cell killing clearly increased with 
increasing glutamylation. Especially at lower N/P ratios, the additional poly(I:C) 
effects in transfections with polyglutamylated isoforms became apparent. Conjugate 
672/4E-MTX-Stp-His with additional histidine modifications in the cationic core 
showed both most effective ligand and combined ligand/poly(I:C) mediated 
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cytotoxicity (> 95 % killing). Obviously, an enhanced buffering in the endosomal pH 
range is also beneficial in context of poly(I:C) polyplexes and causes an additional 
boost of the combined antitumor activity, as both MTX and poly(I:C) 
pharmacologically act in the cytoplasm.  
 
Figure 3.53 Cell viability of KB cells after transfections with poly(I:C) polyplexes at indicated N/P ratios 
determined by MTT assay. N=3 for each compound. *Free MTX was added in equimolar concentrations 
compared to 356 at the indicated N/P values. Transfections were carried out by Valentin Wittmann (graduate 
student, LMU) and Katharina Müller (Pharmaceutical Biotechnology, LMU). Adapted from [214]. 
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4 Discussion 
4.1 The modulation of proton-sponge activity in 
oligo(ethanamino)amides  
In the transfection process, polymer-based pDNA complexes (polyplexes) [60] are 
taken up into cells by endocytic routes and thus are exposed to a varying range of 
different pH values (Scheme 4.1). Opposing requirements have to be considered: on 
the one hand, polymer basicity provides sufficient positive charges for stabilization of 
polyelectrolyte nucleic acid complexes at extracellular neutral pH; on the other hand, 
lower basicity with a shift of pKa values toward the endosomal acidic pH generates 
carriers with proton-sponge character. In this respect, endosomal cationization and 
subsequent membrane destabilization was proposed as mechanism for endosomal 
escape and a most critical step for the delivery process [55, 130, 136, 215].  
 
Scheme 4.1 The pH range within the delivery pathway of polymeric transfecting agents 
 
EC, extracellular space; EE, early endosomes; LE, late endosomes; L, lysosomes; NA: nucleic acid, EL: endo-
lysosomes. Adapted from [183]. 
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Therefore, different basicities have to be combined in order to meet the requirements 
of stable nucleic acid (NA) binding and endo-lysosomal (EL) buffering. The titration 
curves of PLL, PLR and PLH (Figure 3.1) illustrate that each of these polymers only 
covers a narrow buffering range as a result of its distinct pKa value and therefore 
does not strike a balance between high basicity for nucleic acid complexation and an 
additional endosomal buffer capacity. PLL for instance represents an excellent 
nucleic acid binder, which mediates cellular uptake of DNA, however fails in gene 
transfer due to its lack of endosomolytic potency [132, 148]. In contrast, PLH 
provides enormous endosomal buffer capacity, but insufficient nucleic acid binding at 
neutral pH [132]. Therefore, several approaches for the combination of the 
advantages of both polymers have been undertaken, such as histidylation of PLL 
[132, 216], amination of PLH [217], PLH-graft-PLL copolymers [218] or artificial 
histidine-lysine peptides [133]. In contrast to the basic polymers with distinct pKa 
values, PEI represents an ideal compromise between high basicity for pDNA binding 
and an additional endosomal buffer capacity, which explains its reputation as highly 
efficient pDNA transfecting agent. The homogeneous buffering of PEI is based on the 
repetitive diaminoethane motif, which allows the interaction of neighboring amines 
(cf. Figure 3.2, 1,2-DAE). The electronic and sterical hindrance by a neighboring 
protonated group causes a shift of the pKa toward lower pH, which makes 
diaminoethanes a beneficial motif for transfecting agents (Scheme 4.2). 
 
Scheme 4.2 Sequential protonation of the diaminoethane motif (adapted from [55] and [219]) 
 
In the oligo(ethanamino)amides based on the artificial polyamino acids (Gtt, Stp, Gtp, 
Sph) the homogeneous repetitive diaminoethane motif of PEI is dissected into a 
defined number of molecularly precise subunits. Depending on the used polyamino 
acid building block, these subunits provide two, three or four protonatable 
diaminoethane nitrogens (at internal positions of the sequence). It turned out that the 
type of building block and thus the number of protonatable amines within the 
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polyamine subunits determine the protonation characteristics of the final oligomers 
with big impact on different stages of gene transfer. An even-odd correlation between 
the number of neighboring protonatable amines and the endosomal buffer capacity 
has been observed (Figure 3.7). Oligomers comprising building blocks with an even 
number of neighboring protonatable amines (Gtt or Sph) exhibit higher buffer 
capacity than oligomers containing the odd numbered analogs (Stp or Gtp). When 
inspecting the protonation profiles between pH 5 and 7.4 in more detail, Gtt (n=2, 
even) and Stp (n=3, odd) oligomers show interesting profiles in opposite directions: 
Gtt mediates highest buffering in the lowest pH range, Stp in the highest pH range. 
Sph exhibits a rather homogeneous distribution between pH 5 and 7.4. Apparently 
with increasing length of a continuous diaminoethane motif, the even-odd contrasts 
vanish, as it has also been proposed in case of the titrations of bare polyamines 
(Figure 3.3 and 3.4). This even-odd effect is based on the sequential protonation of 
the polyamine units with the tendency to minimize the number of neighboring 
protonated groups (Scheme 4.3).  
 
Scheme 4.3 Simplified illustration of the sequential protonation of bis-acylated polyamines 
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In case of even-numbered polyamine units (Gtt, Sph) the protonation state at pH 7.4 
offers unprotonated amines with one protonated nitrogen in proximity, which can be 
protonated in the range down to pH 5. Therefore, different protonation states exist at 
pH 7.4 and pH 5. In contrast, the alternating distribution of protonated amines at pH 
7.4 in the odd-numbered compounds (Stp, Gtp) results in the proximity of two 
neighboring protonated nitrogens to the unprotonated amines. The subsequent 
protonation is strongly hindered, since an unfavorable state with three neighboring 
charged amines is generated and therefore does not occur above pH 5. In 
consequence, two out of three protonatable Stp (or Gtp) nitrogens are strong bases 
with highly probable protonation above 7.4, whereas the third is a too weak base to 
be biologically active. These findings made for oligomers with bis-acylated polyamine 
units is consistent with the titrations of bare polyamines (cf. Figure 3.3 and 3.4) and 
their reported pKa values at the different protonation states [220]. Moreover, Uchida 
et al. observed an analog odd-even protonation behavior of side chain aminoethylene 
repeats in N-substituted polyaspartamides used for nucleic acid delivery [65, 221]. 
Interestingly, opposing effects were found in pDNA and mRNA transfections with 
these compounds. While an even number of protonatable amines in the side chains 
was beneficial for pDNA transfections, an odd number mediated sustained mRNA 
expression. Obviously for mRNA, which is readily degraded in the cytosol, 
intracellular stability is an additional limiting parameter. In consequence of the lower 
endosomal buffer capacity, the aminoethylene units with an odd number of 
protonatable amines exhibit higher charge density at neutral pH, form more stable 
complexes with mRNA and presumably increase the cytosolic stability. However, for 
the delivery of pDNA with much higher stability the most critical intracellular step is 
represented by the endosomal escape and a tuned buffer capacity is favorable. 
By integration of histidine into the sequence of oligo(ethanamino)amides the total 
endosomal buffer capacity can be increased. Depending on the integrated polyamino 
acid building block (Gtt, Stp/Gtp, Sph), the influence is of greater or lesser extent; in 
case of low-buffering Stp the effect is most pronounced. Importantly, the increased 
buffer capacity is caused by a distinctly enhanced protonation around pH 6 in the 
medium range of the endolysosomal pathway. In all cases the gene transfer 
efficiency in vitro was greatly enhanced by histidylation, independent of the evaluated 
oligomer topology (four arm structures, PEGylated and un-PEGylated two-arm 
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structures). In case of PEGylated polyplexes with exclusively ligand dependent 
cellular uptake, the effect of histidylation could be put down to an improved 
endosomal escape. The confocal imaging of cells, transfected with histidylated 
polyplexes, showed a remarkable release of fluorescent calcein from endosomal 
vesicles into the cytosol, which correlated with an enhanced gene transfer efficiency 
of the carriers (Figure 3.16 and 3.38). The beneficial effect of histidine incorporation 
on in vitro transfections was also observed in the in vivo situation. After the 
intravenous injection of pDNA polyplexes, a four-arm topology histidine containing 
oligomer mediated over 30-fold improved transgene expression (approx. 20000-fold 
above background) in the tumor tissue of Neuro2A tumor bearing mice, compared to 
its histidine lacking analog.  
However, as mentioned before, the endosomal buffer capacity only in part correlates 
with overall transfection performance. For the rather small oligocations, nucleic acid 
binding and polyplex stability is a significant parameter and possible bottleneck in 
transfections. In four-arm oligomers with the Gtt building block (two protonatable 
amines), which offers the highest buffer capacity, the introduction of stabilizing 
terminal cysteines has a much higher impact on the transgene expression than 
histidylation. Nevertheless, also in high-buffering Gtt oligomers the integration of 
histidine improves gene transfer, although the effect on the total endosomal buffer 
capacity is minor. Here the redistribution of the endosomal protonation, mediated by 
histidine, seems to play a role. Gtt is predominantly protonated in the lower range of 
the endosomal pH, whereas histidine enhances the buffering in the medium ranges 
around pH 6, which rather represents the pH of early than late endo- or lysosomes 
[222]. The buffering at an early stage after cellular entry seems to be favorable for the 
gene transfer. This also explains that the combination of Gtp (three protonatable 
amines) with Gtt (two protonatable amines), which allowed the gradual adjustment of 
the buffer capacity between pH 5 and 7.4, failed in pDNA transfections. The use of 
pyridyl amino acids with lower basicity than histidine did not have a positive effect on 
endosomal escape either, whereas the analog with histidine mediated remarkable 
levels of transgene expression. This is consistent with the observation of Funhoff et 
al. that a basic poly(methacrylate) derivative combining two pKa values of 9 and 5 
condensed DNA into small particles, offered buffer capacity between pH 5 and 7, but 
failed in gene transfer due to a lack of endosomal escape [138]. The authors 
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concluded that the validity of the proton-sponge hypothesis was questioned, since 
the high buffer capacity was no predictor for successful endosomal escape. However, 
based on the presented data, the definition of the buffer capacity, which is 
considered beneficial for the endosomal escape, should rather be revisited. It is 
assumed that only an increase of buffer capacity in the high to medium endosomal 
pH ranges, representing an early stage of the intracellular delivery pathway (cf. 
Scheme 4.1), mediates proton-sponge activity in terms of endosomal polyplex 
release and basic groups with a pKa below 6 do not seem to be suitable for this 
purpose. The attempt to introduce an additional buffering nitrogen into the polyamino 
acid building blocks by using iminodiacetic acid derivatives as dicarboxylic acid part, 
unfortunately did not result in oligomers with improved protonation characteristics. 
However, the described synthesis shows a possibility for the introduction of new 
functionalities into the building blocks without modifying the nucleic acid binding 
polyamine motif, which might be a useful approach for future developments. 
 
4.2 Targeted and shielded oligo(ethanamino)amides for receptor-
specific nucleic acid delivery 
The biodistribution and tissue specific delivery of nucleic acids plays an important 
role for an intended use in cancer therapy. Although in an in vivo mouse model a 
predominant transgene expression in the tumor could be achieved by passive 
targeting of pDNA polyplexes based on four-arm oligo(ethanamino)amides (cf. Figure 
3.12), shielding and active targeting of the nanoparticles are requirements for a smart 
and adjustable delivery. The solid-phase synthesis using artificial polyamino acids 
together with α-amino acids and commercially available building blocks allows the 
assembly of multifunction nucleic acid carriers in a modular fashion. Diverse 
topologies can be generated and different (chemically or biologically) functional 
groups can precisely be positioned within the structures. To demonstrate the 
flexibility of the nucleic acid carrier platform in terms of the compatibility with targeting 
ligands of different chemical nature, several PEGylated two-arm 
oligo(ethanamino)amides were assembled. Peptides (B6, cMBP1, cMBP2), a protein 
(mEGF), carbohydrates (thiogalactose, thio-N-acetylgalactosamine) and small 
molecules (FolA, MTX) were used as ligands and evaluated for their individual 
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potency. The studies mostly focused on the screening and evaluation of the targeting 
ligands as one aspect of a modular optimization process. In selected cases (B6, 
FolA, cMBP2, MTX) histidylated carriers were additionally used to demonstrate the 
potential of an optimized ligand/carrier combination. 
The peptidic ligands cMBP1 and cMBP2 were readily integrated in the sequence of 
the PEGylated nucleic acid carriers. Several important findings could be made within 
the study. First, the nucleic acid carrier platform has demonstrated its potential for the 
screening and comparison of different targeting ligands. Because of the very efficient 
shielding due to an appropriate PEGylation, without targeting ligand no considerable 
interaction, in terms of cell binding or gene transfer, could be observed. Therefore, 
the activity of the targeted oligomers is strictly ligand dependent. By this means, the 
more potent c-Met binding peptide cMBP2 was identified. Moreover, the comparison 
with scrambled sequences in similar carrier structures confirmed the sequence-
specificity of cMBP2. Second, the enhancing effect of buffering histidines on 
endosomal escape could be reconfirmed. Similar as found for the ligands B6 and 
FolA, histidylation greatly improved the endosomal escape of cMBP2 targeted pDNA 
polyplexes, as shown by the intracellular calcein release out of endosomes, as well 
as the enhanced gene transfer efficiency. Importantly, the ligand dependent cellular 
association and gene transfer was not affected by the presence of histidine in the 
oligomer backbone. This demonstrates that a separate optimization of different 
modules, such as ligand, PEGylation or oligomer backbone, is possible with the 
nucleic acid carrier class. The potential of the identified optimal ligand/carrier 
combination resulted in the significantly ligand dependent transgene expression in 
vivo after intratumoral injection in the Huh7 xenograft mouse model. For the 
successful gene delivery to the tumor after systemic administration, a new polyplex 
formulation procedure with the use of an untargeted Stp-histidine co-formulation 
oligomer had to be developed. The better compaction of these co-formulation 
polyplexes resulted in the ligand dependent and tumor-specific transgene 
expression, which confirmed the tumor homing potential of the cMBP2 ligand as well 
as the suitability of the used nucleic acid carrier class to mediate targeted gene 
transfer in vivo. 
Murine epidermal growth factor (mEGF) was used as a model protein for the 
conjugation with a PEGylated two-arm oligomer. The strain-promoted alkyne-azide 
   Discussion 
134 
cycloaddition (SPAAC) allowed the site-specific attachment of the DBCO-
functionalized protein at the exposed part of the PEG segment in solution and 
demonstrated its suitability for the conjugation of targeting ligands, which cannot be 
integrated during the solid-phase synthesis. It is expected that other proteins can 
also be coupled to the carriers using the same chemistry. However, the purification 
procedure presumably has to be adjusted to the individual properties, size and 
molecular weight of the protein. In case of mEGF, size-exclusion chromatography 
was suitable to isolate the conjugation product. Importantly, the EGF conjugated 
oligo(ethanamino)amide retained its nucleic acid binding potency, which had to be 
verified, since with increasing size of the targeting ligand a sterical hindrance of the 
relatively small oligocationic core can be expected. The investigations by flow 
cytometry and live cell imaging revealed a notably fast and efficient cellular uptake of 
the mEGF-targeted pDNA polyplexes into EGFR expressing Huh7 cells. Likewise 
observations have been made with EGF-PEI conjugates before. De Bruin et al. 
reported in detailed kinetic studies that the cellular uptake of EGF targeted 
polyplexes was strongly accelerated and much more efficient compared to the 
unmodified PEI polyplexes [83]. In subsequent studies the enhancing effect of EGF 
could be explained by the activation of EGFR signaling, which triggers a rapid 
internalization into clathrin-coated vesicles [98, 223]. The EGF-Stp conjugate also 
showed the potential to mediate transgene expression, however so far only with use 
of chloroquine as endosomolytic agent.  
The synthesis of oligomers with carbohydrate ligands demonstrated the feasibility to 
combine the carbohydrate building blocks provided by the group of Prof. Hartmann 
with the nucleic acid carrier platform in one sequential solid-phase synthesis of glyco-
functionalized conjugates for gene delivery. The ligand dependent cellular interaction 
of the PEGylated two-arm oligomers allowed the comparison of the individual ligand 
potencies and the identification of the most potent candidate. The three multivalent 
GalS ligands mediated a cell-specific but relatively low cell binding to Huh7 cells. The 
ligand density and spatial arrangement, modulated by the number of sugar moieties 
and the introduction of a spacer molecule, did not influence the affinity. However, the 
GalNAcS ligand mediated strong cell binding and notable transgene expression in 
transfections with chloroquine. The strong enhancement of ligand potency due to the 
substitution of GalS by GalNAcS residues correlates with the sugar preference of the 
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AsGPR, since its affinity for GalNAc is approximately 50-fold higher than for Gal [224, 
225]. In combination with an improved nucleic acid carrier, the trivalent GalNAcS 
ligand is expected to be a potent module for hepatic gene delivery. 
The small-molecular drug MTX, which was used in oligo(ethanamino)amide 
conjugates , takes an exceptional position among the presented targeting ligands,   
since it served for both folate receptor mediated cellular uptake and an intracellular 
pharmacologic action. In a combination therapy approach, the assembled 
oligocationic MTX conjugates were used for the co-delivery of pharmacologically 
active antifolate ligands and the cytotoxic double-stranded RNA poly(I:C). 
Combination chemotherapy represents a routine modality in today’s cancer 
treatment. Several combination regimens are established first-line tumor 
pharmacotherapy in a variety of different malignancies. Motivation for the 
administration of multiple therapeutics is the fact that different mechanisms of action 
can trigger additive or even synergistic antitumor effects  and evade drug resistance 
mechanisms [226, 227]. On the one hand this implies the use of drug combinations 
for hitting different cellular subpopulations in heterogeneous tumors [228], on the 
other hand hitting different targets within single cells simultaneously, which are 
supposed to contribute to an enhanced final outcome, e.g. by “crossing the 
threshold” [229] of triggering tumor cell death. However, the latter strategy requires 
co-presence of the different agents in the same cell at the same time, which might be 
problematic in the case of differing pharmacokinetic properties or cellular uptake 
mechanisms. Since in the presented approach each of both pharmacological entities, 
MTX and poly(I:C), represents an essential part of the resulting nanoparticles, the 
spatiotemporal cellular co-delivery can be achieved. However, in contrast to low 
molecular weight (LMW) MTX, the conjugated γ-carboxamides cannot be 
metabolically converted in the cytosol into the more active MTX-polyglutamates. 
Therefore, a synthetic ‘a priori’ polyglutamylation approach was designed and 
evaluated. Enhancing effects of synthetic polyglutamylation could be observed in 
several stages of combined MTX/poly(I:C) activity. A polyglutamylation-degree 
dependent improvement of DHFR inhibition, as well as increased cytotoxic potency of 
the conjugates, were observed. The integration of six additional glutamic acid 
residues caused an almost 13-fold reduction of the EC50 value. Although free MTX 
exhibited the lowest EC50 value (5 nM), its potency could be approached by the 
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hexaglutamylated MTX conjugate (15 nM). This is considered to be a remarkable 
result for the comparison between a monovalent irreversible MTX conjugate and its 
native counterpart, which intracellularly gets converted into MTX-polyglutamates. 
Notably all synthetic MTX conjugates mediated higher maximal cell killing than free 
LMW MTX. An altered cellular uptake route and potentially evaded efflux 
mechanisms of the high molecular weight conjugates are considered as possible 
reasons, which deserve closer attention in future investigations.  
The specificity and ligand dependency of the poly(I:C) polyplex uptake into KB cells 
was shown in two ways. First, the alanine conjugate control sequence 188 lacking 
any targeting ligand failed in mediating any significant uptake of poly(I:C) polyplexes. 
Second, co-incubation with free folic acid significantly decreased the cellular uptake 
levels of both the folate targeted 356 (FolA-Stp) and the tetraglutamylated MTX 
analogue 640 (4E-MTX-Stp) polyplexes, indicating a folic acid uptake route for both 
conjugates. Under the folic acid competition conditions the folate conjugate clearly 
showed higher receptor affinity, which correlates with the much higher FRα affinity for 
folic acid (Kd ≈ 10 pM, determined by isothermal titration calorimetry) than for MTX 
(Kd ≈ 65 nM, determined by isothermal titration calorimetry) [230]. It is of interest to 
note that the cellular uptake of MTX polyplexes also showed some dependance on 
the glutamylation degree, since all polyglutamylated isoforms were superior to the 
simple MTX conjugate 638 (MTX-Stp). Obviously, in the context of macromolecular 
MTX γ-carboxy-PEG conjugates, a polyglutamyl chain is favorable over direct PEG 
attachment without any spacer. The tetraglutamylated conjugate 640 even mediated 
higher cellular uptake levels of polyplexes than the folate targeted analog, in absence 
of free folic acid. The remarkably high uptake levels, mediated by the 
polyglutamylated MTX conjugates, depict the possible use of antifolates as efficient 
ligands for targeting FR, which is overexpressed in several human cancers [231, 
232], due to multivalency on the nanoplex surface [100, 233] and ligand modulation.  
At the stage of combined MTX/poly(I:C) toxicity in transfections of KB cells, two 
important observations were made. First, and in sharp contrast to previous 
experience with targeted polyethylenimine (PEI) conjugates [39, 89], the new class of 
well biocompatible sequence-defined oligomers mediated specific poly(I:C) 
cytotoxicity to a considerable extent only in combination with the cytotoxic MTX 
ligands. The analogous folate ligand containing oligomer 356, despite higher uptake 
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efficiency, did not induce significant poly(I:C) cytotoxicity even when additional free 
MTX was present during the transfections. Second, the degree of polyglutamylation 
not only increased the MTX cytotoxicity but also triggered the poly(I:C) dependent 
cytotoxicity. The antifolate ligands and co-delivered poly(I:C) seem to act 
synergistically and complement each other. Polyglutamylation of MTX in this context 
enhanced the combined toxicity and in fact was required for an efficient final 
outcome. Putting the observations together, obviously the specific separate 
pharmacological modes of action of polyglutamylated MTX and poly(I:C) contribute to 
cross a certain threshold level of cytotoxicity required for triggering cell death. In the 
case of poly(I:C) delivery by PEI conjugates, the inherent cytotoxicity of the polymeric 
carrier [234, 235] provides such a push toward cell death. Notably, the most effective 
combined ligand/poly(I:C) cytotoxicity was achieved with the polyglutamylated and 
histidylated oligomer 672, which demonstrates the benefit of histidines also in case of 
poly(I:C) polyplexes and represents another example of the modular optimization of 
sequence-defined nucleic acid carriers.  
Apart from the presented synergistic concept of antifolate/poly(I:C) codelivery, the 
novel dual-functional MTX ligands, improved by synthetic polyglutamylation, might be 
useful also in context of other drug delivery systems. 
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5 Summary 
Nucleic acid therapeutics represent an innovative class of biopharmaceuticals with 
versatile modes of action and high potential for clinical applications. However, only a 
few examples have so far received marketing authorization. A major hurdle for the 
development of nucleic acid based drugs is the safe and efficient intracellular 
delivery. Just like natural viruses, polymer-based nanocarriers have to fulfill several 
requirements and be multifunctional to pass the separate hurdles of the nucleic acid 
delivery pathway efficiently. Particularly critical parameters are stable nucleic acid 
complexation, specific cellular uptake, endosomal escape and intracellular cargo 
release at the target site. In this work, a recently established solid-phase synthesis 
platform based on artificial polyamino acids has been used for the modular assembly 
of multifunctional, sequence-defined nucleic acid carriers. In two separate parts of the 
thesis, special emphasis has been put on the proton-sponge activity facilitating 
endosomal escape and receptor-mediated cellular uptake.  
In the first part, the protonation characteristics and endosomal buffering of 
oligo(ethanamino)amides with different polyamino acid building blocks and additional 
histidines or pyridylalanines were investigated and correlated with the activity in 
different stages of pDNA delivery. A clear correlation between an even or odd 
number of protonatable nitrogens in the building blocks and the endosomal 
protonation could be observed. The integration of histidine increased the endosomal 
buffer capacity between pH 5 and 7.4 and enhanced transgene expression in vitro 
and in vivo. The beneficial effect of ‘histidylation’ on endosomal release was 
visualized by imaging of fluorescent calcein, which was co-internalized during 
transfections with PEGylated, receptor targeted oligomers. In contrast, neither the 
combination of different polyamino acids nor the integration of pyridylalanines 
enhanced transgene expression, despite increasing the endosomal buffer capacity. 
In both cases, the endosomal buffering resulted from a pronounced protonation in the 
lower pH sub-ranges, whereas histidine mediated buffering in higher ranges around 
pH 6. The results suggest that the exact localization of the maximal buffering within 
the endosomal pH range plays an important role for the proton-sponge activity. In this 
respect, an increased buffering in the early stages of the endosomal pathway seems 
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to be beneficial for an enhanced proton-sponge activity and endosomal escape of 
pDNA polyplexes.  
In the second part, targeting ligands of different chemical nature were used for the 
receptor specific nucleic acid delivery. Peptides (cMBP1, cMBP2), a protein (mEGF), 
multivalent carbohydrates (mimetics of galactose and N-acetylgalactosamine) and 
small molecules (folic acid, methotrexate derivatives) were conjugated to PEGylated 
oligo(ethanamino)amides, and their individual suitability was investigated. In all 
cases, the compatibility with the nucleic acid carrier class could be demonstrated and 
potent ligands within each group were identified. Moreover, the precise architecture 
of the compounds allowed detailed structure-activity relationship studies and a 
stepwise optimization of the multifunctional nucleic acid carriers. By this means, the 
more potent peptide cMBP2, binding to the hepatocyte growth factor receptor (c-
Met/HGFR), was identified in pDNA transfections in vitro. In combination with 
improved histidylated nucleic acid carriers, a cMBP2 dependent and tumor-specific 
transgene expression in vivo could be achieved. A similar modular optimization of 
ligand and carrier backbone was carried out with a set of antifolate ligands. The 
antifolate MTX was conjugated to nucleic acid carriers for the co-delivery of cytotoxic 
poly(I:C) in a cancer combination therapy approach. MTX served as a dual-functional 
ligand for both a folate receptor-mediated cellular uptake and an intrinsic cytotoxic 
action. Additionally, MTX polyglutamates, which represent the pharmacologically 
active forms, were generated by introduction of additional glutamic acid residues 
during solid-phase synthesis. The synthetic polyglutamylation showed enhancing 
effects on several stages of combined MTX/poly(I:C) activity. The most effective 
tumor cell killing in vitro was achieved with a polyglutamylated and histidylated 
nucleic acid carrier, which demonstrated the suitability of histidines to enhance the 
proton-sponge activity also in case of poly(I:C) polyplexes.  
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6 Appendix 
6.1 Abbreviations 
1,2-DAE  1,2-Diaminoethane 
1,3-DAP  1,3-Diaminopropane 
1,4-DAB  1,4-Diaminobutane 
1,5-DAP  1,5-Diaminopentane 
1,6-DAH  1,6-Diaminohexane 
3PAL   3-(3-Pyridyl)-alanine 
4PAL   3-(4-Pyridyl)-alanine 
Ac2O   Acetic anhydride 
Boc   tert-Butoxycarbonyl protecting group 
Boc-IDA  N-(tert-Butoxycarbonyl)iminodiacetic acid 
BPEI   Branched polyethylenimine 
cMBP   c-Met binding peptide 
c-Met   Hepatocyte growth factor receptor 
DCC   N,N’-Dicyclohexylcarbodiimide 
DCM   Dichloromethane 
DCVC   Dry column vacuum chromatography 
DETA   Diethylene triamine 
DHFR   Dihydrofolate reductase 
DIPEA  N,N-Diisopropylethylamine 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF   N,N-Dimethylformamide 
DNA   Desoxyribonucleic acid 
dsRNA  Double-stranded RNA 
EDA   Ethylene diamine 
EDTA   Ethylendiaminetetraacetic acid 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
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ESI-MS  Electrospray ionization mass spectrometry 
EtBr   Ethidium bromide 
FCS   Fetal calf serum 
Fmoc   Fluorenylmethoxycarbonyl protecting group 
FolA   Folic acid 
FR   Folate receptor 
Gal   Galactose 
GalNAc  N-Acetylgalactosamine 
Gtp   Glutaryl-tetraethylene pentamine 
Gtt   Glutaryl-triethylene tetramine 
HBG   Hepes-buffered glucose 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HEPES  N-(2-hydroxethyl) piperazine-N‘-(2-ethansulfonic acid) 
HGF   Hepatocyte growth factor 
HMW   High molecular weight 
HOBt   1-Hydroxybenzotriazole 
IDA   Iminodiacetic acid 
ivDde 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl 
protecting group 
LMW   Low molecular weight 
LPEI   Linear polyethylenimine 
MeCN   Acetonitrile 
MEG   Monoethylene glycol 
mEGF  Murine epidermal growth factor  
M-IDA   N-(Methyl)iminodiacetic acid 
MTBE   Methyl tert-butyl ether 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MTX   Methotrexate 
MWCO  Molecular weight cut-off 
N/P   (Protonatable) nitrogen to phosphates ratio 
NHS   N-Hydroxysuccinimide 
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NMP   N-Methyl-2-pyrrolidone 
NMR   Nuclear magnetic resonance 
PAA   Polyamino acid 
pCMVLuc Plasmid encoding for firefly luciferase under the control of the 
cytomegalie virus (CMV) promoter 
PDI   Polydispersity index 
pDNA   Plasmid DNA 
PEG   Polyethylene glycol 
PEHA   Pentaethylene hexamine 
PLH   Poly-L-histidine 
PLL   Poly-L-lysine 
PLR   Poly-L-arginine 
poly(I)   Polyinosinic acid 
poly(I:C)  Polyinosinic-polycytidylic acid duplex 
PyBOP Benzotriazol-1-yloxy-tripyrrolidinophosphonium 
hexafluorophosphate 
RLU   Relative light units 
RNA   Ribonucleic acid 
RP-HPLC  Reversed-phase high performance liquid chromatography 
RT   Room temperature  
SEC   Size-exclusion chromatography 
SPAAC  Strain-promoted alkyne-azide cycloaddition 
Sph   Succinyl-pentaethylene hexamine 
SPS   Solid-phase synthesis 
Stp   Succinyl-tetraethylene pentamine 
TBE   Tris-boric acid-EDTA buffer 
TEPA   Tetraethylene pentamine 
TETA   Triethylene tetramine 
TFA   Trifluoroacetic acid 
TFE-IDA  N-(Trifluoroethyl)iminodiacetic acid 
THF    Tetrahydrofuran 
TIS   Triisopropylsilane 
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6.2 Sequences of peptidic targeting ligands 
Peptide Sequence (N -> C) References Chapter 
B6 GHKAKGPRK [104, 126, 175, 236] 3.1.2 
cMBP1 YLFSVHWPPLKA [176] 3.2.1 
cMBP2 KSLSRHDHIHHH [177-179] 3.2.1 
cMBP2sc1 LHHHDRKSSIHH * 3.2.1 
cMBP2sc2 KSHHRDHIHLHS * 3.2.1 
cMBP2sc3 HHSIHRLHHKSD * 3.2.1 
cMBP2sc4 RKIHHHLHSHSD * 3.2.1 
* Scrambled sequences of cMBP2 were generated using an online sequence permutation tool (RANDOM.ORG). 
 
6.3 Summary of SPS derived oligomers 
ID Sequence (C -> N) Topology 
Proton. 
Amines 
Chapter 
188 A-dPEG24-K(Stp4-C)2 P-2A 26 3.2.1 - 3.2.4 
202 AK(Stp4-C)2 2A 26 3.1.4 
356 C-Stp4-K(Stp4-C)-dPEG24-FolA P-2A 25 3.2.4 
440 A-dPEG24-HK[H-(Stp-H)4-C]2 P-2A 37 3.2.1 
442 K[dPEG24-HK(H-(Stp-H)4-C)2]-cMBP2 P-2A 37 3.2.1 
443 K[dPEG24-K(Stp4-C)2]-cMBP2 P-2A 26 3.2.1 
479 K(5ANV)-dPEG24-K(Stp4-C)2 P-2A 26 3.2.2 
573 AK[HK(H-Stp-H-Stp-H-Stp-HC)2]2 4A 58 3.1.2 
574 AK[HK(H-Stp-H-Stp-H-Stp-HA)2]2 4A 58 3.1.2 
575 AK[AK(A-Stp-A-Stp-A-Stp-AC)2]2 4A 40 3.1.2 
576 AK[AK(A-Stp-A-Stp-A-Stp-AA)2]2 4A 40 3.1.2 
577 AK[HK(H-Gtt-H-Gtt-H-Gtt-HC)2]2 4A 46 3.1.2 
578 AK[HK(H-Gtt-H-Gtt-H-Gtt-HA)2]2 4A 46 3.1.2 
579 AK[AK(A-Gtt-A-Gtt-A-Gtt-AC)2]2 4A 28 3.1.2 
580 AK[AK(A-Gtt-A-Gtt-A-Gtt-AA)2]2 4A 28 3.1.2 
582 AK[K(KH-(KHH)3-KHK)2]2 4A HK 60 3.1.2 
583 C-Stp4-K(Stp4-C)-dPEG24-AlexaFluor488 P-2A 25 3.2.4 
584 AK[K(KH-(KHH)5-KHK)2]2 4A HK 84 3.1.2 
603 (GalS)3-dPEG24-K(Stp4-C)2 P-2A 26 3.2.3 
604 (GalS)6-dPEG24-K(Stp4-C)2 P-2A 26 3.2.3 
605 (GalS-AEEAc)3-K(Stp4-C)2 P-2A 26 3.2.3 
606 AK[HK(H-Sph-H-Sph-H-Sph-HC)2]2 4A 70 3.1.2 
607 AK[HK(H-Sph-H-Sph-H-Sph-HA)2]2 4A 70 3.1.2 
608 AK[AK(A-Sph-A-Sph-A-Sph-AC)2]2 4A 52 3.1.2 
609 AK[AK(A-Sph-A-Sph-A-Sph-AA)2]2 4A 52 3.1.2 
610 A-Gtt-A-Gtt-A-Gtt-A 1A 7 3.1.2 
611 H-Gtt-H-Gtt-H-Gtt-H 1A 11 3.1.2 
612 A-Stp-A-Stp-A-Stp-A 1A 10 3.1.2 
613 H-Stp-H-Stp-H-Stp-H 1A 14 3.1.2 
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614 A-Sph-A-Sph-A-Sph-A 1A 13 3.1.2 
615 H-Sph-H-Sph-H-Sph-H 1A 17 3.1.2 
616 A-(dPEG24)2-HK[H-(Stp-H)4-C]2 P-2A 37 3.1.2, 3.2.1 
617 B6-(dPEG24)2-AK[A-(Stp-A)4-C]2 P-2A 26 3.1.2 
618 B6-(dPEG24)2-HK[H-(Stp-H)4-C]2 P-2A 37 3.1.2 
619 K[(dPEG24)2-FolA]-AK[A-(Stp-A)4-C]2 P-2A 26 3.1.2 
620 K[(dPEG24)2-FolA]-HK[H-(Stp-H)4-C]2 P-2A 37 3.1.2 
638 K(dPEG24-MTX)-K(Stp4-C)2 P-2A 26 3.2.4 
639 K(dPEG24-E2-MTX)-K(Stp4-C)2 P-2A 26 3.2.4 
640 K(dPEG24-E4-MTX)-K(Stp4-C)2 P-2A 26 3.2.4 
641 K(dPEG24-E6-MTX)-K(Stp4-C)2 P-2A 26 3.2.4 
651 (GalNAcS)3-dPEG24-K(Stp4-C)2 P-2A 26 3.2.3 
672 K[(dPEG24)2-E4-MTX]-HK[H-(Stp-H)4-C]2 P-2A 26 3.2.4 
689 C-(H-Stp)3-HK[H-(Stp-H)3-C]2 3A 43 3.2.1 
694 K[(dPEG24)2-HK(H-(Stp-H)4-C)2]-cMBP2 P-2A 37 3.2.1 
695 K[(dPEG24)2-AK(A-(Stp-A)4-C)2]-cMBP2 P-2A 26 3.2.1 
696 K[dPEG24-K(Stp4-C)2]-cMBP1 P-2A 26 3.2.1 
697 K[dPEG24-K(Stp4-C)2]-cMBP2sc1 P-2A 26 3.2.1 
698 K[dPEG24-K(Stp4-C)2]-cMBP2sc2 P-2A 26 3.2.1 
699 K[dPEG24-K(Stp4-C)2]-cMBP2sc3 P-2A 26 3.2.1 
700 K[dPEG24-K(Stp4-C)2]-cMBP2sc4 P-2A 26 3.2.1 
754 AK(Gtp4-C)2 2A 26 3.1.3, 3.1.5 
755 AK(IDAtp4-C)2 2A 34 3.1.5 
756 AK[(M-IDAtp)4-C]2 2A 34 3.1.5 
757 AK[(TFE-IDAtp)4-C]2 2A 34 3.1.5 
811 A-3PAL-K[(3PAL-Stp)4-3PAL-C]2 2A 37 3.1.4 
812 A-4PAL-K[(4PAL-Stp)4-4PAL-C]2 2A 37 3.1.4 
813 AHK[(H-Stp)4-HC]2 2A 37 3.1.4 
814 AK[(H-Stp)4-C]2 2A 34 3.1.5 
815 AK[(Gtp-Gtt)2-Gtp-C]2 2A 28 3.1.3 
816 AK[(Gtt-Gtp)2-Gtt-C]2 2A 26 3.1.3 
817 AK(Gtt4-C)2 2A 18 3.1.3 
Topology abbreviations: 1A, one-arm (linear); 2A, two-arm; P-2A, PEGylated two-arm; 4A, four-arm; 4A HK, four-
arm HK peptide. Oligomer 202 was synthesized by Dr. Irene Martin (visiting scientist, IRB Barcelona, Spain). 
Oligomers 573-580 were synthesized by Dr. Edith Salcher (Pharmaceutical Biotechnology, LMU). Oligomers 582 
and 584 were synthesized by Wolfgang Rödl (Pharmaceutical Biotechnology, LMU). Oligomer 689 was 
synthesized by Dongsheng He (Pharmaceutical Biotechnology, LMU). 
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6.4 Analytical Data 
6.4.1 Building blocks  
N-(tert-Butoxycarbonyl)iminodiacetic acid (Boc-IDA) 
 
 
 
 
 
 
1H-NMR (CD3OD) 
 
ESI-MS 
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Fmoc-Boc-IDAtp(Boc3)-OH 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3) 
 
ESI-MS 
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Fmoc-M-IDAtp(Boc3)-OH 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3) 
 
ESI-MS 
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N-(Trifluoroethyl)iminodiacetic acid (TFE-IDA) 
 
 
 
 
 
 
 
 
 
1H-NMR (D2O) 
 
ESI-MS 
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Fmoc-TFE-IDAtp(Boc3)-OH 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3) 
 
ESI-MS 
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6.4.2 Oligomers 
1H-NMR spectra of key structures  
Spectra of oligomers were recorded in deuterium oxide (D2O). 
 
Oligomer 442 / Sequence (C -> N): K[dPEG24-HK(H-(Stp-H)4-C)2]-HHHIHDHRSLSK 
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Oligomer 479 / Sequence (C -> N): K(5ANV)-dPEG24-K(Stp4-C)2 
 
Oligomer 603 / Sequence (C -> N): (GalS)3-dPEG24-K(Stp4-C)2 
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Oligomer 606 / Sequence (C -> N): AK[HK(H-Sph-H-Sph-H-Sph-HC)2]2 
 
Oligomer 620 / Sequence (C -> N): K[(dPEG24)2-FolA]-HK[H-(Stp-H)4-C]2 
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Oligomer 672 / Sequence (C -> N): K[(dPEG24)2-E4-MTX]-HK[H-(Stp-H)4-C]2 
 
Oligomer 754 / Sequence (C -> N): AK(Gtp4-C)2 
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Oligomer 755 / Sequence (C -> N): AK(IDAtp4-C)2 
 
Oligomer 756 / Sequence (C -> N): AK[(M-IDAtp)4-C]2 
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Oligomer 757 / Sequence (C -> N): AK[(TFE-IDAtp)4-C]2 
 
Oligomer 811 / Sequence (C -> N): A-3PAL-K[(3PAL-Stp)4-3PAL-C]2 
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Oligomer 812 / Sequence (C -> N): A-4PAL-K[(4PAL-Stp)4-4Pal-C]2 
 
Oligomer 813 / Sequence (C -> N): AHK[(H-Stp)4-HC]2 
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6.4.2.1 Summarized spectral data 
 
Oligomer 188 / Sequence (C -> N): A-dPEG24-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.2-1.5 (m, 9H, βH alanine, βγδH lysine), 2.4-2.6 (m, 
34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 2.9-3.5 (m, 134H, -CH2- 
TEPA, βH cysteine, εH lysine), 3.63 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-
4.3 (m, 4H, αH alanine, αH cysteine, αH lysine). 
 
Oligomer 356 / Sequence (C -> N): C-Stp4-K(Stp4-C)-dPEG24-FolA 
1H-NMR (400 MHz, D2O) δ = 1.2-1.5 (m, 6H, βγδH lysine), 1.9-2.1 (m, 4H, βγH 
glutamic acid), 2.4-2.5 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 
3.0-3.5 (m, 134H, -CH2- TEPA, βH cysteine, εH lysine), 3.60 (s, 98H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 4.0-4.6 (m, 4H, αH amino acids), 6.7-6.8 (d, 2H, Ar-H 
pteroic acid), 7.5-7.7 (d, 2H, Ar-H pteroic acid), 8.75 (s, 1H, Ar-H pteroic acid). 
 
Oligomer 440 / Sequence (C -> N): A-dPEG24-HK[H-(Stp-H)4-C]2 
1H-NMR (500 MHz, D2O) δ = 1.3-1.7 (m, 9H, βH alanine, βγδH lysine), 2.3-2.6 (m, 
34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 3.0-3.5 (m, 156H, -CH2- 
TEPA, βH cysteine, βH histidine, εH lysine), 3.63 (s, 98H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.1-4.3 (m, 3H, αH cysteine, αH lysine), 4.5-4.7 (m, 11H, αH histidine), 7.2-
7.3 (m, 11H, Ar-H histidine), 8.5-8.7 (m, 11H, Ar-H histidine).  
 
Oligomer 442 / Sequence (C -> N): K[dPEG24-HK(H-(Stp-H)4-C)2]-HHHIHDHRSLSK 
1H-NMR (400 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.8-3.5 (m, 176H, -CH2- TEPA, δH arginine, βH aspartate, βH cysteine, βH 
histidine, εH lysine, βH serine), 3.67 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-
4.6 (m, 27H, αH amino acids), 7.1-7.3 (m, 16H, Ar-H histidine), 8.5-8.6 (m, 16H, Ar-H 
histidine). 
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Oligomer 443 / Sequence (C -> N): K[dPEG24-K(Stp4-C)2]-HHHIHDHRSLSK 
1H-NMR (500 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.8-3.6 (m, 154H, -CH2- TEPA, δH arginine, βH aspartate, βH cysteine, βH 
histidine, εH lysine, βH serine), 3.66 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 3.9-
4.6 (comp, 16H, αH amino acids), 7.24-7.25 (m, 5H, Ar-H histidine), 8.61 (s, 5H, Ar-H 
histidine). 
 
Oligomer 479 / Sequence (C -> N): K(5ANV)-dPEG24-K(Stp4-C)2 
1H-NMR (400 MHz, D2O) δ = 1.2-1.8 (m, 18H, βγδ 5-azidonorvaline, βγδH lysine), 
2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 2.9-3.5 (m, 
134H, -CH2- TEPA, βH cysteine, εH lysine), 3.62 (s, 98H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 3.9-4.3 (m, 5H, αH 5-azidonorvaline, αH cysteine, αH lysine). 
 
Oligomer 603 / Sequence (C -> N): (GalS)3-dPEG24-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.4-1.7 (m, 18H, βγδH lysine, βγH 5-mercaptopentanoic 
acid), 2.3-2.8 (m, 58H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24, αδH 5-
mercaptopentanoic acid), 2.9-4.0 (m, 253H, -CH2- TEPA, -CH2-O- dPEG24, -CH2-N- 
dPEG24, βH cysteine, εH lysine, -CH-O- thiogalactose, -CH2-O- thiogalactose), 4.0-
4.3 (m, 3H, αH lysine, αH cysteine), 4.4-4.5 (d, 3H, -S-CH- thiogalactose). 
 
Oligomer 604 / Sequence (C -> N): (GalS)6-dPEG24-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.4-1.7 (m, 30H, βγδH lysine, βγH 5-mercaptopentanoic 
acid), 2.3-2.8 (m, 82H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24, αδH 5-
mercaptopentanoic acid), 3.0-4.0 (m, 274H, -CH2- TEPA, -CH2-O- dPEG24, -CH2-N- 
dPEG24, βH cysteine, εH lysine, -CH-O- thiogalactose, -CH2-O- thiogalactose), 4.1-
4.2 (m, 3H, αH lysine, αH cysteine), 4.4-4.5 (d, 3H, -S-CH- thiogalactose). 
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Oligomer 605 / Sequence (C -> N): (GalS-AEEAc)3-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.5-1.7 (m, 18H, βγδH lysine, βγH 5-mercaptopentanoic 
acid), 2.2-2.8 (m, 58H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24, αδH 5-
mercaptopentanoic acid), 3.0-4.1 (m, 283H, -CH2- TEPA, -CH2-O- dPEG24, -CH2-N- 
dPEG24, βH cysteine, εH lysine, -CH2- 2-(2-(2-aminoethoxy)ethoxy)acetic acid, -CH-
O- thiogalactose, -CH2-O- thiogalactose), 4.1-4.2 (m, 3H, αH lysine, αH cysteine), 
4.4-4.5 (d, 3 H, -S-CH- thiogalactose). 
 
Oligomer 606 / Sequence (C -> N): AK[HK(H-Sph-H-Sph-H-Sph-HC)2]2 
1H-NMR (400 MHz, D2O) δ = 1.1-1.5 (m, 21H, βH alanine, βγδH lysine), 2.3-2.7 (m, 
48H, -CO-CH2-CH2-CO- succinic acid), 2.8-3.9 (m, 290H, -CH2- PEHA, βH cysteine, 
βH histidine, εH lysine), 4.0-4.3 (m, 8H, αH alanine, αH cysteine, αH lysine), 4.6-4.7 
(m, 18H, αH histidine), 7.0-7.5 (s, 18H, Ar-H histidine), 8.59 (s, 18H, Ar-H histidine). 
 
Oligomer 607 / Sequence (C -> N): AK[HK(H-Sph-H-Sph-H-Sph-HA)2]2 
1H-NMR (400 MHz, D2O) δ = 1.1-1.7 (m, 33H, βH alanine, βγδH lysine), 2.3-2.6 (m, 
48H, -CO-CH2-CH2-CO- succinic acid), 2.9-3.9 (m, 282H, -CH2- PEHA, βH histidine, 
εH lysine), 3.9-4.3 (m, 8H, αH alanine, αH lysine), 4.5-4.7 (m, 18H, αH histidine), 7.1-
7.4 (m, 18H, Ar-H histidine), 8.5-8.7 (s, 18H, Ar-H histidine). 
 
Oligomer 608 / Sequence (C -> N): AK[AK(A-Sph-A-Sph-A-Sph-AC)2]2 
1H-NMR (400 MHz, D2O) δ = 1.2-1.5 (m, 75H, βH alanine, βγδH lysine), 2.4-2.6 (m, 
48H, -CO-CH2-CH2-CO- succinic acid), 3.0-3.8 (m, 254H, -CH2- PEHA, βH cysteine, 
εH lysine), 4.0-4.4 (m, 26 H, αH alanine, αH cysteine, αH lysine). 
 
Oligomer 609 / Sequence (C -> N): AK[AK(A-Sph-A-Sph-A-Sph-AA)2]2 
1H-NMR (400 MHz, D2O) δ = 1.2-1.6 (m, 87H, βH alanine, βγδH lysine), 2.4-2.6 (m, 
48H, -CO-CH2-CH2-CO- succinic acid), 2.9-3.8 (m, 246H, -CH2- PEHA, εH lysine), 
3.9-4.4 (m, 26H, αH alanine, αH lysine). 
 
   Appendix 
160 
Oligomer 610 / Sequence (C -> N): A-Gtt-A-Gtt-A-Gtt-A 
1H-NMR (500 MHz, D2O) δ = 1.2-1.6 (m, 12H, βH alanine), 1.7-2.1 (m, 6H, -CH2-
CH2-CH2- glutaric acid), 2.2-2.4 (m, 12H, -CO-CH2- glutaric acid), 3.0-3.8 (m, 36H, -
CH2- TETA), 4.0-4.4 (m, 4H, αH alanine). 
ESI-MS: [M+2H]2+ calcd for C45H88O11N16 1030.6975; found 1030.6975.           
[M+3H]3+ calcd for C45H88O11N16 1031.7053; found 1031.7039.  
 
Oligomer 611 / Sequence (C -> N): H-Gtt-H-Gtt-H-Gtt-H 
1H-NMR (500 MHz, D2O) δ = 1.6-1.9 (m, 6H, -CH2-CH2-CH2- glutaric acid), 2.0-2.4 
(m, 12H, -CO-CH2- glutaric acid), 2.8-3.9 (m, 44H, -CH2- TETA, βH histidine), 4.2-4.7 
(m, 4H, αH histidine), 7.2-7.5 (m, 4H, Ar-H histidine), 8.5-8.7 (m, 4H, Ar-H histidine). 
ESI-MS: [M+2H]2+ calcd for C57H96O11N24 1294.7847; found 1294.7844.           
[M+3H]3+ calcd for C57H96O11N24 1295.7925; found 1295.7915. 
 
Oligomer 612 / Sequence (C -> N): A-Stp-A-Stp-A-Stp-A 
1H-NMR (500 MHz, D2O) δ = 1.2-1.6 (m, 12H, βH alanine), 2.3-2.7 (m, 12H, -CO-
CH2-CH2-CO- succinic acid), 3.0-3.8 (m, 48H, -CH2- TEPA), 3.9-4.4 (m, 4H, αH 
alanine). 
ESI-MS: [M+2H]2+ calcd for C48H97O11N19 1117.7771; found 1117.7766.          
[M+3H]3+ calcd for C48H97O11N19 1118.7850; found 1118.7840. 
 
Oligomer 613 / Sequence (C -> N): H-Stp-H-Stp-H-Stp-H 
1H-NMR (500 MHz, D2O) δ = 2.3-2.7 (m, 12H, -CO-CH2-CH2-CO- succinic acid), 2.9-
3.8 (m, 56H, -CH2- TEPA, βH histidine), 4.2-4.7 (4H, αH histidine), 7.2-7.5 (d, 4H, Ar-
H histidine), 8.5-8.7 (t, 4H, Ar-H histidine). 
ESI-MS: [M+2H]2+ calcd for C60H105O11N27 1381.8643; found 1381.8640.              
[M+3H]3+ calcd for C60H105O11N27 1382.8722; found 1382.8710. 
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Oligomer 614 / Sequence (C -> N): A-Sph-A-Sph-A-Sph-A 
1H-NMR (400 MHz, D2O) δ = 1.1-1.5 (m, 12H, βH alanine), 2.4-2.6 (m, 12H, -CO-
CH2-CH2-CO- succinic acid), 2.9-3.8 (m, 60H, -CH2- PEHA), 3.9-4.3 (m, 4H, αH 
alanine). 
ESI-MS: [M+2H]2+ calcd for C54H112O11N22 1246.9037; found 1246.9034.   
 
Oligomer 615 / Sequence (C -> N): H-Sph-H-Sph-H-Sph-H 
1H-NMR (400 MHz, D2O) δ = 2.3-2.6 (m, 12H, -CO-CH2-CH2-CO- succinic acid), 2.9-
4.0 (m, 68H, -CH2- PEHA, βH histidine), 4.1-4.7 (m, 4H, αH histidine), 7.0-7.6 (d, 4H, 
Ar-H histidine), 8.4-8.8 (t, 4H, Ar-H histidine). 
ESI-MS: [M+2H]2+ calcd for C66H120O11N30 1510.9910; found 1510.9914.               
[M+3H]3+ calcd for C66H120O11N30 1511.9988; found 1511.9979.   
 
Oligomer 616 / Sequence (C -> N): A-(dPEG24)2-HK[H-(Stp-H)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.4 (m, 9H, βH alanine, βγδH lysine), 2.2-2.7 (m, 
36H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 2.9-3.5 (m, 156H, -CH2- 
TEPA, βH cysteine, βH histidine, εH lysine), 3.6-3.7 (s, 200H, -CH2-O- dPEG24, -CH2-
N- dPEG24), 4.2-4.3 (m, 4H, αH alanine, αH cysteine, αH lysine), 4.5-4.7 (m, 11H, αH 
histidine), 7.1-7.3 (m, 11H, Ar-H histidine), 8.4-8.7 (m, 11H, Ar-H histidine). 
 
Oligomer 617 / Sequence (C -> N): KRPGKAKHG-(dPEG24)2-AK[A-(Stp-A)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.2-1.6 (m, 60H, βH alanine, βγδH lysine), 2.3-2.7 (m, 
36H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 2.9-3.6 (m, 146H, -CH2- 
TEPA, βH arginine, βH cysteine, βH histidine, εH lysine, βH proline), 3.64 (s, 200H, -
CH2-O- dPEG24, -CH2-N- dPEG24), 4.2-4.3 (m, 25H, αH alanine, αH arginine, αH 
cysteine, αH glycine, αH histidine, αH proline, αH lysine), 7.24 (s, 1H, Ar-H histidine), 
8.5-8.6 (d, 1H, Ar-H histidine). 
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Oligomer 618 / Sequence (C -> N): KRPGKAKHG-(dPEG24)2-HK[H-(Stp-H)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.1-1.6 (m, 27H, βH alanine, βγδH lysine), 2.3-2.7 (m, 
36H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 2.9-3.5 (m, 168H, -CH2- 
TEPA, βH arginine, βH cysteine, βH histidine, εH lysine, βH proline), 3.64 (s, 200H, -
CH2-O- dPEG24, -CH2-N- dPEG24), 4.2-4.3 (m, 13H, αH alanine, αH arginine, αH 
cysteine, αH glycine, αH lysine, αH proline), 4.6-4.7 (m, 12H, αH histidine), 7.1-7.4 
(m, 12H, Ar-H histidine), 8.5-8.7 (m, 12H, Ar-H histidine). 
 
Oligomer 619 / Sequence (C -> N): K[(dPEG24)2-FolA]-AK[A-(Stp-A)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.1-1.5 (m, 45H, βH alanine, βγδH lysine), 1.8-2.0 (m, 
4H, βγH glutamic acid), 2.3-2.6 (m, 36H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 3.0-3.5 (m, 136H, -CH2- TEPA, βH cysteine, εH lysine), 3.61 (s, 200H, -
CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.4 (m, 16H, αH alanine, αH cysteine, αH 
glutamic acid, αH lysine), 6.6-6.8 (d, 2H, pteroic acid), 7.5-7.7 (d, 2H, Ar-H pteroic 
acid), 8.71 (s, 1H, Ar-H pteroic acid). 
 
Oligomer 620 / Sequence (C -> N): K[(dPEG24)2-FolA]-HK[H-(Stp-H)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.0-1.5 (m, 12H, βγδH lysine), 1.8-2.2 (m, 4H, βγH 
glutamic acid), 2.3-2.6 (m, 36H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24, 
βH glutamic acid), 2.8-3.5 (m, 158H, -CH2- TEPA, βH cysteine, βH histidine, εH 
lysine), 3.61 (s, 196H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.1-4.7 (m, 16H, αH 
cysteine, αH glutamic acid, αH histidine, αH lysine), 6.7-6.8 (d, 2H, Ar-H pteroic acid), 
7.1-7.3 (m, 11H, Ar-H histidine), 7.5-7.6 (d, 2H, Ar-H pteroic acid), 8.5-8.6 (d, 11H, 
Ar-H histidine), 8.71 (s, 1 H, Ar-H pteroic acid). 
 
Oligomer 638 / Sequence (C -> N): K(dPEG24-MTX)-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.5-1.7 (m, 12H, βγδH lysine), 2.2-2.6 (m, 4H, βγH 
glutamic acid) 2.5-2.7 (m, 34 H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 
3.1-3.6 (m, 136H, -CH2- TEPA, βH cysteine, εH lysine), 3.7-3.8 (m, 98H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 4.2-4.5 (m, 5H, αH cysteine, αH glutamic acid, αH lysine), 
6.9-7.1 (d, 2H, Ar-H MTX), 7.7-7.8 (m, 2H, Ar-H MTX), 8.82 (s, 1 H, Ar-H MTX). 
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Oligomer 639 / Sequence (C -> N): K(dPEG24-E2-MTX)-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.2-1.6 (m, 12H, βγδH lysine), 1.7-2.4 (m, 12H, βγH 
glutamic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 3.0-3.6 (m, 136H, -CH2- TEPA, βH cysteine, εH lysine), 3.6-3.7 (m, 98H, -
CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.4 (m, 7H, αH cysteine, αH glutamic acid, αH 
lysine), 6.8-6.9 (m, 2H, Ar-H MTX), 7.6-7.7 (d, 2H, Ar-H MTX), 8.67 (s, 1H, Ar-H 
MTX). 
 
Oligomer 640 / Sequence (C -> N): K(dPEG24-E4-MTX)-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.1-1.5 (m, 12H, βγδH lysine), 1.6-2.3 (m, 20H, βγH 
glutamic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.8-3.5 (m, 136H, -CH2- TEPA, βH cysteine, εH lysine), 3.5-3.6 (m, 98H, -
CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.5 (m, 9H, αH cysteine, αH glutamic acid, αH 
lysine), 6.7-6.8 (d, 2H, Ar-H MTX), 7.5-7.7 (d, 2H, Ar-H MTX), 8.5-8.6 (d, 1H, Ar-H 
MTX). 
 
Oligomer 641 / Sequence (C -> N): K(dPEG24-E6-MTX)-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.2-1.1 (m, 12H, βγδH lysine), 1.6-2.4 (m, 28H, βγH 
glutamic acid), 2.4-2.6 (s, 34 H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 
3.0-3.6 (m, 136H, -CH2- TEPA, βH cysteine, εH lysine), 3.6-3.7 (d, 98H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 4.1-4.6 (m, 11H, αH cysteine, αH glutamic acid, αH 
lysine), 6.8-6.9 (d, 2H, Ar-H MTX), 7.6-7.7 (d, 2H, Ar-H MTX), 8.6-8.7 (s, 1H, Ar-H 
MTX). 
 
Oligomer 651 / Sequence (C -> N): (GalNAcS)3-dPEG24-K(Stp4-C)2 
1H-NMR (500 MHz, D2O) δ = 1.4-1.7 (m, 18H, βγδH lysine, βγH 5-mercaptopentanoic 
acid), 1.9-2.0 (s, 9H, -N-CO-CH3 N-acetylgalactosamine), 2.2-2.8 (m, 58H, -CO-CH2-
CH2-CO- succinic acid, -CO-CH2- dPEG24, αδH 5-mercaptopentanoic acid), 3.0-4.0 
(m, 250H, -CH2- TEPA, -CH2-O- dPEG24, βH cysteine, εH lysine, -CH-O- 
thiogalactosamine, -CH-N- thiogalactosamine, -CH2-O- thiogalactosamine), 4.1-4.3 
(m, 3H, αH lysine, αH cysteine), 4.4-4.5 (d, 3H, -S-CH- thiogalactosamine).  
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Oligomer 672 / Sequence (C -> N): K[(dPEG24)2-E4-MTX]-HK[H-(Stp-H)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.1-1.5 (m, 12H, βγδH lysine), 1.6-2.3 (m, 20H, βγH 
glutamic acid), 2.3-2.6 (m, 36 H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 3.0-3.5 (m, 158H, -CH2- TEPA, βH cysteine, εH lysine), 3.5-3.7 (d, 196H, -
CH2-O- dPEG24, -CH2-N- dPEG24), 4.1-4.7 (m, 20H, αH cysteine, αH glutamic acid, 
αH histidine, αH lysine), 6.8-6.9 (d, 2H, Ar-H MTX), 7.2-7.3 (d, 11H, Ar-H histidine), 
7.6-7.7 (d, 2H, Ar-H MTX), 8.5-8.6 (d, 11H, Ar-H histidine), 8.61 (s, 1H, Ar-H MTX). 
 
Oligomer 694 / Sequence (C -> N): K[(dPEG24)2-HK(H-(Stp-H)4-C)2]-
HHHIHDHRSLSK 
1H-NMR (400 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 36H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.9-3.5 (m, 176H, -CH2- TEPA, δH arginine, βH cysteine, βH histidine, εH 
lysine, βH serine), 3.62 (s, 196H, -CH2-O- dPEG24, -CH2-N- dPEG24), 3.9-4.7 (m, 
27H, αH amino acids), 7.22 (s, 16H, Ar-H histidine), 8.56-8.57 (m, 16H, Ar-H 
histidine). 
 
Oligomer 695 / Sequence (C -> N): K[(dPEG24)2-AK(A-(Stp-A)4-C)2]-
HHHIHDHRSLSK 
1H-NMR (500 MHz, D2O) δ = 1.0-2.0 (m, 73H, βH alanine, βγH arginine, βγδH 
isoleucine, βγδH leucine, βγδH lysine), 2.4-2.6 (m, 36H, -CO-CH2-CH2-CO- succinic 
acid, -CO-CH2- dPEG24), 2.9-3.6 (m, 154H, -CH2- TEPA, δH arginine, βH cysteine, 
βH histidine, εH lysine, βH serine), 3.67 (s, 196H, -CH2-O- dPEG24, -CH2-N- dPEG24), 
4.0-4.7 (m, 27H, αH amino acids), 7.25-7.30 (m, 5H, Ar-H histidine), 8.61 (s, 5H, Ar-H 
histidine). 
 
Oligomer 696 / Sequence (C -> N): K[dPEG24-K(Stp4-C)2]-AKLPPWHVSFLY 
1H-NMR (500 MHz, D2O) δ = 1.0-1.9 (m, 53H, βH alanine, βγδH leucine, βγδH lysine, 
βγH proline, γH valine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.9-3.5 (m, 152H, -CH2- TEPA, βH cysteine, βH histidine, εH lysine, βH 
phenylalanine, δH proline, βH serine, βH tryptophane, βH tyrosine), 3.66 (s, 98H, -
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CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.6 (m, 16H, αH amino acids), 7.0-7.4 (m, 
15H, Ar-H histidine, phenylalanine, tryptophane, tyrosine), 8.61 (s, 1H, Ar-H 
histidine). 
 
Oligomer 697 / Sequence (C -> N): K[dPEG24-K(Stp4-C)2]-HHISSKRDHHHL 
1H-NMR (400 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.8-3.6 (m, 156H, -CH2- TEPA, δH arginine, βH aspartate, βH cysteine, βH 
histidine, εH lysine, βH serine), 3.66 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 3.9-
4.6 (m, 16H, αH amino acids), 7.24-7.25 (m, 5H, Ar-H histidine), 8.61 (s, 5H, Ar-H 
histidine). 
 
Oligomer 698 / Sequence (C -> N): K[dPEG24-K(Stp4-C)2]-SHLHIHDRHHSK 
1H-NMR (400 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.8-3.6 (m, 156H, -CH2- TEPA, δH arginine, βH aspartate, βH cysteine, βH 
histidine, εH lysine, βH serine), 3.66 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 3.9-
4.6 (m, 16H, αH amino acids), 7.24-7.25 (m, 5H, Ar-H histidine), 8.61 (s, 5H, Ar-H 
histidine). 
 
Oligomer 699 / Sequence (C -> N): K[dPEG24-K(Stp4-C)2]-DSKHHLRHISHH 
1H-NMR (400 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 2.8-3.6 (m, 156H, -CH2- TEPA, δH arginine, βH aspartate, βH cysteine, βH 
histidine, εH lysine, βH serine), 3.66 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 3.9-
4.6 (m, 16H, αH amino acids), 7.24-7.25 (m, 5H, Ar-H histidine), 8.61 (s, 5H, Ar-H 
histidine). 
 
Oligomer 700 / Sequence (C -> N): K[dPEG24-K(Stp4-C)2]-DSHSHLHHHIKR 
1H-NMR (400 MHz, D2O) δ = 1.0-2.0 (m, 40H, βγH arginine, βγδH isoleucine, βγδH 
leucine, βγδH lysine), 2.4-2.6 (m, 34H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
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dPEG24), 2.8-3.6 (m, 156H, -CH2- TEPA, δH arginine, βH aspartate, βH cysteine, βH 
histidine, εH lysine, βH serine), 3.66 (s, 98H, -CH2-O- dPEG24, -CH2-N- dPEG24), 3.9-
4.6 (m, 16H, αH amino acids), 7.24-7.25 (m, 5H, Ar-H histidine), 8.61 (s, 5H, Ar-H 
histidine). 
 
Oligomer 754 / Sequence (C -> N): AK(Gtp4-C)2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.5 (m, 9H, βH alanine, βγδH lysine), 1.7-1.9 (m, 
16H, -CH2-CH2-CH2- glutaric acid), 2.1-2.3 (m, 32H, -CO-CH2- glutaric acid), 2.9-3.7 
(m, 134H, -CH2- TEPA, βH cysteine, εH lysine), 4.1-4.3 (m, 4H, αH alanine, αH 
cysteine, αH lysine). 
 
Oligomer 755 / Sequence (C -> N): AK(IDAtp4-C)2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.6 (m, 9H, βH alanine, βγδH lysine), 3.1-3.6 (m, 
134H, -CH2- TEPA, βH cysteine, εH lysine), 3.8-4.0 (d, 32H, -CO-CH2- IDA), 4.1-4.3 
(m, 4H, αH alanine, αH cysteine, αH lysine). 
 
Oligomer 756 / Sequence (C -> N): AK[(M-IDAtp)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.5 (m, 9H, βH alanine, βγδH lysine), 2.9-3.0 (m, 
24H, -CH3 M-IDA), 3.0-3.8 (m, 134H, -CH2- TEPA, βH cysteine, εH lysine), 4.0-4.1 (d, 
32H, -CO-CH2- M-IDA), 4.2-4.3 (m, 4H, αH alanine, αH cysteine, αH lysine). 
 
Oligomer 757 / Sequence (C -> N): AK[(TFE-IDAtp)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.5 (m, 9H, βH alanine, βγδH lysine), 2.9-3.9 (m, 
182H, -CH2- TEPA, βH cysteine, εH lysine, -CO-CH2- TFE-IDA, -CH2-CF3 TFE-IDA, 
4.1-4.3 (m, 4H, αH alanine, αH cysteine, αH lysine). 
 
Oligomer 811 / Sequence (C -> N): A-3PAL-K[(3PAL-Stp)4-3PAL-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.7 (m, 9H, βH alanine, βγδH lysine), 2.2-2.6 (m, 
32H, -CO-CH2-CH2-CO- succinic acid), 2.8-3.7 (m, 156H, -CH2- TEPA, βH cysteine, 
βH 3-(3-pyridyl)-alanine, εH lysine), 4.0-4.3 (m, 4H, αH alanine, αH cysteine, αH 
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lysine), 7.9-8.0 (m, 11H, Ar-H 3-(3-pyridyl)-alanine), 8.4-8.5 (m, 11H, Ar-H 3-(3-
pyridyl)-alanine), 8.6-8.7 (d, 22H, Ar-H 3-(3-pyridyl)-alanine). 
 
Oligomer 812 / Sequence (C -> N): A-4PAL-K[(4PAL-Stp)4-4Pal-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.7 (m, 9H, βH alanine, βγδH lysine), 2.2-2.5 (m, 
32H, -CO-CH2-CH2-CO- succinic acid), 2.8-3.7 (m, 156H, -CH2- TEPA, βH cysteine, 
βH 3-(4-pyridyl)-alanine, εH lysine), 4.1-4.3 (m, 4H, αH alanine, αH cysteine, αH 
lysine), 7.8-7.9 (d, 22H, Ar-H 3-(4-pyridyl)-alanine), 8.6-8.7 (d, 22H, Ar-H 3-(4-
pyridyl)-alanine). 
 
Oligomer 813 / Sequence (C -> N): AHK[(H-Stp)4-HC]2 
1H-NMR (400 MHz, D2O) δ = 1.2-1.7 (m, 9H, βH alanine, βγδH lysine), 2.3-2.6 (m, 
32H, -CO-CH2-CH2-CO- succinic acid), 2.8-3.7 (m, 156H, -CH2- TEPA, βH cysteine, 
βH histidine, εH lysine), 4.1-4.3 (m, 4H, αH alanine, αH cysteine, αH lysine), 4.5-4.6 
(m, 11H, αH histidine), 7.2-7.3 (d, 11H, Ar-H histidine), 8.55 (s, 11H, Ar-H histidine). 
 
Oligomer 814 / Sequence (C -> N): AK[(H-Stp)4-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.8 (m, 9H, βH alanine, βγδH lysine), 2.3-2.6 (m, 
32H, -CO-CH2-CH2-CO- succinic acid), 2.9-3.7 (m, 150H, -CH2- TEPA, βH cysteine, 
βH histidine, εH lysine), 4.0-4.4 (m, 4H, αH alanine, αH cysteine, αH lysine), 4.5-4.6 
(m, 8H, αH histidine), 7.2-7.3 (s, 8H, Ar-H histidine), 8.5-8.6 (s, 8H, Ar-H histidine). 
 
Oligomer 815 / Sequence (C -> N): AK[(Gtp-Gtt)2-Gtp-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.5 (m, 9H, βH alanine, βγδH lysine), 1.6-1.8 (m, 
20H, -CH2-CH2-CH2- glutaric acid), 2.1-2.3 (m, 40H, -CO-CH2- glutaric acid), 2.8-3.7 
(m, 150H, -CH2- TEPA, -CH2- TETA, βH cysteine, εH lysine), 4.1-4.3 (m, 4H, αH 
alanine, αH cysteine, αH lysine). 
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Oligomer 816 / Sequence (C -> N): AK[(Gtt-Gtp)2-Gtt-C]2 
1H-NMR (400 MHz, D2O) δ = 1.3-1.5 (m, 9H, βH alanine, βγδH lysine), 1.7-1.9 (m, 
20H, -CH2-CH2-CH2- glutaric acid), 2.1-2.3 (m, 40H, -CO-CH2- glutaric acid), 2.9-3.7 
(m, 142H, -CH2- TEPA, -CH2- TETA, βH cysteine, εH lysine), 4.1-4.3 (m, 4H, αH 
alanine, αH cysteine, αH lysine). 
 
Oligomer 817 / Sequence (C -> N): AK(Gtt4-C)2 
1H-NMR (400 MHz, D2O) δ = 1.2-1.5 (m, 9H, βH alanine, βγδH lysine), 1.7-1.9 (m, 
16H, -CH2-CH2-CH2- glutaric acid), 2.1-2.3 (m, 32H, -CO-CH2- glutaric acid), 2.9-3.7 
(m, 102H, -CH2- TETA, βH cysteine, εH lysine), 4.1-4.3 (m, 4H, αH alanine, αH 
cysteine, αH lysine). 
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